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1 Introduction 
1.1  Cardiovascular diseases  
1.1.1 Definition and prevalence 
Cardiovascular diseases (CVDs) are considered as the major cause of mortality 
globally, accounting for 17.3 million deaths per year, a number that is expected to 
exceed 23.6 million by 2030 (Mendis, Puska et al. 2011; Smith, Collins et al. 2012). 
Nearly 30 % of the deaths worldwide are attributed to CVDs (Mendis, Puska et al. 
2011). These diseases currently account for half of non-communicable diseases and are 
considered as one of the major causes of morbidity around the world (Mendis, Puska et 
al. 2011; Laslett, Alagona et al. 2012). According to the report presented by the 
American Heart Association, the mortality rate caused by these diseases has decreased 
in North America during the last decade, though the morbidity and the socioeconomic 
burden caused by these ailments still remain high (Roger, Go et al. 2012). On the other 
hand, the distribution of CVDs, once considered to mainly affect developed countries, 
has now shifted to the developing countries due to urbanization, globalization, and 
industrialization (2010). In these countries, nearly 80% of the CVDs- and diabetes-
related deaths usually occur at younger ages than in higher-income countries (Mendis, 
Puska et al. 2011; Smith, Collins et al. 2012). From 2011 to 2025, CVDs account for 
nearly 50% of projected cumulative economic losses due to non-communicable diseases 
in low- and middle- income countries (Laslett, Alagona et al. 2012).  
Cardiovascular diseases are classified into atherosclerotic and non-atherosclerotic. 
The atherosclerotic category includes coronary heart disease, cerebrovascular disease, 
diseases of the aorta and arteries, including hypertension and peripheral arterial disease, 
and diseases of the veins including deep vein thrombosis. The non-atherosclerotic 
diseases include rheumatic heart disease, congenital heart disease, and cardiac 
conduction and valvular disorders. 
1.1.2 Endothelial dysfunction and cardiovascular diseases  
Different mechanisms participate in the pathogenesis of CVDs. These diseases are 
generally caused by stenosis or occlusion of the vessels supplying blood to the end 
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organs, primarily due to atherosclerosis (Libby and Theroux 2005; Jawad and Arora 
2008). Endothelial cells (ECs) have been demonstrated to play a central role in many 
atherosclerotic diseases, including coronary heart disease (Heitzer, Schlinzig et al. 
2001; Libby 2002; Bonetti, Lerman et al. 2003; Kullo and Malik 2007). Upon 
encountering risk factors such as dyslipidemia, glycoxidation products caused by 
diabetes mellitus, pro-inflammatory cytokines derived from adipose tissue, or bacterial 
by-products, ECs augment the expression of particular adhesion molecules such as 
vascular cell adhesion molecule (VCAM) and chemotactic factors such as macrophage 
chemoattractant protein-1 (MCP-1) (Steinberg 2002). This may lead to an increased 
attraction of leukocytes and monocytes, and the accumulation of resident macrophages 
at the subendothelial space (Libby 2002; Mestas and Ley 2008). In addition, the 
oxidation of low-density lipoprotein (LDL) particles and the resulting formation of 
foam cells may be partly promoted by ECs (Luo, Liu et al. 2012), leading to an 
increased expression of scavenger receptors by macrophages (Li and Glass 2002; Moore 
and Tabas 2011). The interaction between resident leukocytes, ECs, and smooth muscle 
cells (SMCs) migrating from the media to the intima leads to, sustains, and promotes 
the formation of atherosclerotic plaques (Libby and Theroux 2005; Sakakura, Nakano et 
al. 2013). Moreover, damage of the endothelial monolayer of atherosclerotic plaques 
can lead to further thrombotic events (Virmani, Burke et al. 2006; Sakakura, Nakano et 
al. 2013). Newer studies dissect novel roles for dysfunctional ECs in vascular 
calcification through the formation of osteoprogenitor cells (Yao, Jumabay et al. 2013).  
Dysfunctional ECs and their  deregulated stimulation and response play a central role 
in several other pathological conditions including diabetes mellitus (Taylor 2001; Tabit, 
Chung et al. 2010; Wong, Wong et al. 2010), hypertension (Versari, Daghini et al. 
2009), aging and smoking (Brunner, Cockcroft et al. 2005), congestive heart failure 
(Kerem, Yin et al. 2010), allograft rejection (Rao, Yang et al. 2007), and pulmonary 
hypertension (Sakao, Tatsumi et al. 2009).  
1.1.3 Therapeutic modalities for cardiovascular diseases  
In addition to risk factor stratification at the early stages, pharmacological or 
interventional therapy may be necessitated in the management of CVDs (Deveza, Choi 
et al. 2012). Surgical procedures are usually preferred in patients with multiple vascular 
bed involvement (McFalls, Ward et al. 2004). However, these procedures may not be 
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always safely used in case of co-morbidities. Therapeutic catheterization procedures 
still remain the gold-standard strategies for the management of many CVDs with 
underlying vascular derangement, especially those with acute events or full vessel 
occlusion. Nevertheless, there are limitations due to restenosis and in-stent thrombosis, 
especially in patients with microcirculatory disorders (Libby, Schwartz et al. 1992; 
Thanyasiri, Kathir et al. 2007; Kim, Suh et al. 2008; Seiler 2010; Brilakis, Patel et al. 
2013). Even under adequate anti-platelet therapy, different factors such as endothelial 
dysfunction may be correlated with thrombotic events after stent implantation (Fujisue, 
Sugiyama et al. 2013).  
Body’s own protective mechanisms may partly prevent the pathological conditions 
related to vascular stenosis. For instance, migration and proliferation of healthy ECs 
may contribute to the repair of damaged ECs (Ross, Bowen-Pope et al. 1982). This can 
be achieved by the body’s innate physiological response to ischemia by upregulation of 
angiogenic growth factors and mobilization of circulating elements that enable new 
vessel formation through different mechanisms (Losordo and Dimmeler 2004). These 
mechanisms include vasculogenesis (de novo formation of primordial ECs from 
undifferentiated ECs or angioblasts), angiogenesis (sprouting of new blood vessels from 
preexisting blood vessels), and arteriogenesis (formation of arteries)(Yancopoulos, 
Klagsbrun et al. 1998; Heil, Eitenmuller et al. 2006; Penn 2008; Carmeliet and Jain 
2011; Xu and Cleaver 2011; Deveza, Choi et al. 2012; Marcelo, Goldie et al. 2013). 
Most of therapeutic studies have focused on angiogenesis (Lu, Pompili et al. 2011) 
through different mechanisms, including upregulation of vasculogenic/angiogenic 
genes, application of potent growth factors, and cellular therapy (Chu and Wang 2012). 
There are several reviews discussing the advances in, as well as hurdles of gene therapy 
approaches (Hedman, Hartikainen et al. 2011; Ishikawa, Tilemann et al. 2011). 
Directed application of selective growth factors, including vascular endothelial growth 
factor (VEGF) has been widely studied and tested  in animal  ischemia models as well 
as  clinical studies (Folkman 1998; Losordo and Dimmeler 2004; Das, George et al. 
2009; Lu, Pompili et al. 2011; Chu and Wang 2012). However, the efficiency and 
clinical benefit of these methods in the induction of a sustainable vasculature has not 
been largely confirmed in clinical trials (Deveza, Choi et al. 2012). 
More recently, cellular therapy approaches or stem cell therapy has gained attention 
in the induction of neovascularization and treatment of CVDs (Kastrup 2010). Patients 
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with CVDs have been estimated to be the largest group benefiting from these 
approaches  compared to other patient groups (Hotkar and Balinsky 2012). Cellular 
therapy in the treatment of CVDs may act both indirectly via induction of growth 
factors (paracrine effects), and directly through homing and proliferation at sites of 
injury (Srivastava and Ivey 2006; Adams, Xiao et al. 2007; Sun and Gerecht 2009; 
Leeper, Hunter et al. 2010).  Most stem cells used in clinical trials have been harvested 
from bone marrow, as the most easily used source for autologous application. However, 
the disadvantages of bone marrow-derived stem cell therapy include the paucity of 
obtainable therapeutically useful stem cells and the need for substantial extended culture 
before use  (Perin, Dohmann et al. 2003; Pittenger and Martin 2004; Horwitz 2008; 
Hotkar and Balinsky 2012).  
Historically, scientists have divided stem cells into two major distinct categories: 
Embryonic stem (ES) cells and adult stem cells (Leeper, Hunter et al. 2010). Induced 
pluripotent stem cells (iPSCs), which are produced through the reprogramming of adult 
somatic cells into multipotent stem cells are another category of stem cells, which have 
recently gained attention in cell therapy. 
 
1.2   Stem cells 
1.2.1 Stem cell properties  
The term “stem cells” originates in the literature as early as 1868 in the brilliant studies 
by the German biologist Ernst Häckel. He described stem cells as the unicellular 
organism from which a multicellular organism originates and portrayed “stem trees” to 
show the hierarchy of evolution (Ramalho-Santos and Willenbring 2007).  Stem cells 
are defined by their characteristics of long-term self-renewal and differentiation 
potential (Gardner and Beddington 1988; Morrison, Shah et al. 1997). Self-renewal is 
the asymmetrical or symmetrical division of a stem cell to one or two daughter stem 
cells with at least one daughter cell having the developmental potential similar to the 
mother cell (He, Nakada et al. 2009). This property, though, is not unique to stem cells. 
For instance, self-renewal may also be seen in lymphocytes as terminally differentiated 
cells (Fearon, Manders et al. 2001), a small number of glial progenitor-type cells 
(Trentin, Glavieux-Pardanaud et al. 2004), and in endodermal cells derived from ES 
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cells in co-culture with mesenchymal cells (Sneddon, Borowiak et al. 2012). 
Nevertheless, this property, which occurs extensively in stem cells, can be generally 
distinguished from limited self-renewal processes in these restricted populations of 
progenitor-type or adult cells. 
Differentiation is another characteristic of stem cells, which happens when the stem 
cells differentiate into one specialized cell type or a multitude of them, and lose their 
self-renewal potential.  
1.2.2 Application of stem cell studies  
A basic insight into the processes occurring during stem cell self-renewal and 
differentiation can be enormously helpful in understanding the in vivo mechanisms 
during growth and regeneration procedures. It may help us understand where is the 
point that the fate of a cell is determined to go through differentiation or stay at a more 
premature state. Through in vitro and in vivo stem cell studies, we may comprehend the 
body’s repair mechanisms in confrontation with internal and external insults (Gardner 
2007). This knowledge may translate into therapeutic approaches for a multitude of 
diseases, as well as understanding of the underlying aging mechanisms.  
One of the aims of regenerative medicine is to provide adequate numbers of cells for 
therapeutic purposes, when the body’s own mechanisms are not able to overcome the 
damages induced by genetic, chemical or physical factors. Cellular therapy has been 
most widely used for the regeneration of epidermis or cornea (Rama, Matuska et al. 
2010; Chadli, Martin et al. 2011), therapy of spinal cord injury (Mothe and Tator 2013), 
as well as treatment of leukemia (Burt, Loh et al. 2008), Parkinson’s and Huntington’s 
disease (Lescaudron, Naveilhan et al. 2012; Nishimura and Takahashi 2013), diabetes 
mellitus (Chhabra and Brayman 2013), and  CVDs (Bartunek, Behfar et al. 2013). 
Application of stem cells as models for understanding and treatment of cancer has also 
gained attention (Bajada, Mazakova et al. 2008). However, many hurdles should be 
overcome before reaching the optimal therapy conditions. One of the concerns is 
immunogenicity in “non- autologous transplantation”. The other issue is defining a 
particular point of time that is ideal for therapeutic purposes, i.e. possess both the 
desired proliferative capacity and target cell properties in vivo. Comprehensive studies 
on stem cell dynamics and their milieu as well as clinical experiments shall provide an 
interface between basic science and medicine for the best targeted applications.  
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One of the new applications of stem cells is drug discovery. This process may benefit 
from the expandability and testability of these cells in vitro. Tissue engineering may 
serve to optimize the stem cell niche and improve the quality assurance of the tested 
drugs (Nirmalanandhan and Sittampalam 2009), by providing a well-designed three- 
dimensional milieu, mimicking the real in vivo circumstances.  
1.2.3 Stem cell categories 
Stem cells are generally classified in two ways: Based on the level of their plasticity i.e. 
the, meaning that they can give rise to all cell types, including extraembryonic 
tissuesability of a cell to become different cell types, and according to the tissue that 
they originate from. On the basis of plasticity, these cells can be divided into totipotent, 
pluripotent, and multipotent. Germ cells and embryos at the 1-or 2-cell stage are 
totipotent.  
Adult stem cells and cord blood stem cells are examples of multipotent cells, giving 
rise to multipotent cells and a particular group of differentiated cells. These types of 
stem cells are undifferentiated cells found in some terminally differentiated tissues with 
a high turnover rate, such as blood and skin, or in organs with a significant regeneration 
capacity, like liver and pancreas (Rando 2006). Adult stem cells are deemed to 
persistently interact with their surrounding milieu or ‘niche’ (Scadden 2006; Greco and 
Guo 2010). The fact that they are isolated from a specific tissue or organ increases the 
chances to direct these cells into a restricted population of adult cells that they are 
destined to be. However, their scarce numbers (with the exception of hematopoietic 
cells), as well as their tendency to transdifferentiate into other cells types (Herzog, Chai 
et al. 2003; Kanji, Pompili et al. 2011; Fukata, Ishikawa et al. 2013; Scarlett 2013), 
make their isolation very difficult due to the possibility of contamination with other 
intervening cells types (Brignier and Gewirtz 2010). Cord blood cells as another type of 
multipotent stem cells have recently gained attention for therapeutic purposes (Bissels, 
Eckardt et al. 2013). 
Embryonic stem cells and embryonic germ cells (EGCs) are examples of pluripotent 
stem cells. Pluripotent cells can give rise to all cells types, except for totipotent cells and 
extraembryonic tissues. Embryonic germ cells are isolated from primordial germ layers 
in the post-implantation period commencing at E 6.5 through a nuclear re-programming 
event (Hayashi, de Sousa Lopes et al. 2007; Saitou, Kagiwada et al. 2012). These cells 
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demonstrate the typical ES cell markers and have the ability to contribute to chimeras 
(Leitch, Blair et al. 2010). Embryonic stem cells, which are obtained from the inner cell 
mass (ICM) of the embryo, have gained enormous attention during the last 2 decades 
for developmental as well as experimental therapeutic purposes. In the next section, a 
brief overview about embryonic stem cells is discussed.  
 
1.3  Embryonic stem cells  
1.3.1 Origin of embryonic stem cells  
After formation of the zygote, cells undergo division. At the 16-cell morula stage, 
polarization and compaction of the embryo occurs. At this time point, cells consist of 
two layers. The outer layer comprises the trophoectoderm, giving rise to the outer layer 
of placenta and umbilical cord. The inner layer gives rise to ICM, where all the cellular 
lineages of the embryo (ectoderm, mesoderm and endoderm), allantois, amnion, and 
yolk sac originate. At embryonic day 3 in mouse and embryonic days 5-6 in human, 
cavitation (blastocoel formation) occurs and ICM increases in size (Figure 1 A). 
Embryonic stem cells were first isolated in 1981 by separation and culture of cells from 
the ICM of blastocysts (Evans and Kaufman 1981; Martin 1981). The efficiency of 
mouse ES cell isolation strongly relies on the genetic background of the mice. In some 
inbred animals, the isolation efficiency is much more robust compared to others (Yu 
and Thomson 2008).  
At day 4.5 in mouse and days 8-9 in human, the embryo implants in the uterus wall 
through the syncytiotrophoblast, which comprises the outer layer of the trophoblast (De 
Miguel, Fuentes-Julian et al. 2010). At this bilaminar stage (Figure 1 B), ICM is divided 
into two layers: hypoblast and epiblast. Hypoblast or the primitive endoderm 
contributes to the extraembryonic tissues such as the lining of the primitive yolk sac. 
Epiblast or the primitive ectoderm gives rise to all germ layers, including ectoderm, 
mesoderm, and endoderm, and is a source for epiblast-derived stem cells. These cells 
are pluripotent and unlike ES cells, are derived from the post-implantation embryo 
(Tesar, Chenoweth et al. 2007).  
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Figure 1 Schematic view of the mammalian embryo.  
(A): Blastocyst stage; (B): Bilaminar stage. Adapted and modified from De Miguell et al. Stem 
Cell Rev 6(4), 633-649 (2010).  
 
1.3.2 Pluripotency and self-renewal in mouse embryonic stem cells  
At the time mouse ES cells were for the first time isolated, they were cultured on 
mitotically inactivated mouse embryonic fibroblasts (MEFs) to maintain their 
undifferentiated state (Evans and Kaufman 1981; Martin 1981). Later, analysis of the 
medium led to the identification of leukemia inhibitory factor (LIF) as a cytokine 
keeping mouse ES cells in their undifferentiated state (Smith, Heath et al. 1988; 
Williams, Hilton et al. 1988). Leukemia inhibitory factor is a member of the interleukin 
(IL)-6 family, which acts through heterodimerization of its receptor and glycoprotein 
(Gp)130. The LIF-induced activation of its receptor and Gp130 triggers a cascade of 
events via different signaling pathways, leading to the maintenance of pluripotency and 
self-renewal of ES cells through the activation of transcription factors (Zhang, 
Owczarek et al. 1997; Burdon, Smith et al. 2002) (Figure 2).  
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An autoregulated circuit between some of the transcription factors such as octamer-
binding transcription factor (Oct)-4, sex determining region Y-box (Sox) 2, and the 
homeodomain protein Nanog results in the induction and maintenance of stemness and 
self-renewal in ES cells (Boyer, Lee et al. 2005). Despite some common features, there 
are differences between mouse and human systems. For instance, c-Myc has a 
regulatory role in stemness in mice, but not in human (Kidder, Yang et al. 2008). 
Another difference is the existence of  the stage specific embryonic antigen (SSEA)-1 in 
mice and  SSEA-3/4 in human (De Miguel, Fuentes-Julian et al. 2010).   
Embryonic stem cells have been typically cultured in serum-containing medium. 
Fetal bovine serum (FBS) contains a low amount of antibody and a high content of 
growth factors, making it a versatile condition for the culture of a variety of cells. Due 
to some unknown interactions between serum components and cells, some techniques 
have been more recently invented to keep cells in a more unanimously undifferentiated 
Figure 2 Parallel signaling pathways contributing to pluripotency in 
mammalian embryonic stem cells 
The Jak–Stat3 pathway activates Klf4, while the PI(3)K–Akt pathway stimulates the 
transcription of Tbx3. The MAPK pathway antagonizes the nuclear localization of Tbx3. Klf4 
and Tbx3 mainly activate Sox2 and Nanog, respectively, and maintain expression of Oct3/4. 
Transcription of all these transcription factors is positively regulated by Oct3/4, Sox2 and 
Nanog, conferring stable expression in the absence of all signals. Klf4: Kruppel-like factor 4; 
Tbx3: T box transcription factor 3; PI(3)K-Akt: phosphatidylinositide 3-kinases-Akt pathway; 
Oct3/4: octamer-binding transcription factor—3/4. Sox 2: sex determining region Y-box 2.   
Adapted and modified from Niwa H et al. Nature 460, 118-122 (2009).  
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state. Application of a combination of cytokines such as LIF and bone morphogenic 
protein (BMP)-4, as well as a mixture of  inhibitors, namely GSK inhibitor 
(CHIR99021) and MEK inhibitor (PD0325901) in a serum-free condition has been 
shown to maintain ES cells in their ground state (Niwa, Ogawa et al. 2009; Li and Ding 
2010; Kanda, Sotomaru et al. 2012; Lee, Chuang et al. 2012)(Figure 3). Despite the 
existing evidence for a higher expression level of markers of undifferentiated state in 
serum-free culture using small molecules, this method has not been shown to improve 
human ES cell derivation from blastocysts (Van der Jeught, O'Leary et al. 2013). 
Moreover, these studies have not been used in large scale, high-throughput systems. The 
high costs of these inhibitors and cytokines is another issue that must be taken into 
account. As a result, these methods have not been yet considered as ideal for high-
throughput experiments. 
 
Figure 3 Maintenance of self-renewal in mouse embryonic stem cells using 
cytokines and chemical inhibitors 
(A): Inhibition of differentiation by LIF and BMP (B): Inhibition of differentiation by 3 inhibitors 
(3i) (C): Inhibition of differentiation by 2 inhibitors (2i). LIF: leukemia inhibitory factor; BMP: bone 
morphogenic protein; ESCs: embryonic stem cells; FGF-4: fibroblast growth factor-4.  Adapted 
and modified from Hirai H, et al.  Biochem J. 438 (1) 11-23 (2011).  
 
1.3.3 Differentiation of mouse embryonic stem cells  
In the absence of MEFs and LIF in medium, ES cells spontaneously differentiate into 
various cell types (Robertson 1997). When ES cells are injected into the blastocyst, they 
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can undergo the process of differentiation just in a way similar to the native cells of the 
ICM (Bradley, Evans et al. 1984). Once ES cells are cultivated in suspension culture 
conditions, i.e. under circumstances that discourage their attachment to the culture plate, 
they tend to form aggregates that are called embryoid bodies (EBs)(Doetschman, 
Eistetter et al. 1985). The differentiation in EBs recapitulates cell differentiation in the 
ICM, where the outer layer forms a primitive endoderm and the inner cells undergo 
apoptosis and contribute to the amniotic cavity (Coucouvanis and Martin 1995; Sasaki, 
Fassler et al. 2004; Fujiwara, Hayashi et al. 2007). Upon differentiation of ES cells, a 
variety of different cell types arise. These cell types include cardiomyocytes (Wei, 
Juhasz et al. 2005), smooth muscle cells (Vazao, das Neves et al. 2011),  osteogenic 
cells (Yamashita, Nishikawa et al. 2010), chondrogenic cells (Toh, Guo et al. 2009), 
neuronal cells (Hayashi, Guerreiro et al. 2010), endothelial cell (EC)s (Li, Hu et al. 
2011), hepatic and pancreatic cells (Medine, Lucendo-Villarin et al. 2008; Schulz, 
Young et al. 2012; Sivertsson, Synnergren et al. 2013), and hematopoietic cells  (Lim, 
Inoue-Yokoo et al. 2013) (Figure 4).  
 
 
 
Figure 4  Schematic view of culture and differentiation of embryonic stem cells  
Mouse embryonic stem cells are obtained from the inner cell mass of the embryo. In the 
absence of LIF and MEFs (feeder cells), mouse embryonic stem cells form embryoid bodies, 
which under certain culture conditions can give rise to different cell types. ICM: inner cell mass; 
LIF: leukemia inhibitory factor; MEFs: mouse embryonic fibroblasts.  
1 Introduction 
12 
 
1.3.4 Differentiation of mouse embryonic stem cells to endothelial 
cells 
Mesodermal cells in the early embryo, which are developed from the ICM of the 
embryo, are positive for brachyury. In 1998, Gordon Keller and his co-workers 
identified a precursor called blast-colony-forming cells (BL-CFC), as an in vitro 
equivalent of hemangioblasts (Choi, Kennedy et al. 1998). These cells are positive for 
both brachyury and fetal liver kinase (Flk)-1, and have the potential to develop into 
ECs. Under the influence of different transcription factors and environmental stimuli, 
the same precursor can develop into SMCs, as well as contribute to the definitive 
hematopoiesis (Lancrin, Sroczynska et al. 2010)(Figure 5). Definitive hematopoiesis 
occurs after the early wave of primitive hematopoiesis in the yolk sac and is mediated 
through the hemogenic endothelium. These cells originate from the dorsal aorta in close 
propinquity to the endothelium wall of the aorta (de Bruijn, Speck et al. 2000; Eilken, 
Nishikawa et al. 2009; Lancrin, Sroczynska et al. 2009). 
 
Figure 5 Model of endothelial and blood cell formation from the hemangioblast 
 
In the figure, the specific phenotypes of differentiated cell populations derived from the 
hemangioblast, and the key regulators and transcription factors involved in endothelial and 
hematopoietic development are depicted (adapted and modified from Lancrin et al. J Mol Med; 
88: 167-172 (2010)).  
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Derivation of ECs from ES cells has been widely based on EB formation and 
subsequent plating of EBs on different modified substrates in the presence of growth 
factors to enhance the formation of vascular networks. Blood islands and vascular 
networks in EBs are excellent models for vasculogenesis and angiogenesis in the early 
embryo, especially under pathological conditions such as hypoxia or tumor growth. 
These models underlie the ongoing studies on EC development as well as therapeutic 
applications and drug discovery (Kim, Kim et al. 2008; Huang, Niiyama et al. 2010; 
Kim, Bae et al. 2012).  
1.4  Background to endothelial cells  
Endothelial cells are a group of cells that originate from mesodermal cells in the body 
and line the inner part of the vasculature. The total number of ECs in adult human is 
approximately 1x 10
13
 (Sumpio, Riley et al. 2002). There are two general properties that 
apply to all ECs: 1) As an anatomical property, ECs adhere to each other to form a 
seamless inner lining of vessels in the body; 2) Functionally, these cells are selectively 
permeable and act as an active interface with body cells and fluids (Voelkel and Rounds 
2009). Endothelial cells, once recognized as a homogeneous cell population, are now 
considered to be quite “heterogeneous”, with broad morphological and functional 
variations (Aird 2012).  
1.4.1 Ontogeny of the vasculature 
The vasculature in the body is formed through two different major mechanisms: 
vasculogenesis and angiogenesis. These two mechanisms may also work in coordination 
to form body blood vessels (Figure 6). Angiogenic remodeling is another mechanism 
contributing to vasculature formation, which entails the reconstitution of the existing 
angiogenic plexus.  
Vasculogenesis is defined as the de novo formation of primordial ECs from 
undifferentiated ECs or individual angioblasts, where blood vessels are formed through 
clustering of individual angioblasts into linear cords. This mechanism is followed by the 
formation of a patent lumen, which is also termed as tubologenesis (Risau and Flamme 
1995; Xu and Cleaver 2011). Vasculogenesis is the primary mechanism through which 
the vasculature in the early embryo develops, including primitive blood vessels of the 
endocardium and primary aorta, as well as of the yolk sac. It implies a series of events 
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including angioblast proliferation, migration, adhesion, and differentiation (Voelkel and 
Rounds 2009).   
 
 
Figure 6 Schematic illustration of different mechanisms contributing to blood 
vessel formation.  
a) Vasculogenesis is the de novo formation of endothelial cells through the aggregation of 
angioblasts in the mesoderm. b) Sprouting angiogenesis is the formation of new blood vessels 
through the formation of new sproutings out of the pre-existing vessels. c) Blood vessel 
formation through coordinated vasculogenesis and angiogenesis in the developing organs.  
Adapted and modified from The pulmonary Endothelium: Function in Health and Disease, 
Voelkel N and Rounds S, Wiley-Blackwell (2009).  
 
The primary vasculature that has been formed through vasculogenesis is expanded 
through angiogenesis. Angiogenesis occurs through two mechanisms: Sprouting 
angiogenesis and angiogenic remodeling. Sprouting angiogenesis encompasses the 
elongation and sprouting of new blood vessels out of the pre-existing ones, leading to 
the expansion of vascular networks (Yancopoulos, Klagsbrun et al. 1998; Penn 2008; 
Carmeliet and Jain 2011; Marcelo, Goldie et al. 2013). This is mediated via 
proliferation of the quiescent cells at vessel walls and proteolytic degradation of the 
extracellular matrix, after which new sprouts starts to extend. Angiogenic remodeling is 
the mechanism through which the cells undergo changes in their size and shape, to 
adapt to cell demands and hemodynamic changes. An example in the early embryo is 
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the formation of the branching angiogenic tree out of the homogenous network, 
resembling a fisherman’s net. Examples in the adult stage include remodeling in the 
female reproductive system, wound healing, and pathological conditions such as 
angiogenic tumors (Voelkel and Rounds 2009).  
Arteriogenesis as a later maturation step leads to the formation of arteries, and is 
characterized by the coating of vascular beds via pericytes and SMCs (Heil, Eitenmuller 
et al. 2006). Angiogenesis and arteriogenesis play a major role in postnatal 
neovascularization procedures (Carmeliet and Jain 2011). Most of the therapeutic 
studies have been focused on angiogenesis (Lu, Pompili et al. 2011).  
 
1.4.2 Transcription factors and key molecules in vascular 
development 
The role of certain transcription factors in vascular development has been investigated 
in recent studies. Despite the redundancy of many of these transcription factors, a few 
of them such as Tal1 have shown a unique role in vascular development, especially in 
close interactions with Flk-1 and vascular endothelial (VE)-cadherin (Pham, Lawson et 
al. 2007). There is a narrow window for the expression of many of these transcription 
factors, which tend to be down-regulated, once the cells differentiate into a more adult 
phenotype (Kataoka, Hayashi et al. 2011). Some of these transcription factors such as 
Sox17 and Sox18 are essential for the specification of ECs to a particular phenotype 
(Marcelo, Goldie et al. 2013).  
The VEGF family (VEGF A-E) and its receptors are key molecules in EC 
development, survival, and differentiation, as well as blood vessel formation. VEGF-A 
is highly expressed in the extraembryonic endoderm at the time of blood island 
formation in the yolk sac, as early as day 7.5 (Breier, Clauss et al. 1995). Absence of 
one of the VEGF-A alleles leads to early death of mice during embryogenesis, due to a 
variety of vascular defects (Carmeliet, Ferreira et al. 1996). On the other hand, VEGF-A 
overexpression is also lethal to the embryo (Miquerol, Langille et al. 2000). Different 
isoforms of VEGF-A (120, 164, 188 in mouse and 121, 145, and 165 in human) have 
distinct biological activities, the coordination of which leads to vascular development. 
VEGF-A 165 is an example of a smaller, more diffusible VEGF, which has been 
extensively used in vitro. Recent studies have shown that VEGF may principally induce 
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proliferation and propagation of ECs, rather than driving the cells into a special 
endothelial phenotype (Marcelo, Goldie et al. 2013). Flk-1 or vascular endothelial 
growth factor receptor-2 (VEGFR-2) is one of the most reliable markers for EC 
proliferation. Mice lacking Flk-1 die at E8.5 - E9.5 due to the lack of blood island and 
vascular plexus (Shalaby, Rossant et al. 1995). Likewise, ES cells lacking Flk-1 
develop ECs, which are incapable of propagation (Schuh, Faloon et al. 1999). 
BMP-4 is another key molecule in the induction of mesoderm, as well as its 
differentiation towards hematopoietic and endothelial fate (Marom, Levy et al. 2005; 
Chiang and Wong 2011). Fibroblast growth factor (FGF)-2 works downstream of   
BMP-4 and participates in hemangioblast formation in murine stem cells (Pearson, 
Sroczynska et al. 2008). However, no such role has been identified for FGF-2 in human 
ES cell studies (Kelly and Hirschi 2009).  
1.4.3 Arterial versus venous versus lymphatic differentiation  
Vessels can be classified into arteries, veins, and lymphatic vessels, based on their 
functional and anatomical properties, as well as the direction of fluids. This 
specification occurs very early during the development of primordial ECs of the yolk 
sac (Figure 7), according to a predefined pattern (Wang, Chen et al. 1998). On the other 
hand, assumption of a venous or arterial fate has been demonstrated to be plastic and 
reversible in line with the environmental stimuli and body demands (le Noble, Moyon et 
al. 2004; Nasu 2005). 
The ephrin family of receptor tyrosine kinases is the largest family among the growth 
factor receptors, using membrane-tethered ephrin as their ligand (Marcelo, Goldie et al. 
2013). EphrinB2 (EfnB2) ligand is expressed in arteries, while EphrinB4 receptor 
(EphB4) is enriched in veins. Activation of Flk-1 via VEGF may trigger the activation 
of EfnB2 and suppression of EphB4, thereby favoring an arterial  identity (Lawson, 
Scheer et al. 2001). Chicken ovalbumin upstream promoter transcription factor (COUP 
TF)-II, on the other hand, has been shown to be one of the key genes for venous fate 
specification (You, Lin et al. 2005). Thus, an interrelation of all these genes and the 
reciprocal signaling may play a role in the specification of an arterial vs. venous 
phenotype. 
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The lymphatic circulation has an essential role in the immune system, as well as in 
returning the extravasated proteins and cells to the blood. Prospero homeobox protein 
(Prox)1 has been found to be highly expressed in the venous ECs, contributing to the 
lymphatic system (Srinivasan, Dillard et al. 2007). Venous ECs start to express Prox1 at 
day 9.5. By day 11.5, clusters of Prox1-positive venous ECs begin to emerge along the 
cardinal vein (Srinivasan, Dillard et al. 2007; Francois, Short et al. 2012). 
The Sox18 gene, which is also essential for specification of a venous fate, has been 
shown to regulate Prox1 expression (Francois, Caprini et al. 2008; Marcelo, Goldie et 
al. 2013). However, the presence of Sox18 is not sufficient for lymphatic specification, 
as arteries also express Sox18 (Pennisi, Gardner et al. 2000). COUP-TFII, has also been 
shown to be highly expressed in lymphatic ECs (Lee, Kang et al. 2009), playing a role 
together with Sox18 in activation of Prox1 and the development of endothelial 
lymphatic progenitors (Srinivasan, Geng et al. 2010). Despite these proceedings, the 
exact mechanisms of arterial vs. venous vs. lymphatic endothelial differentiation still 
needs further declaration.  
       
 
  
 
Figure 7 Specification toward an arterial vs. venous vs. lymphatic fate in the 
early embryo  
 
Major extrinsic and intrinsic factors that regulate endothelial cell specification throughout 
embryonic vascular development. BMP4: bone morphogenetic protein 4; FGF2: fibroblast 
growth factor 2; IHH: Indian hedgehog; RA: retinoic acid; VEGFR2: VEGF receptor type II. 
Adapted and modified from Marcelo et al. Circ Res.112(9):1272-87 (2013).  
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1.4.4 Phenotypic diversity of endothelial cells 
Apart from the specification of vessels to arteries, veins, and lymphatic vessels, there is 
a high level of endothelial phenotypic heterogeneity in various organs and vascular beds 
(Atkins, Jain et al. 2011). The basic mechanisms leading to the specification of a special 
EC phenotype in different organs are mostly unknown. Endothelial cells are generally 
classified into a continuous type, which is further subcategorized into non-fenestrated 
and fenestrated subgroups, and a discontinuous or sinusoidal type. The continuous non-
fenestrated type is mostly found in the vessels of lung, brain, heart, muscle, and skin, 
and is characterized by tight and adherens junctions (Dejana 2004). The continuous 
fenestrated type is characterized by diaphragms, which allow the transport of water and 
small molecules, and is typically found in the capillaries of exocrine and endocrine 
glands and in the renal vasculature, where a high amount of transendothelial transport is 
required (Marcelo, Goldie et al. 2013). The discontinuous type is characterized by large 
fenestrae, and is found in certain sinusoidal vascular beds, including liver and bone 
marrow (Marcelo, Goldie et al. 2013). This diversity has an important impact in cellular 
therapy approaches.  
1.4.5 Endothelial cell markers in early and late stages of endothelial 
cell differentiation 
Endothelial cells are derived from a population of cells that are positive for brachyury 
(Lancrin, Sroczynska et al. 2010). Some endothelial-specific genes are expressed in 
both early and late stages of EC development with different expression levels and 
functional profiles. Flk-1, which is one of the earliest markers of ECs, may also give 
rise to a whole population of cells, including hematoendothelial cells and SMCs 
(Lancrin, Sroczynska et al. 2009). The high expression of this gene in ECs potentially 
makes it a versatile option for conventional purification of ECs. However, the 
expression of this marker in non-EC populations (Ahlbrecht, Schmitz et al. 2008) and 
the capacity of Flk-1-positive cells to give rise to non-ECs, including SMCs, 
hematoendothelial cells, and epithelial cells (Ishitobi, Wakamatsu et al. 2011), makes it 
less favorable for achieving pure populations of ECs. VE-cadherin, as another specific 
endothelial marker is predominantly expressed on more mature ECs, though its 
expression is also found on premature stages of EC development (Vittet, Prandini et al. 
1996). Cluster of differentiation (CD)31 or platelet endothelial adhesion molecule 
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(PECAM)-1 as another EC marker is expressed in both early and late stages of EC 
differentiation, though its function may alter during the course of differentiation (Li, 
Wang et al. 2005; Mariappan, Winkler et al. 2009). Thus, most of these markers, 
though relatively specific to ECs, may not characterize definitie populations of early 
and late stages of EC development.  
Endothelial progenitor cells (EPCs) are a distinct category of multipotent stem cells, 
which originate from the peripheral blood, cord blood, and bone marrow (Asahara, 
Murohara et al. 1997; Asahara, Masuda et al. 1999). These cells express both 
hematopoietic stem cell markers such as CD34 and CD133, and endothelial markers 
such as VE-cadherin, CD31, and Flk-1 (Hur, Yoon et al. 2004; Fadini, Losordo et al. 
2012). Endothelial progenitor cells are divided into two subgroups of early and late 
EPCs (Hur, Yoon et al. 2004). Early EPCs, which appear after short-term culture of 
mononuclear cells from peripheral blood, express mononuclear cell markers and 
promote vasculogenesis through the production of cytokines and growth factors 
(Urbich, Aicher et al. 2005; Medina, O'Neill et al. 2010). Late EPCs, on the other hand, 
are involved in vasculogenesis and angiogenesis through physical incorporation into the 
vascular regeneration processes and highly express VE-cadherin and Flk-1 (Yoder, 
Mead et al. 2007; Medina, O'Neill et al. 2010). 
In the experiments underlying my thesis, the promoter of VE-cadherin, as one of the 
most specific markers of ECs, was used for labeling and tracking of ECs by designing a 
vector in which the specific labeling protein GFP is expressed under the control of this 
promoter. On the other hand, due to the abundance and robustness of CD31 expression 
in different developmental stages of ECs, transgenic ES cell-derived ECs were selected 
based on the expression of this molecule for later experimental research such as cell 
purification for therapeutic purposes. Thereafter, the selective EC gene pattern during 
the course of differentiation in this population was assessed.  In the next two sections, a 
brief overview of CD31 and VE-cadherin is provided.  
1.4.5.1 VE-cadherin  
VE-cadherin is the major endothelial-specific cell adhesion molecule, playing an 
important role in vascular development and growth (Lampugnani and Dejana 1997). 
This molecule is the cadherin number 5 among the cadherin family named cadherin -4 
to 11, and is the only endothelial-specific among them. Different cDNA mappings have 
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shown a homology of VE-cadherin to the other known cadherins with the exception of 
differences within the cytoplasmic tail (Suzuki, Sano et al. 1991). Cloning of            
VE-cadherin has shown its specificity to the vascular system in embryonic tissue 
(Breier, Breviario et al. 1996; Larson, Wadman et al. 2004), so that mice lacking this 
gene die due to severe hemorrhage (Matsuyoshi, Toda et al. 1997). This molecule is 
represented as a dimer with extracellular domains 1-5, which interact with catenin 
proteins p120, β-catenin, and plakoglobin. β-catenin and plakoglobin connect to           
α-catenin, which is related to actin fibers (Figure 8). Some of the proteins that interact 
with VE-cadherin have enzymatic activity, while others have scaffolding properties. 
This interaction leading to the formation of complex structures, regulation of VE-
cadherin activity, and signal transduction (Dejana, Orsenigo et al. 2008).  The structural 
roles of VE-cadherin are crucial for the maintenance of the integrity of ECs and the 
barrier function.  
 
Figure 8 Molecular organization of VE-cadherin  
VE-cadherin is shown as a dimer, the minimal functional unit of cadherins. EC1-EC5 are the 
homologous extracellular domains of VE-cadherin. The formation of multimolecular complexes, 
comprising signaling, regulatory, and scaffolding proteins is promoted by clustering of VE-
cadherin.The interacting proteins include the catenin proteins p120, β-catenin (βcat) and 
plakoglobin (plako). β-catenin and plakoglobin connect directly with VE-cadherin and α-catenin 
(αcat). EC1-5: Extracellular domains. Adapted and modified from Dejana et al. J Cell Sci. 121(Pt 
13):2115-22 (2008). 
Apart from structural function, VE-cadherin has been shown to play a role in 
angiogenesis processes. This molecule is dispensable for the initial vasculogenesis, but 
is fundamentally required for the later angiogenesis and remodeling processes (Gory-
Faure, Prandini et al. 1999; Bäumer, Keller et al. 2006). VE-cadherin supports the 
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survival signals of Flk-1 through transmission of antiapoptotic signals
 
(Carmeliet, 
Lampugnani et al. 1999). This property has been used to design anti-VE-cadherin 
antibodies, which may potentially help to prevent the metastatic growth of tumors 
(Liao, Li et al. 2000). On the other hand, this molecule may play inhibitory functions on 
Flk-1 signaling, thus reducing the proliferation rate and contributing to vascular 
integrity (Vestweber 2008; Dejana and Giampietro 2012).  A 2.5-kb region of the VE-
cadherin promoter has been shown to direct an endothelial-specific reporter gene 
expression in vivo (Gory, Vernet et al. 1999). 
1.4.5.2 CD31 
CD31 is a type I transmembrane glycoprotein, consisting of an extracellular region with 
6 immunoglobulin-like homology domains, a transmembrane domain, and a 
cytoplasmic tail. This molecule is highly expressed on ECs as a major constituent of the 
intercellular junctions (Newman 1997), and has a critical role in the maintenance of the 
vascular integrity in response to inflammatory stimuli (Carrithers, Tandon et al. 2005). 
This has been partly ascribed to its modulatory roles on other regulating molecules such 
as catenins  and sphingosine-1-phosphate (S1P) (Komarova, Mehta et al. 2007). An 
anti-inflammatory role has been also attributed to CD31 through maintenance of 
vascular integrity, suppression of pro-inflammatory cytokines, inhibition of 
inflammatory signaling pathways (Carrithers, Tandon et al. 2005; Goel, Boylan et al. 
2007), and inhibition of leukocyte transmigration through the rearrangement of the 
cytoskeleton (Chen and Tzima 2009).  
In proportion to anatomic and physiological conditions, CD31 has been shown to be 
involved in seemingly contradictory functions. In areas where the blood turbulence and 
shear stress is disrupted, CD31 contributes to pro-inflammatory cascades (Harry, 
Sanders et al. 2008), while in other areas of the vasculature, the anti-inflammatory 
functions such as cytokine suppression predominate (Goel, Schrank et al. 2008). Some 
of the opposing functions of CD31 in inflammation might be ascribed to the isoform-
specific actions of CD31 in different cell types due to alternative splicing, which may 
affect all the inflammatory functions, such as vascular integrity, angiogenesis, and 
leukocyte adhesion to ECs (Wang and Sheibani 2006; Bergom, Paddock et al. 2008). 
CD31 is also expressed in the hematopoietic lineage (Newman 1997; Newman and 
Newman 2003). 
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1.5  Gene transfer in embryonic stem cells and their 
derivatives   
1.5.1    Non-viral methods  
The ability of ES cells for clonal expansion makes them ideal candidates for gene 
modification studies and production of individually-modified ES clones. The methods 
used for transient transfection of ES cells include electroporation, use of cationic lipids 
and non-liposomal cationic vectors, and viral-mediated infection (Yates and Daley 
2006). Chemical transfection includes introduction of the DNA material into cells via 
cationic lipids (such as lipofectamine®) and non-liposomal polycationic polymers (such 
as FuGENE®).  
The disadvantages of these methods in ES cell transfection include low efficiency 
rates (as low as 1%) as well as poor integration into the genome and silencing. For these 
reasons, it is difficult to establish stably transfected ES cell lines using these methods 
(Liew, Draper et al. 2007). Electroporation leads to a temporary pore formation in the 
plasma membrane through exposure of the cells to voltage pulses and entry of DNA 
into the cells. This method has been considered successful for ES cell transfection. As 
an advantage of electroporation over chemical transfection, the size of inserted DNA is 
not a restrictive factor (Nolkrantz, Farre et al. 2002; Hohenstein, Pyle et al. 2008). One 
disadvantage, however, is its limitation for high throughput systems (Moore, van Laake 
et al. 2005).  
1.5.2 Viral methods  
1.5.2.1 Retroviral vectors 
Viral vectors are frequently used in ES cell gene transfer studies. Previously, retroviral 
vectors were commonly used to establish stable transfection of ES cells and integration 
of the transgene into the host. However, the common problem of transcriptional gene 
silencing, resulting in a relative to complete loss of transgene function remained 
unsolved, especially in the case of replication-deficient retroviruses. On the other hand, 
the issue of proto-oncogene activation by retroviral insertional mutagenesis and 
tumorigenesis has been thoroughly investigated in previous studies with retroviral 
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constructs (Mikkers, Allen et al. 2002; Du, Spence et al. 2005). For these reasons, more 
advantageous methods are required as safer as well as more efficient alternatives 
compared to retroviral vectors.  
1.5.2.2 Lentiviral vectors  
Lentiviral constructs as a modified subclass of retroviruses  have emerged as means to 
provide a durable and permanent expression of transgenes in both germ line and somatic 
cells, including non-dividing ones (Naldini, Blomer et al. 1996; Lois, Hong et al. 2002; 
Nguyen, Oberholzer et al. 2002). Lentiviral vectors may minimize silencing compared 
to retroviruses. Furthermore, random integration of the transgene into the genome, as a 
drawback of retroviruses, is significantly reduced in lentiviruses. In addition, 
tumorigenicity as one of the negative aspects of retroviruses has not been frequently 
reported with lentiviruses (Montini, Cesana et al. 2006; Cattoglio, Facchini et al. 2007). 
This method of genetic modification is used for both experimental research and 
therapeutic purposes. The genome of the virus is in the form of RNA, which is reverse-
transcribed to DNA upon entering the cell. The formed proviruses are able to integrate 
into the host genome and replicate indefinitely. 
 Most currently available lentiviral constructs are based on the second or third 
generation lentiviral vectors, designed for improved safety and infectivity (Sakuma, 
Barry et al. 2012). The second generation transduction methods entail use of the main 
construct, packaging vector, and envelope vector in separate plasmids (Figure 9). 
Packaging plasmids encode the virion proteins, including the reverse transcriptase and 
capsid. The respiratory syncytial virus (RSV) promoter upstream of 5' long terminal 
repeat (LTR) in the lentivector allows efficient production of viral RNA, reducing the 
number of genes from human immunodeficiency virus (HIV)‐1 that are used for 
packaging, replication and transduction to three genes (gag, pol, rev). The envelope 
plasmid encodes a heterologous envelope for vesicular stomatitis virus-G (VSV-G) to 
pseudotype the vector. Furthermore, a deletion in the enhancer of the U3 region of 
3'LTR ensures self‐inactivation of the lentiviral construct after transduction and 
integration into the genomic DNA of target cells. More recently, third generation 
lentiviral vectors have been generated. The four plasmids used to generate these vectors 
are a packaging construct containing only gag and pol genes, a plasmid expressing rev, 
an envelope plasmid (VSV-G), and the main transgene construct (Escors and Breckpot 
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2010; Sakuma, Barry et al. 2012; Schambach, Zychlinski et al. 2013). The third 
generation lentiviral systems are considered to further decrease the biohazard risks of 
transduction systems as well as the risk of insertional mutagenesis. Lentiviral genetic 
material is generated in the packaging cells (Human embryonic kindney (HEK) 293T 
cells) (Figure 9).  
 
 
Figure 9 Mechanism of lentiviral transduction using second generation 
vectors. 
Pseudoviral particles are produced in packaging cells through a combination of the main 
lentivector, packaging vector, and envelope plasmid. Reverse transcriptase and capsid are 
encoded by packaging vector (psPAX2), while envelope is encoded by a separate plasmid 
(pMD2.G). Another vector carries the genetic material, which is transcribed to produce the 
single-stranded RNA demonstrated by ψ (psi) sequence. The produced pseudoviral particles 
are used for the transduction of target cells.  
 
 
1.6  Labeling and purification of embryonic stem cell-derived 
endothelial cells  
The ability to follow and study cell survival, migration and differentiation both ex vivo 
and in vivo is fundamental for the success of cell-based therapies. Some of these 
methods include imaging through nanoparticles (Bhirde, Xie et al. 2011), magnetic 
resonance imaging (Srinivas, Boehm-Sturm et al. 2012), and genome technology 
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engineering methods. The latter includes construction of reporter genes, for instance 
green fluorescent protein (GFP), under the control of a promoter of interest using 
different vector backbones.  
Establishment of ES cell clones with reporter gene expression under the control of 
markers of the undifferentiated state of ES cells has been previously performed 
successfully (Cao, Lin et al. 2006).  In order to study the ES cell-derivatives, it is 
required to design a construct, whereby the reporter gene is activated under a promoter 
of interest upon differentiation. For instance, ES cell-derived ECs require a specific 
reporter gene system, which will be exclusively expressed upon differentiation to ECs. 
On the other hand, cells need to be differentiated into a highly pure population of cells, 
in order to overcome the problem of teratoma formation, as well as differentiation into 
other cell types. Up to now, different techniques have been applied for the purification 
of ES cell-derived ECs. One of these methods is fluorescence activated cell sorting 
(FACS) using antibodies against various endothelial markers (Yamashita, Itoh et al. 
2000; Levenberg, Golub et al. 2002; McCloskey, Lyons et al. 2003). One of the 
disadvantages of mechanical sorting procedures of wild type ES cells based on 
endogenous endothelial markers is the need for an additional labeling process for 
tracking purposes. 
Selection of  ECs based on a drug resistance gene, as well as FACS-sorting of the 
cells based on GFP expression under a specific promoter has also been used, yielding in 
varying and usually relatively low degrees of pure endothelial-like cell populations 
(Marchetti, Gimond et al. 2002; Li, Wu et al. 2007; Kim and von Recum 2009). There 
have been few reports about the selection of cells based on the simultaneous expression 
of antibiotic-resistance genes and GFP under the control of different specific promoters 
using conventional non-viral transfection systems. These studies have been associated 
with the disadvantage of unstable expression of GFP due to gene silencing (Kim and 
von Recum 2010). 
Labeling and selection methods of ES cell-derived ECs shall allow us to study pure 
populations of cells with a high degree of robustness and reliability, and to provide 
means for precise developmental studies and experimental research.  
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1.7  Aims of the project  
Studies on ES cells enable us to address a significant number of unresolved questions 
about regeneration and self-renewal in the human body, as well as development and 
differentiation into adult tissues. Furthermore, these cells serve as an extremely precious 
population for studies on cell-based therapeutic approaches. Endothelial cells are one of 
the target populations derived from ES cells that have gained great interest due to their 
potential use in various diseases originating from vascular lesions. 
As for basic research studies and therapeutic purposes, it is fundamental to track cells 
during their proliferation, development, differentiation, and migration. One of the aims 
of this study was to establish an efficient approach for the generation of an ES cell line 
with specific expression of GFP under the control of the VE-cadherin promoter. This 
eliminates the need for repetitive steps of cell labeling, which should be performed in 
addition to cell purification processes. With the lentiviral system, the issue of silencing 
related to conventional reporter systems is also alleviated. Moreover, it was aimed to 
produce high amounts of a pure population of cells expressing endothelial-specific GFP, 
as a prerequisite for experimental therapeutic applications, as well as developmental 
studies. 
In order to achieve these aims, the underlying objectives were followed:  
 Establishment of optimal growth conditions for ES cells in their undifferentiated 
stage as well as during their  differentiation to ECs 
 Establishment of a lentiviral vector with expression of GFP under the control of 
the VE-cadherin promoter for transduction of ES cells  
 Validation of the generated ES cell line expressing GFP under the control of the 
VE-cadherin promoter using different visualization techniques along with 
molecular methods 
 Utilization of different purification procedures for an efficient selection of ES 
cell-derived ECs 
 Study the purification of ES cell-derived ECs using antibiotic selection 
 Purification of the transgenic ES cell-derived ECs expressing GFP under the 
control of the VE-cadherin promoter based on CD31 as another specific marker 
for ECs  
 Comparing the sorting efficiency using GFP and CD31 in achieving functional 
ECs based on molecular biology and  cell culture methods  
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 Analysis of the pattern of selective endothelial-specific gene expression together 
with stem cells in undifferentiated state and early differentiation in the sorted 
populations over time 
 Definition of a distinct time point for the robust and accurate isolation of ES 
cell-derived ECs based on flow cytometry, gene analysis, and microscopy 
 Culture and analysis of pure ECs with a specific GFP expression in vitro 
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2 Materials and Methods 
2.1  Materials 
2.1.1  Equipment 
Cell counter Neubau chamber (Marienfeld, Germany) 
Cell culture dishes (2.5-, 5-, 10-, and 20-cm) and plates (6-, 12-, 24-, 48-, and 96- well) 
(Greiner Bio One, Germany) 
Cell culture incubator (Nuaire, USA) 
Chamber slides (Thermo Scientific, Germany) 
Cold centrifuge (Thermo Scientific, USA)  
Confocal microscope (Zeiss, Germany)  
Disposable pipettes (2 ml, 5 ml, 10ml, 25 ml, 50 ml) (Greiner Bio-One, Germany) 
Dissecting instruments (F. S. T. Fine Science Tools, Germany) 
Electrophoresis system (Peqlab, Germany) 
Electroporator gene pulser (Biorad, Germany) 
Eppendorf tubes (0.5 ml, 1.5 ml, 2.0 ml) (Eppendorf, Germany) 
FACS machine (BD-Bioscience, Germany) 
Falcon tubes (15 ml and 50 ml) (Greiner Bio-One, Germany) 
Fluorescence micrsocope (Leica, Microsystems, Germany) 
Gel documentation (Intas, Germany) 
Heating block (HLC, UK) 
Heating chamber (Heraeus, UK) 
Incubator shakers (New Brunswick Scientific, Germany) 
Laminar flow (Nuaire, Germany) 
Microwave (Sharp, Germany) 
Microcentrifuge 22 R (Hettich, Germany) 
PCR machine (Eppendorf, Germany) 
Petri dishes (Greiner Bio-One, Germany) 
Pipetboy (Integra bioscience, Germany) 
Pipettes tips: 2; 20; 200; 1000 μl (Eppendorf, Germany) 
Photometer (SmartSpec Plus, Bio-Rad, Germany) 
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RT-PCR machine (Biorad, Germany) 
Special accuracy weighing machine (Denver Instruments) 
Spectrophotometer- Nanodrop (Peqlab, Germany) 
Vacuum pump (KNF lab, USA) 
Vortex machine (VWR, Germany) 
Water bath (Microm, USA) 
Weighing machine (A&D, USA) 
2.1.2 Reagents and chemicals  
100 base-pair DNA ladder (New England Biolabs, USA) 
1 Kb base-pair DNA ladder (New England Biolabs, USA) 
Acetone (Roth, Germany) 
Agarose (USB Corporation, USA) 
ß-Mercaptoethanol (2-ME) (Sigma, Germany) 
DNase I, RNase free (Fermentas, Germany) 
dNTPs (Invitrogen, Germany) 
Dimethyl sulfoxide (DMSO) (Serva, Germany) 
DNA gel loading buffer (Roti®-Load DNA Roth, Germany) 
Ethanol (EtOH) (Roth, Germany) 
Ethidium bromide (EthBr) (Roth, Germany) 
Ethylenediaminetetraacetic acid (EDTA) (Fluka, Germany) 
Glycerol (Sigma, Germany) 
HEPES (PAA, Gemany) 
Isopropanol (Roth, Germany) 
Kalium chloride (Roth, Germany) 
Kalium hydrogen phosphate (Roth, Germany) 
LB-Agar (Lenox) (Roth, Germany) 
LB-Medium (Lenox) (Roth, Germany) 
Methanol (Roth, Germany) 
Mowiol (Sigma Aldrich, Germany) 
n-Buthanol (Roth, Germany) 
Natriumhydrogenphosphat dihydrate (Roth, Germany) 
Paraformaldehyde (Roth, Germany) 
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Random primer (Invitrogen, Germany) 
Reverse transcriptase (RT)-Buffer (Invitrogen, Germany) 
Sodium hydroxide (Roth, Germany) 
Sodium chloride (Roth, Germany) 
Super optimal Broth medium (SOB) (Roth, Germany) 
Sybr Green fluorescein mix (ABgene, Germany) 
Tris (hydroxymethyl) aminomethane (TRIS) base (Roth, Germany) 
Triton X 100 (Roth, Germany) 
Trypan blue (Sigma Aldrich, Germany) 
Tween 20 (Sigma Aldrich, Germany) 
2.1.3 Antibodies  
Table 1 List of primary antibodies  
 
 
 
 
 
 
 
 
 
The secondary antibodies included Alexa-488, -555, and -647 and PE- conjugated    
anti-rat and anti-rabbit antibodies.  
 
 
 
 
 
Antibody 
 
Company 
CD31 rat anti-mouse BD, Germany 
CD34  rat anti-mouse BD, Germany 
copGFP  rabbit anti-mouse Evrogen, Germany 
Dynabeads M280 sheep anti-rat IgG Invitrogen, Germany 
Flk-1 at anti-mouse BD, Germany 
Rat IgG2a,  isotype control BD, Germany 
SMA Clone 1 A 4 AbD serotec, Germany 
Turbo-GFP rabbit anti-mouse Evrogen, Germany 
VE-Cadherin rat anti-mouse 
 
BD, Germany 
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2.1.4 Primers 
Table 2 Primer sequences used for polymerase chain reactions  
Gene Primer sequence  
Brachyury fw  GGA GAG CGA GCT GTG GCT GC (20 bp) 
Brachyury  rev  TGA GGG TGG GAG CTG GCA GG (20 bp) 
CD31 fw  CCC TTG AGC CTC ACC AAG CTC TG (23 bp) 
CD31 rev  TTG GGC CTT CGG CAT GGA ACG (21 bp) 
CD34 fw  CGA GAA GTG AGG TTG GCC CAG G (22 bp) 
CD34 rev  GGG AGC AGA CAC TAG CAC CAG C (22 bp) 
CD45 fw  TGG CCT TTG GAT TTG CCC TTC TGG (24 bp) 
CD45 rev  AAG AGT TGT GAG GCT GGC ACC ATC (24 bp) 
C-kit fw  AGC GTC TTC CGG CAC AAC GG (20 bp) 
C-kit rev  AGC AGC GGC GTG AAC AGA GTG (21 bp) 
c-Myc fw  GCA GAC AGC CAC GAC GAT GCC (21 bp) 
c-Myc rev  GAC CAG TGG GCT GTG CGG AG (20 bp) 
Ephb2 fw  CTA CGA CAG CAA CGG CTG AGC TG (23 bp) 
Ephb2 rev  CCG GAT GAA TTT GGT CCG CAG CC (23 bp) 
Ephb4 fw  TCA GCC AAA GTG AGG CGG CG (20 bp) 
Ephb4 rev  TGC GGA CGC TGT GCT GTT CC (20 bp) 
Flk-1 fw AAA CCT CTT GGC CGC GGT GC (20 bp) 
Flk-1 rev AGG GCT CGA TGC TCG CTG TG (20 bp) 
Id1 fw  CGC CTC AAG GAG CTG GTG CC (20 bp) 
Id1 rev  TGG AAC ACA TGC CGC CTC GG (20 bp) 
Mesdc2 fw  TTG TGC CTT ACG CTG GGC AGT C (22 bp) 
Mesdc2 rev  TGG GGT TCC CAG ACA CGG TGA C (22 bp) 
Nanog fw  CTT GCT CTT TCT GTG GGA AGG CTG C (25 bp) 
Nanog rev  GGC CTG GCT GCT CCA AGT TGG (21 bp) 
Nestin fw  CAG GAG CGC AGA GAG GCG C (19 bp) 
Nestin rev  GGG ATG GGA GTG CTG GCC AAG (21 bp) 
Nos3 fw TGG GTT TAG GGC TGT GCG GC (20 bp) 
Nos3 rev GCC TGG GCA CTG AGG GTG TC (20 bp) 
Oct4 fw  GCC CCA ATG CCG TGA AGT TGG AG (23 bp) 
Oct4 rev  GGG GCC GCA GCT TAC ACA TGT TC (23 bp) 
PBGD fw ATG TCC GGT AAC GGC GGC (18 bp) 
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2.1.5 Restriction endonucleases 
Table 3 List of restriction endonucleases  
 
 
 
 
 
 
 
 
 
All restriction enzymes were purchased from Fermentas, Germany.  
PBGD rev GGT ACA AGG CTT TCA GCA TCG C (22 bp) 
Prox1 fw CAC CCA GCA CCG CAG AAG GAC (21 bp) 
Prox1 rev GCA TGT TGG AGC TGG GGT AGC G (22 bp) 
Sox2 fw  TGC ACT TCG CCC GTC TCG AG (20 bp) 
Sox2 rev  CAG GGC GCT GAC GTC GTA GC (20 bp) 
Sox17 fw TAA ATG GGA GGG AGG GTC ACC ACT G (25 bp) 
Sox17 rev CTA TGG CCA CGG GAC ACG CC (20 bp) 
Sox18 fw ACC GCG CAG CCC CGA ATC (18 bp) 
Sox18 rev CAC GCT TTG CCC AGC ATC TTG C (22 bp) 
SSEA1 fw  ACG CAC GGA TAA GGC GCT GG (20 bp) 
SSEA1 rev  TGC CCA GGG GGA CGA GAA CC (20 bp) 
Tal 1 fw  GGC CGA GCG CTG CTC TAT AGC (21 bp) 
Tal 1 rev  CTG TTG GTG AAG ATG CGC CGC (21 bp) 
Tie1 fw  GCT GCG CTT TGC CAG TGA TGC (21 bp) 
Tie1 rev  ATG GCC ATC CAA CGC ACA GGG (21 bp) 
Tie2 fw  GGG TTA CGG ATG GAT GCC GCC (21 bp) 
Tie2 rev  GCC TCG GTG TTC ACA TGC TCC C (22 bp) 
VE-cadherin fw GCT CTC CAC AAA GCT CGG CCC (21 bp) 
VE-cadherin rev GCC CAG GAA GGC TCC CAA AGC (21 bp) 
Restriction endonuclease Sequence  
BamHI g|gatcc 
ClaI  at|cgat 
MluI  a|cgcgt 
XbaI  t|ctaga 
BspTI  c|ttaag 
EcoRI  g|aattc 
NheI  g|ctagc 
SalI  g|tcgac 
XhoI  c|tcgag 
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2.1.6 Vectors  
Table 4 List of Vectors  
2.1.7 Enzymes used for polymerase chain reactions and cloning  
Table 5 List of enzymes for molecular biology techniques  
 
 
 
 
 
2.1.8 Cell culture reagents 
ß-mercaptoethanol (Sigma-Aldrich, Germany) 
Collagenase B (Roche, Germany) 
DNase I (Roche, Germany) 
Dulbecco’s modified eagle medium containing 4.5 g/l glucose (DMEM) (Invitrogen, 
Germany) 
Fetal bovine serum (FBS) (PAA, Germany) 
Gelatin (Sigma-Aldrich, Germany) 
Heparin (Sigma-Aldrich, Germany) 
Vectors Definition 
 
pGZ-CMV backbone construct 
psPax2 
 
packaging plasmid 
PMD2.G  
 
envelope plasmid 
p-VE-cadherin  (initial vector used for the isolation of the VE-cadherin promoter) 
  
pGZ-VE cadherin generated vector 
 
Enzyme 
 
Company 
MangoMix  
 
 Bioline, Germany 
Pfu Polymerase  
 
Fermentas, Germany 
T4 Ligase  
 
Fermentas, Germany 
Taq Polymerase  
 
Bioline, Germany 
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Iscove’s modified Dulbecco medium (IMDM) with stable glutamine (Biochrom-AG, 
Germany) 
Leukemia inhibitory factor (LIF) (ESGRO®, Germany) 
L-Glutamine, 2mM (Invitrogen, Germany) 
Matrigel (BD, Germany) 
MCDB 131 medium (Sigma-Aldrich, Germany) 
Mitomycin C (Sigma-Aldrich, Germany)  
Non-enzymatic dissociation solution (Millipore, Germany) 
Non-essential amino acids (NEAA) (Invitrogen, Germany) 
Opti-MEM (Invitrogen, Germany)   
PBS Ca & Mg - free (PAA, Germany) 
Penicillin/Streptomycin (Pen/strep) (PAA, Germany)  
Polybrene (Hexadimethrin Bromid) (Millipore; Germany) 
Poly (2-hydroxyethyl methacrylate) (polyHEMA) (Sigma-Aldrich, Germany) 
Sodium pyruvate (PAA, Germany) 
Trypsin-EDTA (Gibco, Germany) 
Vascular endothelial growth factor (VEGF) (Peprotech, Germany) 
Zeocin (invivogen, Germany)  
2.1.9 Cell lines/Cells 
E14Tg2a.4 mouse ES cells 
Endothelioma cells  
HEK 293 T cell line 
Mouse embryonic fibroblasts  
 
2.2  Cell culture techniques  
2.2.1 Preparation of cell culture media, buffers, and solutions  
1% PBST 
1000 µl Triton X-100 +  
100 ml 1x phosphate buffered saline (PBS) 
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10 x PBS 
2g KH2PO4   
12.5g Na2HPO4   
 2g KCl  
 Dissolved in 1 l ddH2O, PH set to 7.4 
 
Collagenase B Solution 
 0.2% Solution in distilled H2O+ 
10 μg/ml DNase I  
 
Differentiation medium  
 IMDM 
15% FBS 
1% NEAA, 1% Pen/Strep 
1mM Pyruvate 
100 μm  ß-Mercaptoethanol 
 
ES cell medium  
Differentiation medium + LIF 1000 U/ml  
 
FACS Buffer 
3 mM EDTA +  
5% FBS in PBS 
 
Freezing medium  
DMEM  
50% FBS  
10% dimethyl sulfoxide (DMSO) 
 
HEK 293T cell Medium 
DMEM  
10% FBS  
1% Pen/Strep 
 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) Buffer  
21.21 g NaCl  
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1.2 g KCl 
0.18 g KH2PO4 
0.24 g Na2HPO4×7H2O   
3 g Glucose     
0.03 g Phenol red  
14.3 g HEPES  
Dissolved in 2.5 L Cell culture water, PH set to 7.3, autoclaved, and stored in the 
fridge.   
 
Mouse embryonic fibroblasts medium (MEF Medium) 
DMEM 
15% FBS 
1% NEAA 
1% Pen/Strep  
 
Mouse endothelioma cells medium (mEndo Mediuhhm) 
MCDB 131  
15% FBS 
1% L-Glutamin  
1% Pen/Strep  
50 μg/ml VEGF 
100 μg/ml Heparin 
 
Medium for the inactivation of mouse embryonic fibroblasts  
(Inactivation medium) 
DMEM  
5% FBS 
1% Pen/Strep 
1% NEAA  
10 μg/ml mitomycin C 
 
Soc Medium 
SOB (Super Optimal Broth, Roth) medium filter sterilized with 
20mM Glucose  
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Tris-EDTA (TE) Buffer 
For 500ml solution:  
5ml 1M Tris pH 8 
1ml 0.5M EDTA pH 8 
496ml dH2O 
Autoclave to sterilize 
2.2.2 Cell culture routine  
All cells were maintained in humidified 37°C incubators provided with 7% CO2 and 
centrifuged at 200 g x 5 min, unless otherwise stated. Except for HEK 293 T cells, all 
culture plates were pre-coated with 0.2 %-0.5% gelatin solution in cell culture water 
(HEK 293 T cells easily adhere to the surface of adhesive culture plates; therefore, no  
substrates are required for plating of these cells). 
2.2.2.1 Thawing 
The frozen cell cryovials were taken from -196°C liquid nitrogen tank and immediately 
thawed in 37°C water bath. The cells were carefully mixed with MEF medium and 
centrifuged at 200 g x 5 min. The cell pellet was subsequently resuspended in an 
appropriate amount of medium for further experiments or culture.  
2.2.2.2 Freezing 
Cells were harvested by trypsinization and pelleted by 200 g x 5 minutes. Afterwards, 
they were carefully resuspended in 500 µl freezing medium and placed in cryovials. The 
vials were immediately transferred to -80°C freezers, and after overnight storage, 
transported to -196°C liquid nitrogen tanks for long-term storage.  
2.2.2.3 Passaging  
When cells reach confluency, they can be passaged on a new culture plate/flask. To 
begin with passaging, the medium was aspirated and cells were thoroughly washed with 
PBS (HEPES buffer for ES cells). Two methods were adopted for passaging: In the first 
method, cells were treated with 0.25% trypsin –EDTA and left in the 37°C incubator for 
1 minute. Following the aspiration of trypsin-EDTA, cells were resuspended in an 
appropriate amount of medium and cultured onto new plates. In the second method, 
cells were kept in the incubator for a longer period after treatment of trypsin-EDTA 
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(approximately 5 minute, or until the cells detached). Subsequently, cells were 
resuspended in 5-times the volume of trypsin in a medium containing 10% serum, 
harvested by centrifugation (200 g x 5 min), and splitted according to the cell density.   
2.2.3 Inactivation of mouse embryonic fibroblasts  
The first passage MEFs were a kind gift from Dr. Sven Becker. These cells had been 
originally isolated from the embryos of the midgestation pregnant mice. The first 
passage MEFs were subcultured to produce the second passage MEFs, which were 
inactivated and used as feeder cells for ES cell culture. To prepare mitotically 
inactivated feeder cells, 2 vials from passage 1 MEFs were thawed on a 145 mm culture 
plate. After reaching confluency, cells were splitted on a total number of 10 culture 
plates (145 mm) over 2 passages. Cells were subsequently treated with inactivation 
medium. After 2-4 hours, they were thoroughly washed, harvested, immediately 
transferred to -80°C for overnight storage, and kept in a liquid nitrogen tank for long 
term. Normally, the 2 initial first passage mouse embryonic fibroblast cryovials gave 
rise to 50 vials of inactivated feeders. Upon demand, feeder cells were thawed and 
plated in ES medium on culture plates pretreated with 0.2% gelatin. One vial should 
generally suffice the coverage of the surface of a 6-well plate. One day after plating, ES 
cells were cultured on feeder cells, which were preconditioned with ES cell medium one 
hour prior to ES cell culture.  
2.2.4 Embryonic stem cell culture  
2.2.4.1 Undifferentiated state  
E14Tg2a.4 cell line obtained from 129P2/OlaHsd mice was used for all ES cell 
experiments. The cells were thawed on a 60mm tissue culture plates pre-coated with a 
layer of inactivated MEFs. Upon confluency, ES cells were splitted with a dilution of 
1:50-1:20 onto 6x35 mm or a 6-well plate pre-coated with inactivated MEFs. Routinely, 
the ES medium was exchanged every day, and ES cells were splitted every second day.  
Too big ES cell colonies, may lead to a decreased pluripotency potential. On the other 
hand, too low ES cell confluencies, may decrease the propagation capacities of the cells. 
In general, ES cells should be splitted when ES colonies reach a confluency of around 
70%.  
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2.2.4.2 Differentiation culture  
Embryonic stem cells start to differentiate upon removal of LIF and feeders. Usually, 
differentiation is induced through the formation of three-dimensional spheroidal 
structures, called EBs. In the current experiments, the method of embryoid body 
formation in suspension was used, which is one the most commonly used methods for 
EB formation. 
Prior to differentiation, MEF depletion was performed by dissociation of ES cells 
and their subsequent plating in differentiation medium (ES cell medium without LIF) 
with a dilution of 1:300 on gelatin-coated plates for 45 minutes. Feeder cells adhere 
more rapidly than ES cells, so that the supernatant contains a high proportion of pure ES 
cells. To form EBs, a total number of 1500000 cells from the supernatant were 
resuspended in 15 mL differentiation medium (100000 cells/mL), transferred onto non-
adhesive 10-cm culture dishes, and incubated on a rotator orbital shaker with a speed of 
25 rpm at 37°C /7% CO2 for 4 days. The medium was exchanged at the 4
th
 day of EB 
formation. For medium exchange, the medium containing EBs was transferred to 50 ml 
Falcon tubes. Embryoid bodies were allowed to settle down in Falcon tubes for 10 
minutes. The supernatant was carefully aspirated and replaced with new medium.  
Afterwards, EBs were either plated on gelatin-coated plates or kept in suspension for 
time course studies. Alternatively, ES cells underwent a predifferentiation stage before 
EB formation. The MEF-depleted ES cells were cultured for 2 days on gelatin-coated 
plates. This stage is suggested to increase the percentage of Flk-1-positive cells.  
2.2.5 In vitro tubule formation assay 
Cells were cultured on matrigel (BD) to test the ability of both dissociated EBs and 
isolated ECs to form vascular tubular structures in vitro. Matrigel coating was 
performed according to the manufacturer's protocol.  
2.2.6 HEK 293 T cells  
HEK 293 T cells were used for the production of pseudoviral particles. These cells were 
cultured on adhesive plates without the need for gelatin pre-coating. HEK 293 T cells 
were thawed, propagated once, and grown to a confluency of 70% before virus 
production.  
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2.2.7 Endothelioma cells  
Mouse endothelioma cells were used for the validation of the pGZ-VE-cadherin 
construct. These cells were cultured on gelatin-coated plates in mouse endothelioma 
medium. The medium was exchanged at least twice a week. Prior to passaging, cells 
were kept in PBS for 15 minutes, in order to facilitate cell detachment.  
 
2.3  Molecular biology techniques  
Molecular biology techniques were used for the construction of transgenes, as well as 
analysis of transgenic cells in both undifferentiated and differentiated stages. 
2.3.1 PCR  
PCR reactions were used for both generation of the transgenes and analysis of the 
bacterial colonies. Mango mix (containing Taq polymerase) was used for the screening 
of bacterial colonies after cloning procedures, while Pfu polymerase was applied for the 
amplification and subcloning of VE-cadherin promoter into the lentiviral vector. The 
VE-cadherin promoter had been previously extracted from the genomic DNA of the 
black six mice by Dr. Sven Becker in our lab and incorporated into a conventional non-
viral vector. In the present experiments, the VE-cadherin promoter (insert) was 
amplified and subcloned into the lentiviral vector. The oligonucleotides that were used 
for this purpose consisted of 36 base pairs: primers (25-base), restriction sites (6 bases), 
and random bases (5 bases) (Figure 10). Cloning was designed using Vector NTI 
program.  
 
Figure 10  Forward and reverse primers used for amplification of VE-cadherin 
promoter  
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VE-cadherin promoter was amplified according to the underlying PCR reaction and 
settings:  
 
PCR protocol  
H2O   36 µL  
10 x Buffer  5 µL   
dNTPs   2 µL  
fw  primer  2.5 µL 
rev primer  2.5 µL  
template DNA 1 µL  
Pfu  polymerase 1 µL  
-------------------------------------- 
Total   50 µL 
 
 
Thermal cycler program 
  
95 ° C  2 min  
------------------------- 
95 ° C  30 s   
59 ° C  30 s    x35 
72 ° C  5 min 30 s 
-------------------------- 
72 ° C  15 min  
-------------------------- 
4 ° C  ∞ 
   
2.3.2 Restriction digestion 
Restriction digestion was used for subcloning of VE-cadherin promoter into the 
lentiviral vector by replacing the cytomegalovirus (CMV) promoter. Restriction 
enzymes were purchased from Fermentas and digestion procedures were done based on 
the manufacturer’s instructions.  A total of 5 µg of vector and 1 µg of insert were used 
in the reactions with 2 restrictions enzymes in a total volume of 30 µl. The reaction has 
been demonstrated on the next page.  
 
 
Insert (VE-cadherin promoter ) 
H2O   9 µL  
1xTango buffer  5 µL   
XbaI    1 µL  
ClaI    1 µL 
template DNA 16 µL  
-------------------------------------- 
Total   30 µL 
Plasmid (pGZ-CMV)  
H2O   22.8 µL  
1xTango buffer  5 µL   
XbaI    1 µL  
ClaI    1 µL 
template DNA 2.2 µL  
-------------------------------------- 
Total   30 µL
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2.3.3 PCR clean-up  
This step was done to purify DNA molecules from dNTPs, salts, and primers after PCR 
and enzymatic digestion reactions. The procedure was performed based on 
manufacturer’s protocol (Qiaquick PCR purification kit). 
2.3.4 Agarose gel electrophoresis 
Agarose gels were prepared by dissolving agarose in Tris EDTA (TE) buffer at 
concentrations of 0.8-2.5%. After adding ethidium bromide, agarose was cooled, and 
gels were poured into casting trays. Electrophoresis was performed in Mupid gel tanks 
at 100-140V in 0.5x TE buffer. The bands were visualized by UV transillumination; 
images were captured using Intas image software.  
2.3.5 Gel extraction 
Nucleic acids were loaded on 0.8%-1% agarose gels. After electrophoresis, bands were 
cut using a sharp scalpel on a transilluminator using QIAquick Gel Extraction Kits 
(Qiagen) and DNA was isolated according to the manufacturer’s protocol. The isolated 
DNA was eluted using 30 μl distilled H20, and subsequently used for ligation.   
2.3.6 Dialysis  
Dialysis was performed after digestion of the amplified insert and gel extraction of the 
vector. This procedure modified DNA purity by decreasing salt concentrations.   
2.3.7 Ligation   
After digestion of the vector and insert with the same enzymes, the compatible ends 
were coupled, using a reaction catalyzed by T4 ligase. This leads to the formation of the 
phosphodiester bond between the free 5'-phosphate und 3'- hydroxy groups. This 
reaction was performed according to the manufacturer’s directions (Fermentas) in a 
total volume of 20 µl. For this reaction, a total amount of 100ng vector DNA with a 
vector/insert molar ratio of 1:3 was used. 
This reaction can occasionally lead to the formation of different products. For 
instance, the vector DNA that is extracted from the gel may be contaminated with non-
digested vector. In some other instances, a re-ligation of the vector DNA may happen. 
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To control these effects, a negative control reaction was assigned. As the negative 
control, a ligation reaction was performed with no insert in the reaction. Ligation was 
performed according to this formula:  
 
Ligation    pGZ-VE construct   Ligation control  
H2O    13.4 µL    14.7 µL  
10x ligation buffer  2 µL      2 µL  
pGZ-CMV (vector)  1.3 µL     1.3 µL  
VE-cadherin promoter (insert)  1.3 µL    0 
T4 DNA ligase    2 µL     2 µL  
----------------------------------------------------------------------------------------------- 
Total    20 µL    20 µL  
 
 
Figure 11 shows a schematic view of the generation of a construct with VE-cadherin 
promoter driving the expression of GFP and a zeocin resistance gene from a lentiviral 
backbone vector with a CMV promoter. 
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2.3.8 Bacterial transformation 
One hundred microliters of Competent XL1-Blue E. Coli (Escherichia coli) bacteria 
were thawed on ice. The XL-1 bacteria are tetracycline resistant and endonuclease 
deficient, leading to an increased quality of DNA samples. Furthermore, these bacteria 
are recombinant deficient, improving the stability of the insert. Twenty microliters of 
Figure 11  Generation of pGZ-VE cadherin construct from pGZ-CMV vector. 
RSV-5'LTR: Hybrid from the promoter of the respiratory Syncytial Virus and long terminal 
repeat, gag: packaging signal, RRE: rev responsive element, cPPT: central polypurine tract; 
copGFP: GFP from Copepodes, Zeo: Zeocin-Resistence gene; WPRE: posttranscriptional 
regulatory element of woodchuck hepatitis virus, Amp: Ampicillin resistence, ori: Start point of 
the Replication, pA: Polyadenylation signal.  
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plasmid DNA was mixed with bacteria on ice. The mixture was then transferred to 
electroporation cuvettes and electroporated at 1.8 kV; 25 μFD; 200 Ohm; capacitance 
extender 250). The transformed bacteria were immediately mixed with 800 µl pre-
warmed Soc medium. After 40 minutes incubation on 37°C heating blocks shaking at 
500 rpm, bacteria were plated on selective LB agar plates containing ampicillin. Agar 
plates were kept overnight in 37°C incubator and checked for growth of bacterial 
colonies. Colonies were picked the next day and checked for accuracy by gel runs. 
2.3.9 Plasmid purification 
Single bacterial colonies were picked from plates and put into growth Luria Broth (LB) 
medium containing 100μg/ml ampicillin on a shaker overnight at 37 °C. Mango mix, 
which contains Taq polymerase, was used for screening of positive bacterial clones. 
Plasmid DNA was isolated by Miniprep (QIAprep Spin Miniprep Kit (Qiagen) 
according to the manufacture’s protocol and the bacteria were frozen in -80°C. The 
Miniprep reactions gave rise to an average of 20µg DNA. Sequences were validated 
using the ABI Prism BigDye Terminator v3.1 Cycle Sequencing system. Maxipreps 
were later prepared from the Minipres, using the NucleoBond® Xtra Maxi Kits 
(Macherey Nagel). This led to the production of an average amount of 1mg total DNA, 
which was stored at -20°C and used for the transduction of ES cells.  
2.3.10 RNA extraction 
RNA isolation was performed using Fermentas kit. Up to 10 million cells were 
trypsinized, washed in PBS, and re-suspended in lysis buffer, which was supplemented 
with ß-mercaptoethanol. The lysates were immediately subjected to RNA isolation 
according to the manufacturer’s protocol. A maximum of 100 µL distilled water was 
used to elute RNA. The eluted RNA concentration was measured using 
spectrophotometer (nanodrop). 
2.3.11 Reverse transcription  
High-capacity cDNA reverse transcriptase kit (Applied Biosystems) with random 
primers was used for reverse transcription, according to the manufacturer’s protocol. A 
minimum of 100n g RNA was used as template. The synthesized cDNAs were either 
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kept at -20 °C or used freshly. A 1:10 dilution of cDNA was used for PCR and qRT-
PCR reactions.  
2.3.12 Quantitative real-time RT-PCR (Sybr Green realtime RT-PCR) 
Sybr Green-based quantitative real-time RT-PCR (qRT-PCR) employs Sybr Green as a 
dye, which emits fluorescence upon binding the double stranded (ds)DNA. The 
intensity of fluorescence correlates with the amount of dsDNA in the reaction. Primers 
were designed using Primer-Blast. All of the primers were designed to have a melting 
temperature of approximately 60°C (59°C-61°C). The amplicon length was 50-250 base 
pairs (bp) and the final primer concentration was 400 nanomolar (nm). To avoid 
amplification of genomic DNA, intron-spanning primers were used.  The other 
inclusion criterion was having a maximum of 1 GC clamp at the 3' end of the primer. 
Reactions were performed in a standard 25μl final reaction mix. As RT-PCR controls, 
the template was replaced with PCR-grade water. The process was performed using a 
standard cycler program. MasterMix was pipetted into 96-well reaction plates to which 
2μL cDNA was added directly. The list of primers is provided in table 2. All 
experiments were performed at least in triplicates. Prism 5 was used for the analysis of 
the qRT-PCR results. Student’s t-test as well as one-way ANOVA with Tukey’s post 
hoc was applied for the statistical analysis. Results are expressed either as ∆Ct or fold 
change in gene expression, using the 2
-∆∆Ct 
method, where ∆∆Ct= (Ct, target – Ct, 
housekeeping gene)population1 – (Ct, target – Ct, housekeeping gene) population2.   
PCR settings for qRT-PCR  
PCR master mix  12.5 µL  
Fw primer   0.5 µL   
Rev primer   0.5 µL  
sterile water   9.5 µL  
cDNA     2 µL  
------------------------------------------------ 
Total    25 µl 
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2.4  Lentiviral transduction  
Lentiviral transduction system is an efficient method for the stable integration of 
transgenes into the genome (Figure 12). The 5' and 3' LTRs promote the transcription 
and polyadenylation of the virion RNA. Central polypurine tract (cPPT) is responsible 
for transporting HIV provirus into the nucleus. The addition of this element between the 
LTRs improves the transduction efficiency. The RSV promoter upstream of the 5' LTR 
allows efficient Tat-independent production of viral RNA, reducing the number of 
genes from HIV-1 in the packaging system. Packaging signal is produced by gag in the 
packaging plasmid. Rev response element (RRE) binds gag and is involved in 
packaging of viral transcripts. Woodchuck hepatitis virus post-transcription regulatory 
element (WPRE) promotes RNA processing and maturation, enhances vector 
packaging, and increases viral titer. The envelope plasmid contains pseudotyping viral 
vectors with VSV-G, enabling the transduction of an extensive range of cell types from 
different species. This constellation makes lentiviral transduction an efficient method 
for transgenesis. Lentiviral transduction consists of 2 consecutive steps: transfection of 
HEK 293 T cells and transduction of target cells.  
2.4.1 Transfection of HEK 293 T cells  
HEK 293T cells were cultured on adhesive plates. After reaching 90% confluency, the 
cells were transfected with the main construct (pGZ-VE-cadherin) together with 
packaging and envelope plasmids, psPax2 and pMD2.G, respectively (Figure 12). Serial 
amounts of DNA were diluted in 400µl serum-free DMEM medium and used for 
transfection optimization. Turbofect (transfection reagent) was added to the respective 
samples, mixed by pipetting, and left at room temperature for 20 minutes. The mixture 
was dropwise added to HEK 293 T cells. Supernatants containing pseudoviral particles 
were collected 48 and 72 hours after transfection. The successive stages of transfection, 
as well as the amounts of DNA and transfection reagent are provided in tables 6 and 7. 
 
 
 
 
 
2 Materials and Methods 
48 
 
 
 
 
 
Figure 12  Vectors used for transfection of HEK 293 T cells; a combination of the 
main construct (pGZ-VE-cadherin), packaging vector (psPax2), and envelope 
vector (pMD2.G). 
 
(A): PGZ-VE-cadherin construct (description in Figure 11). (B): Packaging plasmid CMVenh: 
Cytomegalovirus enhancer; CApro: Chicken beta actin Promotor, CAintron: Chicken beta actin 
Intron, Gag: group antigen, Pro: Protease, Pol: Polymerase; dEnv: envelope proteins including 
the genes for Tat und Rev, RRE: rev response element, pA: Polyadenylation signal, SV40 ori: 
simian virus 40 origin, Amp: Ampicillin resistance gene. (C): Envelope plasmid CMV: 
Cytomegalovirus promoter, VSV-G: Glycoprotein of the vesicular stomatitis virus, pA: 
Polyadenylation signal, Amp:  Ampicillin resistence gene.  
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Table 6 Transfection of HEK 293 T cells and production of pseudoviral 
particles   
 Time Procedure  
Day 1 Seed  HEK 293T cells on plates (Confluency should reach 70%-90% 
by day 2) 
 
Day 2 Combine the main vector/construct, envelope and packaging 
plasmids with serum-free medium and transfection reagent (as in 
table 7)  
Day 3 18 hours post transfection: Check for GFP expression; replace 
medium with high serum medium (50% FBS)  
 
Day 4 24 hours after medium exchange: Harvest virus, Spin at 3000 rpm /5 
min at room temperature; filter through 0.22 µm filters; replace with 
high serum medium (50% FBS) 
Day 5 24 hours after harvest 1: Harvest virus, discard packaging cells, 
freeze the pseudoviral particles at -80°C or use freshly on target 
cells  
 
Table 7 Ratio of vectors and reagent for the transfection of HEK 293 T 
cells with total amounts of 8µg and 18 µg DNA 
8 µg DNA 18 µg DNA 
12  µl Turbofect 25  µl Turbofect 
pGZVE-Cad 
(µg) 
psPAX2 
(µg) 
pMD2.G 
(µg) 
pGZVE-Cad 
 (µg) 
psPAX2 
(µg) 
pMD2.G 
(µg) 
4     2.67 1.33 9 6 3 
The ratio of the pGZ-VE-cadherin: psPAX2: pMD2.G is 3:2:1.  
2.4.2 Transduction of embryonic stem cells 
A total number of 2000 single undifferentiated mouse ES cells were cultured in 500µl 
ES medium containing double concentration of LIF on a 24-well plates and transduced 
with a total amount of 8µg and 18µg virus DNA and 16 µg/ml polybrene. After 12 
hours, ES cells were subcultured onto 10-cm feeder-coated plates and left at 7% CO2 
incubator for 5-7 days to grow to ES cell colonies.   
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2.4.3 Clone picking  
After the ES cells had grown to confluent colonies, 192 ES colonies were picked, 
dissociated with trypsin, and cultured onto MEF-coated 96-well plates. After reaching 
confluency, ES cells were passaged onto duplicate MEF-coated 96-well plates. Half of 
the cells were frozen at -80°C, and the rest were grown on gelatin-coated plates in ES 
differentiation medium as the predifferentiation stage. Two days later, cells were 
dissociated with trypsin and transferred to polyhema-coated 96-well plates to form EBs. 
At day 4, EBs were cultured on gelatin-coated 96-well plates with 5ng/mL VEGF. After 
2 days, clones were selected based on the appearance of GFP-positive vessel-like 
structures, using high throughput screening with a fluorescence microscope. The GFP-
positive ES cell clones that were kept in liquid nitrogen were then thawed and 
propagated and the rest were discarded. A total number of 24 clones out of the 192 
frozen clones were positive for GFP-positive vessel-like structures. The positive clones 
were propagated on 10cm plates, harvested, and frozen in liquid nitrogen for further 
experiments.  
2.4.4 Safety measures  
In addition to the safety consideration in designing the vector to neutralize the 
infectivity of HIV particles, the following measures were taken to decrease the risk of 
contamination with pseudoviral particles: Wearing double gloves and lab coat was 
mandatory. The work was performed in a special S2 lab with Class II laminar flow 
hood. Care was taken to minimize the creation of splashes or aerosols. Work surfaces 
were decontaminated at least twice a day and after any spill of viable material. All 
cultures, stocks, and other regulated wastes were decontaminated before disposal by 
autoclaving. Materials were kept in a durable, leakproof, properly marked and sealed 
waste.  
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2.5  Immune-based techniques 
2.5.1 Immunohistochemistry  
Immunofluorescence staining was carried out using different primary antibodies and 
Alexa fluor-conjugated secondary antibodies. Whole EBs as well as dissociated EBs 
were washed with 0.01% PBST, fixed in ice-cold methanol or 4% PFA, and 
permeabilized using 0.1% Triton X. Cells were washed with 0.01% PBST and 
incubated in 10% goat serum in 0.01% PBST for 1 hour at room temperature as the 
blocking step. Primary and secondary antibodies were diluted in the blocking solution. 
The dilution of the primary antibodies was as follows: VE-cadherin (BD), CD31 (BD), 
Flk-1 (BD): 1:100; α-SMA (Sigma): 1:500; anti-TurboGFP (Abcam) and anti-cop-GFP 
(Evrogen): 1:1000. Cells were incubated in primary antibody solution either for 3 hours 
at room temperature or overnight at 4°C. Secondary antibody incubation was performed 
under dark conditions in room temperature for 1 hour with a dilution of 1:500. 
Secondary antibodies included anti-rat and anti-rabbit antibodies conjugated with Alexa 
fluor -488, -555, and -647 (all BD). Nuclear counterstaining was carried out using Sytox 
blue (Life Technologies), Draq-5 (eBiosciences) and DAPI (Life Technologies) with a 
dilution of 1:1000 for a maximum of 20 minutes at room temperature. Cells and EBs 
were mounted using Mowiol. Samples were analyzed using Zeiss confocal and Leica 
fluorescence microscopes. 
2.5.2 Flow cytometry  
2.5.2.1 Analysis of cell populations  
Whole EBs were dissociated using 0.05% trypsin/0.2mM EDTA, non-enzymatic cell 
dissociation solution, or collagenase B (0.3 PZ U/ml) at 37°C supplemented with DNase 
(0.01 mg/mL; Sigma). All the next steps were performed on ice. Dissociated cells were 
passed through 40 µm cell strainers, washed with FACS buffer, and blocked with 10% 
FBS in FACS buffer for 30 minutes on ice. A total number of 500000 cells were treated 
with primary antibody with a dilution of 1:100 in 100 µL of blocking solution and 
incubated on ice for 30 minutes. Cells were afterwards washed with FACS buffer by 
cold centrifugation at 1000 rpm for 5 minutes. Subsequently, cells were incubated in 
100µL of blocking solution containing secondary antibodies with a dilution of 1:500 for 
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another 30 minutes. Secondary antibodies were coupled to fluorophors, which were 
identified and analyzed using the FACS machine. Cells were washed with FACS buffer 
3 times using cold centrifuge at 1000rpm for 5 minutes before the analysis. IgG staining 
and unstained populations were regarded as control. FACS analysis was performed 
using FACS LSR II machine (BD). 
2.5.2.2 Cell sorting  
EBs were dissociated as discussed in the previous section. Single cells were sorted to 
GFP-positive and -negative populations using FACS Aria sorter. Wild type EBs were 
used to set parameters for GFP expression in each stage. Dead cells were excluded pre-
and post-sorting using Topro-3 staining. Sorted cells were separated, counted, and later 
used for culture as well as direct RNA analysis.   
2.5.3 Sorting based on magnetic beads 
2-12 day old EBs were dissociated using collagenase B (0.3 PZ U/ml) and DNase 
(0.01mg/mL-Sigma) on a shaker in 37°C for 40 minutes. Subsequently, cells were 
washed in HEPES buffer by centrifugation at 1000 rpm for 5 minutes. The pellet was 
resuspended in HEPES buffer, passed through 40 µm cell strainers, and blocked in FBS. 
Afterwards, the cell suspension was filled up to 10ml with 0.3% BSA in PBS. After 
counting, cells were pelleted and resuspended in FBS with a final concentration of 
1×10
6
/100μl.  CD31 antibody (BD) was added according to the manufacturer’s protocol 
(4μl solution/1×106 cells) and cells were incubated on ice for 20 minutes. After washing, 
cells were resuspended in 500μl buffer and incubated with 25μl sheep anti-rat secondary 
antibody conjugated with magnetic beads (Dynal beads, BD) on a shaker in 4°C. The 
cells were subjected to a strong magnetic field and selected after several stages of 
washing. The negative and positive isolated cells were either directly cultured or used 
for further RNA analyses. 
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3 Results  
3.1  Culture and differentiation of embryonic stem cells  
Embryonic stem cells were cultured on inactivated MEFs in medium containing LIF 
(Figure 13 A). In the absence of LIF, ES cells differentiate and form homogenous EBs 
in suspension culture (Figure 13 B).  
   
Figure 13 Undifferentiated and differentiated states of embryonic stem cells  
(A): Embryonic stem cell colonies grown in the presence of leukemia inhibitory factor on 
inactivated mouse embryonic fibroblasts. (B): Day 3 embryoid bodies grown in suspension 
culture in the absence of leukemia inhibitory factor and inactivated mouse embryonic 
fibroblasts. Bar size represents 100 µm in A und 150 µm in B.  
 
Embryoid bodies spontaneously developed vessel-like structures upon plating on 
gelatin-coated culture dishes. The expression of EC markers such as Flk-1, CD31 and 
VE-cadherin was assessed using immunofluorescence microscopy (Figure 14 A-F). As 
shown in the figures, α-SMA, which is a marker of myofibroblasts, is also markedly 
expressed in the plated EBs. 
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Figure 14 Characterization of different endothelial cell markers in embryoid 
bodies day 4 plated for 4 additional days in differentiation medium on gelatin-
coated plates 
(A): VE-cadherin (red); (B): VE-cadherin (red) merged with α-SMA (yellow) and nuclear 
counterstaining with Sytox-blue (blue). (C): CD31 (red) (D): CD31 (red) merged with α-SMA 
(yellow) and nuclear counterstaining with Sytox-blue (blue). (E): Flk-1 (red); (F): Flk-1 (red) 
merged with α-SMA (yellow) and nuclear counterstaining with Sytox-blue (Blue).  Bar sizes 
represent 50 µm.  
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3.2  Validation of the functionality of GFP expression in the 
backbone lentiviral  pGZ-CMV vector  
The backbone lentiviral construct expressed GFP and a zeocin resistance gene under the 
control of the CMV promoter (pGZ-CMV vector). To investigate the functionality of 
this vector in driving GFP expression in ES cells upon differentiation, HEK 293 T cells 
were infected using pGZ-CMV vector, together with the packaging and envelope 
plasmids. Pseudoviral particles were used to transduce ES cells. After transduction, EBs 
were derived from ES cells and were monitored for GFP expression (Figure 15). At the 
initial stages of EB formation, a robust GFP expression under the control of the CMV 
promoter could be detected (Figure 15 A). Over time, GFP expression was reduced 
(Figure 15 B), most probably as a result of silencing and/or the dominant 
autofluorescence in the older transgenic EBs.  
 
    
Figure 15 Assessing GFP expression in embryoid bodies derived from 
embryonic stem cells that were transduced with pGZ-CMV vector 
(A) CMV-GFP+ embryoid bodies day 4; (B) CMV-GFP+ embryoid bodies day 10. Bar sizes 
represent 150 µm in A and 200 µm in B.  
 
3.3  Validation of the pGZ-VE-cadherin construct and 
optimization of transduction conditions  
To validate the generated, lenitiviral-based pGZ-VE-cadherin construct and to optimize 
the transduction conditions, different amounts of DNA were used for the infection of 
HEK 293 T cells and subsequent transduction of MEFs and mouse endothelioma cells, 
as negative and positive control, respectively. Transduction efficiency was tested in the 
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presence and absence of polybrene. Mouse endothelioma cells transduced with the 
construct showed the strongest GFP expression, when a total amount of 8µg DNA (4µg 
pGZ-VE-cadherin, 1.33µg envelope plasmid and 2.67µg packaging plasmid) in the 
presence of polybrene was used. In contrast, transduced MEFs showed virtually no GFP 
expression, thus confirming the specificity of the transgene (Figure 16 A, B). 
 
 
Figure 16 GFP expression in mouse embryonic fibroblasts (MEFs) and mouse 
endothelioma cells transduced with the pGZ-VE-cadherin construct 
(A) MEFs as negative control; (B) mouse endothelioma cells as positive control. Scale bars 
represent 100 µm.  
 
3.4  Transduction of embryonic stem cells with the pGZ-VE-
cadherin construct and visualization of the GFP-positive 
vessel-like structures  
The optimized conditions were applied to transduce single ES cells with pseudoviral 
particles produced by HEK 293T cells. Following transduction, 192 ES colonies derived 
from single ES cells were picked carefully and directed to differentiation. EBs were 
monitored based on the intensity of GFP expression and the visualization of vessel-like 
structures. From day 8 of differentiation, GFP-positive vessel-like structures started to 
appear. Before plating, GFP was expressed in the center of the EBs, while after plating 
of EBs on gelatin-coated plates and their treatment with 5ng/mL VEGF, GFP was 
expressed in the sproutings inside and around the EBs. From day 6 differentiation on 
gelatin-coated plates, 12.5% of the clones showed GFP-positive vessel-like structures. 
One of the clones displayed the highest level of GFP expression in association with 
vessel-like structures and the highest survival capacity in culture (Figure 17 A-D) and 
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was thus used in all the subsequent experiments. Figure 17 D shows the tubular 
structures derived from dissociated EBs originating from this clone, which were re-
plated on matrigel. The image was taken 48 hours after culture of the cells.   
 
Figure 17 GFP expression in mouse embryoid bodies (EBs) derived from mouse 
embryonic stem (ES) cells transduced with the pGZ-VE-cadherin construct both 
in suspension culture and plated on gelatin 
Mouse ES cells were transduced with a total amount of 8 µg DNA in the presence of polybrene. 
EBs at differentiation day 4 (bright field (A), GFP channel (B)) and EBs at differentiation day 6 
plated for 2 additional days on gelatin-coated plates (C) are shown. (D): Vascular tube 
formation assay in day 6 dissociated EBs cultured on matrigel for 2 additional days. Scale bars 
represent 100 µm in A and B, 50 µm in C and 20 µm in D. 
 
3.5  Characterization of the GFP-positive embryonic stem cell-
derived endothelial cells in both whole plated bodies and 
dissociated state   
3.5.1 Whole embryoid bodies 
In order to investigate the co-expression of GFP and vascular markers in ES cell-
derived vascular structures, immunofluorescence staining was performed on plated EBs 
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at day 8 of differentiation.  Figure 18 (A-F) shows the co-expression of GFP with VE-
cadherin, as well as with CD31, in plated whole EBs at differentiation day 8.  
 
Figure 18 Co-localization of GFP and endothelial cell markers in vascular 
structures observed in plated embryoid bodies that were derived from transgenic 
embryonic stem cells 
(A-C): Co-localization of GFP (A) and VE-cadherin (B) in day 4 whole embryoid bodies plated 
on gelatin-coated culture dishes for 4 additional days in the presence of 20ng/mL VEGF; 
merged figures counterstained with Sytox blue (C). (D-F): Co-localization of GFP (D) and CD31 
(E) in day 4 whole EBs plated on gelatin-coated culture dishes for 4 additional days in the 
presence of 20ng/mL VEGF; merged figures counterstained with Sytox blue (F).Scale bars 
represent 100 µm.  
3.5.2 Dissociated embryoid bodies  
In order to study ES cell-derived ECs as single cells while preserving cell surface 
expression of VE-cadherin to the utmost, EBs were dissociated utilizing different 
dissociation solutions.  Some of the dissociation solutions such as accutase and EDTA-
based dissociation solutions led to a great loss of the surface markers upon dissociation. 
Conversely, collagenase B resulted in the highest degree of surface marker preservation 
compared to other tested solutions, and was therefore used together with DNase for 
single cell-dissociation of EBs (Figure 19). After dissociation, EBs were re-seeded on 
gelatin-coated plates. A high association of GFP with VE-cadherin and CD31 localized 
to tube-like structures was noted in the dissociated and re-seeded EBs (Figure 20, A-F). 
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Figure 19 Expression patterns of endothelial markers upon dissociation of day 5 
embryoid bodies with different dissociation solutions 
(A): Collagenase B; (B): Accutase; (C): Non-enzymatic cell dissociation solution. Red: IgG 
Isotype control; Yellow: VE-cadherin; Blue: Flk-1; Dark Green: VE-cadherin positive control; 
Bright green: Flk-1 positive control.  
 
 
 
Figure 20 Co-localization of GFP and endothelial cell markers in vascular 
structures observed in dissociated and re-plated embryoid bodies derived from 
transgenic embryonic stem cells 
(A-C): Co-localization of GFP (A) and VE-cadherin (B) in day 5 dissociated EBs plated on 
gelatin-coated culture dishes for 4 additional days in the presence of 20 ng/mL VEGF; merged 
figures counterstained with Sytox blue (C). (D-F): Co-localization of GFP (D) and CD31 (E) in 
day 5 dissociated EBs plated on gelatin-coated culture dishes for 4 additional days in the 
presence of 20ng/mL VEGF; merged figures counterstained with Sytox blue (F). Scale bars 
represent 25 µm in A-C and 100 µm in D-F. 
 
3 Results 
60 
 
3.6  Selection and characterization of GFP-positive cells 
representing endothelial cells  
3.6.1 Treatment of cells with antibiotic (zeocin)  
As the generated construct also expressed a zeocin resistance gene under the control of 
the VE-cadherin promoter, it was next attempted to select GFP-positive cells by treating 
the EBs derived from transgenic ES cells with different concentrations of zeocin.  
However, even with a concentration as high as 1 mg/mL, fibroblasts/myofibroblasts 
were not completely eliminated and the transgenic cells representing ECs appeared to 
be unhealthy with only weak GFP expression (Figure 21). Therefore, I opted for other 
methods which facilitated a more efficient selection. 
 
Figure 21 Treatment of cultured dissociated embryoid bodies expressing GFP 
and a zeocin resistance gene with different concentrations of  zeocin 
(A): Dim and temporary expression of GFP (green) as well as α-smooth muscle actin (yellow) in 
dissociated embryoid bodies at differentiation day 10 (2 days after treatment with 400 µg/ml 
zeocin). (B): Even with concentrations as high as 1 mg/mL some fibroblasts were still present in 
culture.  
3.6.2 Flow cytometric analysis of the GFP-positive cells 
representing endothelial cells  
In preparation for immune-based sorting of ECs, a time-course expression analysis of 
GFP, CD31, and the hematopoietic marker CD34 was performed in transgenic EBs at 
differentiation days 2.5-12 (Figure 22). There was some expression of GFP and CD31 
in day 2.5 EBs, which did not represent a distinct population. Day 6 represented the 
highest number of CD31-positive cells (30%). On day 8, a GFP- and CD31-double 
positive population became distinct. Afterwards, the expression of both GFP and CD31 
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decreased significantly. Distinct CD34 expression became evident from day 10. Only a 
small population of these cells co-expressed GFP (2.15%) ( Figure 22).  
 
Figure 22 Flow cytometric time-course analysis of GFP, CD31 and CD34 in 
embryoid bodies (EBs) derived from transgenic embryonic stem (ES) cells 
at differentiation days 2.5-12 
In the top left corner, the negative and positive controls for GFP are demonstrated (wild 
type EBs and lentivirally-transduced EBs with a CMV-GFP construct, respectively). Top 
panel: Pattern of GFP expression in EBs day 2.5 to day 12, expressing GFP under the 
control of the VE-cadherin promoter. Middle panel: Pattern of CD31 versus GFP 
expression in EBs day 2.5 to day 12, expressing GFP under the control of the VE-
cadherin promoter. Bottom panel: Pattern of CD34 versus GFP expression in EBs day 
2.5 to day 12, expressing GFP under the control of the VE-cadherin promoter.  
 
3.7  Sorting of dissociated EBs expressing GFP under the 
control of the VE-cadherin promoter  
3.7.1 GFP-sorting  
After profiling the endothelial markers at different stages of the differentiation of EBs, 
cells were sorted on different stages of EB development based on GFP expression using 
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a flow cytometer. As the highest percentage of GFP-positive cells was at day 8, sorted 
cells on day 8 were used for RNA isolation and subsequent expression analyses of 
endothelial-specific markers. GFP-positive cells demonstrated a significantly higher 
expression of the majority of the investigated EC markers compared to the GFP–
negative population (Figure 23). However, after a few days in culture, cells were weak 
and fragile, so that their maintenance for an extended period of time was not possible.  
 
 
 
 
 
 
 
 
 
 
Figure 23 Gene expression analysis in GFP-sorted transgenic embryoid bodies  
Transgenic embryoid bodies (EBs) at day 8 of differentiation were sorted based on GFP 
expression and subjected to gene expression analyses of endothelial cell-specific markers. 
Results are represented as ∆CT values for the GFP-positive (closed columns) vs. –negative 
(open columns) populations. PBDG served as the housekeeping gene. Data are presented as 
mean ± SD. Results were assessed for statistical significance using student’s t-test **P < 0.01, 
***P < 0.001.  
3.7.2 CD31-sorting 
In the next step, magnetic beads were used for the selection procedure based on CD31 
expression at different stages of EB development (days 2-8). The dissociated cells were 
first treated with rat CD31 antibody, and in the second step coated with sheep anti-rat 
secondary antibody conjugated with magnetic beads.  Afterwards, the tubes containing 
cell solution were transferred into a strong magnetic field and the CD31-positive cells 
were selected. Figure 24 demonstrates the CD31-selected cells conjugated with 
magnetic beads in culture.  
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Figure 24 CD31-positive cells derived from dissociated embryoid bodies 
expressing GFP under the control of the VE-cadherin promoter  
The isolation was performed based on magnetic beads. The images represent the sorted 
CD31+ cells after 2 days in culture.  Bar sizes represent 100 µm in A and 50 µm in B.   
 
3.8  Gene analysis of the transgenic embryonic stem  cell-
derived embryoid bodies expressing GFP under the control 
of  the VE-cadherin promoter based on CD31 
qRT-PCR reactions were performed on CD31-positive vs. CD31-negative populations 
for different markers expressed early and late during the course of differentiation of ES 
cells to ECs with an endothelial-specific GFP expression (Figure 25). 
 From day 3 on, the known vasculogenesis transcription factors such as c-kit and 
Tal1 showed an increased expression in the CD31-positive vs. CD31-negative 
populations. Additionally, many other EC markers along with genes involved in the 
development of ECs were expressed to a higher degree in CD31-positive vs. CD31-
negative populations. Most pronounced gene fold increases were noted for VE-
cadherin, Tyrosine kinase with immunoglobulin-like and EGF-like domains (Tie)2, and 
Sox18. On day 4, the biggest fold increase in endothelial-specific gene expression in the 
CD31-positive vs. CD31-negative population was observed for Tie-1, followed by Tie-2 
and Tal 1 (Figure 25 C). From day 6 on, all the investigated earlier and late stage EC 
differentiation markers, as well as transcription factors of vascular development were 
markedly higher in CD31-positive vs. CD31-negative populations. The highest gene 
fold increase was noted for Tie-1 (43.9 fold) followed by Sox18 (39.9 fold), VE-
cadherin (27.7 fold), and Nitric oxide synthase (Nos)3 (25.8 fold). These differences 
became more pronounced at day 8 of differentiation with Nos3 and VE-cadherin 
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representing a 604-fold and a 565-fold increase in CD31-positive vs. CD31-negative 
populations, respectively (Figure 25 D and E).  
In these studies, the pattern of expression of 2 markers of hematopoietic cells namely 
CD34 and CD45 in the CD31-positive vs. CD31-negative population was also 
examined. The results showed a decrease in the fold gene expression of CD45 on day 8 
in the CD31-positive vs. CD31-negative population, along with the specification to ECs. 
CD34 showed a trend to an increased gene fold expression in later days. A markedly 
increased expression of this marker in the CD31-positive vs. CD31-negative population 
could be expected in the later days of differentiation (from day 10), based on the later 
overall expression of CD34 (Figure 22) according to a later commitment to 
hematopoietic cells. 
Compared to the GFP-positive population, the expression of most of the studied 
endothelial markers was slightly higher in the CD31-positive population at the same 
time point (Figure 25 F).  
 
 
Figure 25 Gene expression analysis in CD31-sorted transgenic embryoid bodies 
(EBs)  
(A, B): Transgenic EBs at days 2 (A) and 3 (B) of differentiation were sorted based on CD31 
expression and subjected to gene expression analyses of endothelial cell specific markers. 
Results are expressed as n-fold change in gene expression in the CD31-positive vs. CD31-
negative populations using the 2
-∆∆Ct
 method, where ∆∆Ct= (Ct, target – Ct, housekeeping 
gene)CD31pos – (Ct, target – Ct, housekeeping gene)CD31neg.  PBDG served as the housekeeping 
gene. 
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Figure 25 (continued) Gene expression analysis in CD31-sorted transgenic 
embryoid bodies (EBs)  
(C-F): Transgenic EBs at day 4 (C), 6 (D), and 8 (E) of differentiation were sorted based on 
CD31 expression and subjected to gene expression analyses of endothelial cell specific 
markers. Results are expressed as n-fold change in gene expression in the CD31-positive vs. 
CD31-negative populations using the 2
-∆∆Ct
 method, where ∆∆Ct= (Ct, target – Ct, housekeeping 
gene)CD31pos – (Ct, target – Ct, housekeeping gene)CD31neg. (F): N-fold change in gene 
expression of endothelial cell specific markers in the CD31-positive vs. GFP-positive 
populations as assessed by the 2
-∆∆Ct
 method.  PBDG served as the housekeeping gene.  
 
Next, the time course expression of EC surface markers in the CD31-positive 
population regardless of the CD31-negative population was evaluated. The expression 
of Flk-1, Tie-2, Tie-1, and VE-cadherin increased in the CD31-positive populations 
over time. The surge in the expression of Flk-1, Tie-2, and VE-cadherin happened from 
day 2 to day 3 (Figure 26 A). A second surge in the expression of VE-cadherin occurred 
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from day 6 to 8. For Tie-1, there was a tendency for increased expression in later stages 
as compared to the earlier stages of EC differentiation. 
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Figure 26 Time course gene expression analysis in the CD31-positive cell 
population 
The CD31-positive cell population derived from transgenic EBs at days 2-8 of differentiation was 
subjected to gene expression analyses of (A) endothelial cell surface markers and (B) 
transcription factors of vasculogenesis Results are expressed as ∆CT values. PBDG served as 
the housekeeping gene. Data are presented as mean ± SD. Results were assessed for 
statistical significance using one-way ANOVA with Tukey's multiple comparison test *P < 0.05, 
**P < 0.01, ***P < 0.001).  
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Figure 26 (continued) Time course gene expression analysis in the CD31-positive 
cell population 
The CD31-positive cell population derived from transgenic EBs at days 2-8 of differentiation was 
subjected to gene expression analyses of (C) markers that characterize particular vessel types. 
Results are expressed as ∆CT values. Data are presented as mean ± SD. PBDG served as the 
housekeeping gene. Results were assessed for statistical significance using one-way ANOVA 
with Tukey's multiple comparison tests *P < 0.05, **P < 0.01, ***P < 0.001.  
 
The transcription factors involved in vasculogenesis showed a distinct pattern of 
expression (Figure 26 B). C-kit showed a sharp increase in expression from day 2 to 3 
and from day 6 to 8 after a down-regulation in the intermediate phase. Tal-1 was up-
regulated up to day 4, following by a steady decrease in expression in the later stages. 
Id1 showed a pattern comparable to c-kit with the highest expression level on day 4. 
Additionally, some markers characterizing particular vessel types (arterial vs. venous vs. 
lymphatic) such as EphB4, Nos3, Prox1, Sox17 and Sox18 were examined. These 
markers demonstrated a higher overall expression in the CD31-positive vs. CD31-
negative population. EphB4 showed a significantly increased expression from day 3 
compared to day 2. Following a sharp down-regulation of Nos3 at day 3, there was an 
increasing expression in the later days of differentiation in the CD31-positive 
population, with the highest level on day 8. The expression of Prox1, as a marker of 
lymphatic ECs, decreased on days 3 and 4 and later again slightly increased, while the 
expression of Sox17 decreased from day 3 and stayed at a low level during the later 
differentiation days in the CD31-positive population (Figure 26 C).  
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Eventually, the time course expression of markers of the undifferentiated state of ES 
cells and early differentiation genes in the isolated CD31-positive population as well as 
in comparison to the CD31-negative population at various differentiation stages was 
dissected (Figures 27 and 28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 Gene expression analyses in CD31-sorted transgenic embryoid bodies 
(EBs) for embryonic stem cell markers as well as markers of early differentiation 
Time course gene expression analysis in the CD31-positive cell population The CD31-positive 
cell population derived from transgenic EBs at days 3, 6, and 8 of differentiation was subjected 
to gene expression analyses of (A) markers of the undifferentiated state of ES cells, and (B) 
early differentiation genes. Results are expressed as ∆CT values. PBDG served as the 
housekeeping gene. Data are presented as mean ± SD. Results were assessed for statistical 
significance using one-way ANOVA with Tukey's multiple comparison tests *P < 0.05, **P < 0.01, 
***P < 0.001.  
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The expression of markers of the undifferentiated state such as Sox2, Oct-4, Nanog, 
and c-Myc decreased from the early to the later stages of development (day 3 to 8; 
Figure 27 A). The expression of some of the examined early differentiation markers 
such as snail, nestin, and GATA4 showed a statistically significant down-regulation in 
the later differentiation days in the CD31-positive population (Figure 27 B). The pattern 
of expression of these markers was also evaluated at different time points in CD31-
positive vs. CD31- negative populations (Figure 28). Except for c-Myc, day 8 of 
differentiation represented a lower level of expression of all these markers in CD31-
positive vs. CD31-negative populations underscoring the rather mature typical, 
endothelial-like characteristics of the CD31-positive versus CD31-negative population 
at that time point as compared to the earlier stages of development, where CD31 may 
also be present in non-ECs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28  Difference in the expression of markers of the undifferentiated state and early 
markers of differentiation in the CD31+ (closed columns) vs. CD31- (open columns) at 
differentiation day 8 
Results are expressed as ∆CT values. PBDG served as the housekeeping gene. Data are 
presented as mean ± SD. Results were assessed for statistical significance using student’s t-
test.  *P < 0.05, **P < 0.01. NS: Not significant.  
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3.9  Culture of sorted cells  
According to flow cytometry, day 8 represented a distinct population with the highest 
percentage of cells co-expressing CD31 and GFP (Figure 22). qRT-PCR confirmed a 
markedly higher expression of EC-specific markers on days 6 and 8 in the CD31-
positive vs. CD31-negative populations (Figure 25). EB with endothelial-specific GFP 
expression were sorted and cultured at differentiation days 6 and 8 based on CD31 
expression.  
  
 
Figure 29 Culture of CD31-positive cells derived from EBs at differentiation day 8 
on matrigel 
(A): GFP; (B): VE-cadherin; (C): Nuclear counterstaining with draq 5; (D): Merged figures. Cells 
were treated with 20 ng/mL VEGF. Scale bars represent 20 µm.  
 
Embryoid bodies that were sorted on day 8 and cultured on matrigel contributed to 
sproutings with GFP and VE-cadherin co-expression, rather than forming a cobblestone 
morphology (Figure 29). Embryoid bodies that were sorted and cultured on day 6 
developed a characteristic EC cobblestone morphology, co-expressed GFP and different 
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endothelial markers, and contributed to a high-purity EC culture (Figure 30 A-L). These 
cells were passageable and maintained a good level of GFP expression in the next 
passages. 
 
 
 
Figure 30 Isolation of CD31-positive cells derived from EBs on differentiation day 
6 and their culture on gelatin-coated plates 
(A): GFP; (B): Flk-1; (C): Nuclear counterstaining with draq 5; (D): Merged figures. Cells were 
treated with 20 ng/mL VEGF. Scale bars represent 20 µm.  
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Figure 30 (continued) (E): GFP; (F) VE-cadherin; (G) nuclear counterstaining with draq 5; 
(H) Merged figures.  Cells were treated with 20 ng/mL VEGF. Scale bars represent 50 µm. 
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Figure 30 (continued) (I) GFP; (J) VE-cadherin; (K) Nuclear counterstaining with draq 5; (L) 
Merged figures. Cells were treated with 20 ng/mL VEGF. Scale bars represent 20 µm. This 
image is the magnification of the image on the previous page, representing a pure group of GFP 
-labeled cells in a cobblestone structure, typical of ECs.  
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Endothelial cells isolated on day 6 also eventually contributed to tube-like structures 
(Figure 31).  
 
 
 
Figure 31 Formation of GFP-positive tube-like structures in CD31-positive cells  
(A): GFP; (B): VE-cadherin; (C): Nuclear counterstaining with draq 5; (D): Merged figures. Cells 
were treated with 20ng/mL VEGF. Scale bars represent 20 µm.
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4 Discussion  
Embryonic stem cells are established from the inner cell mass of blastocysts (Evans and 
Kaufman 1981; Martin 1981) and when grown in the presence of LIF, form pluripotent 
ES cell colonies (Hirai, Karian et al. 2011). Upon LIF removal, ES cells spontaneously 
differentiate into three-dimensional structures, termed embryoid bodies, which contain 
derivatives of the three primitive germ layers and are a potential source for all ES cell 
lineages (Keller 1995; Murry and Keller 2008). 
Embryoid bodies contain blood island- and vascular-like structures, mimicking 
vasculogenesis and angiogenesis in the embryo. These three-dimensional structures are 
one of the most commonly used means for the development of ES cell-derived ECs 
(Risau, Sariola et al. 1988; Wang, Clark et al. 1992; Kim, Kim et al. 2008). Embryonic 
stem cells can serve as an abundant source for functional ECs both in progenitor and 
mature stages with applications in regenerative medicine (Huang, Niiyama et al. 2010), 
vascular developmental studies (Glaser, Gower et al. 2011), as well as drug discoveries 
(Kim, Bae et al. 2012). The structure of EBs is an amalgam of different cell types, 
which interferes with the aforementioned applications. In this study, a lentiviral-based 
construct was generated, with the promoter of VE-cadherin as a specific EC marker 
(Vestweber 2008) driving the expression of GFP and a zeocin resistance gene for 
labeling and selection purposes. Thereafter, the functionality of the transgenic cells in 
developing vascular structures was examined. To obtain a pure EC population, as well 
as to dissect the EC gene profile on different days of EB differentiation, the cell 
populations were purified based on CD31 expression, as another specific marker for 
ECs (Ilan and Madri 2003; Newman and Newman 2003; Woodfin, Voisin et al. 2007).  
 
4.1 Generation of a lentiviral construct (pGZ-VE-cadherin) for 
labeling and later characterization of embryonic stem cell-
derived endothelial cells   
Silencing is one of the general problems usually encountered with ES cells being 
transfected with the conventional non-lentiviral vectors, especially during maturation 
processes. In order to overcome this hurdle, viral-based vectors such as adenoviruses 
and retroviruses have been put into use. In recent years, lentiviruses, which are derived 
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from the viral family Retroviridae, have been successfully used for transgenesis 
purposes. Lentiviral transduction is an efficient method for the insertion of exogenous 
genetic material into cells. This method leads to a stable integration of as big as 10 kb 
cDNA inserts  into the genome of both non-dividing and dividing cells, and clonal 
distribution in dividing cells (Freed and Martin 1994; Barde, Salmon et al. 2010; 
Sakuma, Barry et al. 2012). These vectors lack viral particles and are devoid of 
replication competent viruses. Additionally, they have the advantage to transduce non-
dividing cells (Escors and Breckpot 2010; Sakuma, Barry et al. 2012).  
Use of lentiviral vectors with reporter gene expression under the control of a 
constitutively active promoter or ubiquitin has been shown in both undifferentiated and 
differentiated states of ES cells or iPSCs without silencing during the course of 
proliferation and differentiation (Pfeifer, Ikawa et al. 2002; Huang, Niiyama et al. 2009; 
Huang, Niiyama et al. 2010; Jiang, Lin et al. 2010; Huang, Okogbaa et al. 2012). 
Clonal selection and expansion of ES cells leads to the development of clones of 
interest with a target transgenic pattern. Lentiviral vectors have been successfully used 
for this purpose, which is greatly facilitated when an antibiotic resistance cassette is 
expressed under a constitutively active promoter. 
For the selection of ES-cell derived ECs, an EC-specific promoter is required, 
driving the expression of a reporter and/or antibiotic resistance gene upon its activation 
during differentiation. VE-cadherin, as one of the most specific EC adhesion molecules,  
is expressed on EBs day 5 (Vittet, Prandini et al. 1996). In addition to adhesive roles, 
other functions of VE-cadherin include anti-apoptotic and angiogenic effects, as well as 
regulation of leukocyte transmigration (Carmeliet, Lampugnani et al. 1999; Gory, 
Vernet et al. 1999; Bäumer, Keller et al. 2006; Dejana and Giampietro 2012).  In a 
study by Li and his colleagues, the promoter of this molecule was used to generate a 
conventional non-lentiviral vector expressing GFP under the control of the VE-cadherin 
promoter for transfection and production of ES cell clones, which expressed GFP upon 
differentiation to ECs (Li, Wu et al. 2007). The use of other markers of later stages of 
EC development such as Tie-1 has also been reported in previous studies (Iljin, Petrova 
et al. 2002; Marchetti, Gimond et al. 2002; Kim and von Recum 2010). Depending on 
application, more progenitor type promoters like Flk-1or Tie-2 have also been used for 
the isolation of ECs (Hirai, Ogawa et al. 2003; Magid, Martinson et al. 2003). 
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In this study, the VE-cadherin promoter was used in a lentiviral construct to generate 
ES cell clones expressing GFP upon activation of the VE-cadherin promoter, leading to 
the labeling of ES cell-derived ECs. VE-cadherin–driven GFP expression of human ES 
cell-derived ECs in a lentiviral vector has been also recently shown by James and his 
co-workers (James, Nam et al. 2010; James, Zhan et al. 2011).  The authors describe a 
consistent amount of the transgene in ES cells through passaging of transduced ES cell 
colonies in parallel cultures (James, Nam et al. 2010).  Later, they demonstrate a 
method of selection, which was facilitated by a preliminary FACS-sorting of  the clones 
that temporarily showed an unspecific GFP expression in undifferentiated ES cells, 
possibly leading to enrichment of clonal derivatives with viral integration. Transgenic 
clones were later characterized by the identification of GFP-positive, vessel-like 
structures during differentiation (James, Zhan et al. 2011). However, the reason for this 
temporary GFP expression in undifferentiated ES cells and its possible impact on later 
cell functionality could not be dissected. In the current experiments, undifferentiated ES 
cells did not express any GFP, while a temporary GFP expression in day 2 EBs was 
observed, prior to the long-lasting GFP expression in later differentiation days. Our 
applied approach precluded the initial unspecific GFP sorting. It is not known whether 
this initial GFP expression has a relevance to the later specific GFP expression. In 
addition, unlike the method taken by James and his colleagues which was based on 
transduction of ES cell colonies, ES cells in the present study were transduced at a 
single cell level. Following the formation of ES colonies, they were passaged onto 10cm 
MEF-coated plates. After reaching confluency, the whole grown ES colonies were 
picked manually with a 100 µL pipette tip, using no dissociation solution. In our view, 
this may confer a higher clonal integrity and purity, avoiding cross-contamination of 
different ES cell colonies.  
 
4.2  Characterization of embryonic stem cell-derived 
endothelial cells  with specific GFP expression in both whole 
plated and dissociated embryoid  bodies  
In the present experiments, formation of vascular-like structures started from day 8 
differentiation of EBs or 4 days after plating of day 4 EBs. This correlates with the later 
expression of VE-cadherin in EBs, compared to the earlier markers of EC 
4 Discussion 
78 
 
differentiation such as Flk-1, Tie-2, and CD31. Before that time, GFP-positive 
structures appeared in non-specific, poorly organized structures essentially concentrated 
in the center of EBs. 
In order to analyze the cells at a single cell level, various dissociation solutions were 
used to test the resistance of EC surface markers under enzymatic and    non-enzymatic 
procedures and to optimize the dissociation procedures. Among endothelial markers, 
VE-cadherin is particularly sensitive to proteolytic enzymatic activity, especially due to 
metalloproteinases, elastase, and cathepsin G released during inflammation (Xiao, 
Allison et al. 2003; Luplertlop, Misse et al. 2006). Minimal amounts of trypsin even in 
the presence of calcium also lead to the elimination of all surface VE-cadherin 
molecules in cell culture (Lampugnani, Resnati et al. 1992). Furthermore, EDTA-based 
dissociation solutions disassemble VE-cadherin by chelating calcium, leading to the 
dysfunction and dissociation of the molecule (Gao, Kouklis et al. 2000). The best 
results regarding the preservation of VE-cadherin molecule was obtained with 
collagenase B.  
Internalization, destabilization and diminishment of VE-cadherin molecules at the 
cell surface has been reported with conditions such as Flk-1 activation through VEGF 
exposure and FGF signaling inhibition, leading to dissociation of EC contacts (Gavard 
and Gutkind 2006; Murakami, Nguyen et al. 2008). It is therefore not an unexpected 
finding to temporarily or permanently lose a proportion of the extracellular domain of 
VE-cadherin during dissociation to single cells. In the present study, following 
dissociation, VE-cadherin expression started to reappear after 2 days in culture. This 
period was possibly required for retrieval of the internalized domains of VE-cadherin. 
However, on rare occasions, GFP expression was not accompanied by VE-cadherin 
expression, possibly explained by the degradation of the molecule, promoter switch-off, 
or transdifferentiation processes due to paracrine effects during stress imposed by 
degradation procedures (Xiao, Allison et al. 2003). Decreased VE-cadherin expression 
has been demonstrated to be associated with endothelial-mesenchymal 
transdifferentiation in endothelial monolayers and intimal inflammation in sites of 
neovascularization (Bobryshev, Cherian et al. 1999; Frid, Kale et al. 2002). These 
observations suggest that regulated changes in VE-cadherin levels have important 
consequences on endothelial function and pathophysiology. 
 
4 Discussion 
79 
 
4.3  Selection and characterization of embryonic stem cell-
derived endothelial cells  
4.3.1 Treatment of cells with antibiotic  
Pure cell populations are essential for cell-based therapies and should alleviate the 
problem of teratoma formation when ES cells are implanted in vivo (Blancas, Lauer et 
al. 2008). Antibiotic selection of pure mature cells, especially ECs from ES cells, has 
not been in extensive use before. A Tie-1 promoter driving a puromycin resistance gene 
has shown to be effective in selecting ECs upon treatment with puromycin (Kim and 
von Recum 2010). 
As a zeocin resistance gene was also designed under the control of the VE-cadherin 
promoter, EBs were also treated with different concentrations of zeocin for the 
purification of GFP-expressing cells. The addition of antibiotic to the whole 3-
dimensional structures of EBs was not efficient enough to penetrate through the EBs. 
Accordingly, EBs were dissociated, re-plated at different confluencies, and treated with 
different concentrations of zeocin. However, even with high zeocin concentrations, it 
was not possible to completely eliminate cells with a fibroblast/myofibroblast 
phenotype as indicated by α-SMA expression in culture. Previous studies have also 
shown the presence of these cells, which may be derived from EPCs or due to a 
transdifferentiation step with increased reactivity to transforming growth factor (TGF)-β 
and laminin (Yamashita, Itoh et al. 2000; Marchetti, Gimond et al. 2002). This may also 
partly result from the suboptimal efficiency of antibiotics in the elimination of non-
transgenic cells. There are studies about increasing the stringency of selection based on 
zeocin resistance gene by introduction of different initiation codons or smaller peptides 
at the beginning of the zeocin resistance gene (Van Blokland, Hoeksema et al. 2011). In 
these experiments, GFP-positive cells after zeocin treatment in culture showed a dim 
GFP expression with no overall healthy phenotype. A reason might be that the 
recombinant cells are not completely protected from the adverse effects of zeocin such 
as break and methylation of DNA strands (Oliva-Trastoy, Defais et al. 2005). In 
selection of cells with antibiotics, special measures must be undertaken to increase the 
efficiency of antibiotics, while at the same time protecting the cells from their harmful 
effects.  
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4.3.2 Selection of cells based on GFP expression  
Due to the suboptimal results of EC selection with antibiotic treatment, the cells were 
next sorted on different days of EB differentiation based on GFP expression. 
 In a series of studies by Kim and his colleagues, the cells that were selected with 
antibiotics expressed some of the EC markers in culture. Though, GFP, which was 
concomitantly expressed under EC-specific promoters, was not detectable in the 
selected cells.  In their experiments, as well as in the studies by Marchetti and his 
colleagues, VE-cadherin was a weaker promoter than its counterparts like Tie-1 
(Marchetti, Gimond et al. 2002; Kim and von Recum 2010). Moreover, purification of 
ES cell-derived ECs based on GFP expression under the control of the VE-cadherin 
promoter was not possible because of the weak GFP expression and differentiation 
plasticity of the cells (Kim and von Recum 2010). In the present experiments, GFP 
expression in vascular structures was quite strong, and the EC gene profiling studies of 
the GFP-sorted EBs confirmed the functionality of the construct as well as the 
feasibility of sorting. However, maintenance of GFP-positive cells in culture after 
sorting procedures for an extended period of time was not possible due to their 
weakness and fragility after protracted FACS procedures.   
4.3.3 Selection of endothelial cells based on CD31 expression   
In the next step, magnetic bead-sorting based on CD31 expression was applied for the 
purification of ECs in order to overcome the difficulties in getting sufficient numbers of 
viable cells after the harmful dissociation procedures and protracted course of FACS. 
This approach also made it possible to identify cells double-positive for GFP and CD31, 
thus facilitating the characterization of ES cell-derived ECs based on more than 1 
marker (Kim and von Recum 2010). Further, early and late markers of EC development 
in the CD31-sorted populations derived from could be analyzed EBs in time course 
studies. Hence, an optimal time point for the selection of functional ECs could be 
dissected. A multitude of data have challenged the concept of hemangioblast as a 
common precursor for both endothelial and hematopoietic cells by showing the 
hemogenic endothelium giving rise to hematopoietic cells (Choi, Kennedy et al. 1998; 
Chung, Zhang et al. 2002; Huber, Kouskoff et al. 2004; Vogeli, Jin et al. 2006). In view 
of that, a significant proportion of hematopoietic cells are developed from an 
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endothelial origin (Goldie, Lucitti et al. 2008; Zovein, Hofmann et al. 2008; Boisset, 
van Cappellen et al. 2010; Zape and Zovein 2011). Therefore, labeling and purification 
of  ES cell-derived ECs based on dissimilar markers may additionally bring more 
insight into the identification and later application of functional cells (Hirschi 2012). 
CD31 is a 130-kDa glycoprotein with six extracellular immunoglobulin-like 
domains, a transmembrane domain and a cytoplasmic tail, which is highly expressed on 
ECs, and at lower levels on blood cells such as platelets (Newman 1994). Some of the 
functions of endothelial CD31 include maintenance of EC monolayer integrity, cellular 
signaling, mechanoception, and leukocyte transmigration (Muller, Ratti et al. 1989; 
Newman and Newman 2003). CD31 has been used for the derivation of human ES cell- 
and iPSC-derived endothelial lineages (Levenberg, Golub et al. 2002; Glaser, Gower et 
al. 2011; Li, Hu et al. 2011). The non-endothelial CD31-positive population in human 
bone marrow has also been reported to contribute to vasculogenesis/angiogenesis (Kim, 
Cho et al. 2010). Unlike human system, which shows peak expression of CD31 in EBs 
days 13-15, the first expression of CD31 in mouse EBs occurs on day 4, after a transient 
expression of some isoforms in ES cells (Li, Wang et al. 2005) and the following down-
regulation in early EBs, possibly related to splicing of different CD31 isoforms (Li, 
Wang et al. 2005; Mariappan, Winkler et al. 2009). In mice, this occurs in a successive 
manner after the expression of Flk-1, followed by Tie-2, Tie-1 and VE-cadherin both in 
vitro and in vivo (Dumont, Fong et al. 1995; Vittet, Prandini et al. 1996). 
In the present experiments, CD31 expression peaked on day 6, while a population co-
expressing GFP was characterized 2 days later. This was comparable to previous 
developmental studies, including the investigations performed with a Tie-1 promoter 
driving GFP in murine ES cells (Vittet, Prandini et al. 1996; Marchetti, Gimond et al. 
2002). 
 
4.4  Specific gene profiling of the sorted populations 
Development of ECs based on the isolation of CD31-positive cells in day 8 mouse EBs 
has been shown in a study previously (Mariappan, Winkler et al. 2009). However, 
characterization of the early and late markers during the course of EC differentiation in 
the CD31-sorted populations and on the basis of that, the best time point for the 
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isolation and culture of functional ES cell-derived ECs has not been investigated in 
detail before. Accordingly, several markers of different vessel phenotypes, such as 
EphB4, Prox1, and homeobox genes such as Sox17 and Sox18, cell surface  receptors 
such as Flk-1, Tie-1, and Tie-2, transcription factors involved in vasculogenesis such as 
Tal1, c-kit, and Id1, hematopoietic markers such as CD34 and CD45, and VE-cadherin 
as one of the most specific adhesive molecules were analyzed. The gene expression 
analyses demonstrated a pronounced surge in the expression of EC surface markers and 
transcription factors involved in vascular development between differentiation days 2 
and 3 in the isolated CD31-positive population, yielding a mature cell population at the 
later differentiation days 6 and 8. This was characterized by a high expression of 
endothelial-specific markers, and a decreased expression of markers of the 
undifferentiated stage and early differentiation. Furthermore, at these later 
developmental stages, the expression of surface markers of ECs and transcription 
factors of vascular development in the CD31-positive vs. CD31-negative population 
was significantly higher, indicating the efficiency of CD31-based selection in driving 
functional ECs. Moreover, the results of gene expression analyses comparing CD31-
positive versus GFP-positive populations suggested the superiority of the CD31-based 
purification. 
Accordingly, differentiation days 6 and 8 were chosen for culture of CD31-sorted 
EBs, whereby the sorted cells particularly developed typical EC cobblestone 
morphology at day 6 and eventually formed tube-like structures. The pattern of 
expression of some of the investigated EC-specific genes in the sorted populations and 
their possible roles in vascular development are discussed in the following section.  
4.4.1  Early markers of vascular development  
Flk-1 as well as Tie and Eph family belong to receptor tyrosine kinases and have a 
critical role in vascular development (Adams and Alitalo 2007). Flk-1 is a cell surface 
receptor, mediating the responses by VEGF. Flk-1-positive cells have been shown to 
give rise to hemangioblasts with the potential to differentiate into endothelial, 
hematopoietic, and smooth muscle cells from murine ES cells (Nishikawa, Nishikawa et 
al. 1998; Adams and Alitalo 2007; Blancas, Lauer et al. 2008). Tie-2 is a surface 
molecule mediating a vascular protective role through both angiostasis and angiogenesis 
depending on the spatial localization and interactions with its ligand (Fukuhara, Sako et 
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al. 2008; Heinke, Patterson et al. 2012). When murine ES cells are put into 
differentiation, a robust expression of Flk-1 and Tie-2 starts around day 3 (Vittet, 
Prandini et al. 1996). According to the results of this study, Flk-1 and Tie-2 showed a 
remarkable surge on day 3 in CD31-positive cells, with a steadily high expression level 
during the later differentiation days. In human, on the contrary, Flk-1 and Tie-2, as well 
as the hematopoietic marker CD34 are highly expressed in undifferentiated ES cells (Li, 
Wilson et al. 2009).  
In these studies, a continuous increase in expression of Flk-1 in the CD31-positive 
vs. CD31-negative population was observed over time, suggesting its association with a 
more EC-specific characteristic in the later stages compared to the earlier stages, at 
which Flk-1 may also contribute to non-EC populations, including SMCs and 
hematopoietic cells. The highest fold increase in the expression of Tie-2 in the CD31-
positive vs. CD31-negative populations was observed in the intermediate differentiation 
period (days 3-6), in association with the beginning of specification to ECs, along with 
CD31 peak expression. This association was also noted in a recent study (Gu and 
Shively 2011). Hematopoietic cells expressing Flk-1 or Tie-2 have the capacity of re-
endothelialization, which may have impact in cellular therapy approaches (Nowak, 
Karrar et al. 2004; Sarkar, Rey et al. 2012). 
4.4.2 Transcription factors involved in vasculogenesis and 
endothelial cell differentiation 
Tal1(Scl) is one of the key regulators for the development of hemangioblasts and of 
hematopoiesis which is driven by GATA2. GATA2 as a potent factor also gives rise to 
Flk-1-positive mesodermal cells, as well as regulates CD31 expression. A Population of 
double Flk-1-/ Tal1-positive cells as blast colony-forming units leads to the induction of 
EC-specific genes and generation of ECs (Gering, Rodaway et al. 1998; Chung, Zhang 
et al. 2002; Dooley, Davidson et al. 2005; Lugus, Chung et al. 2007). 
Despite the known role of Tal1 in hemangioblast formation, its role has been 
considered to be dispensable for vasculogenesis. It has been shown that ECs or 
hematopoietic cells can still be characterized after Tal1 ablation or knockout in the face 
of vascular or hematopoietic defects, indicating possible compensatory pathways for 
vascular differentiation and/or hematopoiesis (De Val 2011). In my study, Tal1 
expression was markedly higher in the CD31-positive vs. CD31-negative population 
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from day 3 EB formation, with the biggest difference, as well as the highest Tal1 
expression in the CD31-positive population alone, at day 4. This was concomitant with 
a peak expression of Id1.  Id1 is a transcription factor from the loop-helix-loop family 
with a major role in maintaining ES cell self-renewal (Romero-Lanman, Pavlovic et al. 
2012) as well as EPC proliferation upon VEGF stimulation (Ciarrocchi, Jankovic et al. 
2007; Wang, Yu et al. 2010; Li, Wang et al. 2012). In the human system, Id1 is 
essential for the TGF-β inhibition-mediated growth and maintenance of ES cell-derived 
ECs (James, Nam et al. 2010). However, there are no studies on the possible role of Id1 
in murine ES cell-derived ECs. Along with the specification of CD31 to a more 
endothelial-specific identity on day 6, Id1 also showed a higher expression in the CD31-
positive vs. CD31-negative population, suggesting a possible role in the induction of ES 
cell-derived ECs in the mouse system, which requires further investigation.   
According to previous studies, a population of c-kit-positive mesodermal cells gives 
rise to ECs, vascular SMCs and cardiac progenitors with a high proliferation and 
expansion capacity (Wu, Fujiwara et al. 2006; Tallini, Greene et al. 2009). Furthermore, 
c-kit has been shown to be essential for the maintenance of hematopoiesis in bone 
marrow (Kimura, Ding et al. 2011). The c-kit-positive population isolated from 
amniotic fluid has been demonstrated to produce some  phenotypes of ECs (Benavides, 
Petsche et al. 2012). According to the present results, the expression of c-kit was higher 
in the CD31-positive vs. CD31-negative population from day 3 on, with its peak level of 
expression in the CD31-positive population on day 3, which was 1 day earlier than the 
peak expression of Id1 and Tal1. A second increase in expression occurred on day 8 in a 
manner comparable to Id1. This may indicate a role for c-kit in the induction of EC 
development both at early and later stages of differentiation.  
4.4.3 Specific markers of different vessel phenotypes 
The venous and arterial vascular systems demonstrate distinct anatomical, functional, as 
well as molecular differences (Aranguren, Luttun et al. 2007; Yamashita 2007). The 
venous vascular system, which might be the default EC differentiation target (Red-
Horse, Ueno et al. 2010), is characterized by EphB4 and COUP-TFII expression. 
Arterial differentiation, on the other hand, is characterized by EfnB2, delta-like (Dll)-4, 
Notch1 and 4, Jagged-1, and connexin-40 expression. Prox1 is considered as the most 
specific lymphatic endothelial marker (Wang, Chen et al. 1998; Swift and Weinstein 
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2009; Salvucci and Tosato 2012). In addition to the known role of ephrin family ligands 
and receptors in venous and arterial specification, their function has been shown to be 
also particularly important for vascular development and angiogenesis (Swift and 
Weinstein 2009; Salvucci and Tosato 2012). 
In the present study, some of the above-mentioned factors were assessed in 
populations of ECs isolated based on CD31 expression on different days of 
differentiation of EBs. EphB4 showed a statistically significant increase in expression 
on differentiation days 3 to 8 in comparison to day 2. The expression pattern of EphB2 
was also analyzed, which showed a higher expression only in the earlier isolated CD31-
positive population (not shown). This gene as another member of the ephrin receptor 
family has been implicated in vascular SMC proliferation (Woods, Blystone et al. 
2002), and may regulate EC branching and chemotaxis in orchestration with EphB4 
(Salvucci, de la Luz Sierra et al. 2006).  
Nos3 is a mediator of commitment of EPCs to ECs, and is up-regulated during ES 
cell-derived EC development (Rossig, Urbich et al. 2005). Furthermore, down-
regulation of Nos3 may lead to dilated and aberrant vasculature in CD31- knockout 
mice (Dimaio, Wang et al. 2008). The present experiments revealed a 604-fold increase 
in the expression of Nos3 in CD31-positive vs. CD31-negative populations on day 8. 
This may underscore the efficiency of CD31-sorting and subsequent development of 
functional vessel structures in later days of EB differentiation. 
Prox1 is a master regulator of lymphatic EC specification and maintenance (Wigle, 
Harvey et al. 2002; Johnson, Dillard et al. 2008). The transcription factors Sox18 and 
Coup-TFII are critical for the induction of Prox1 expression in lymphatic EPCs located 
within the embryonic veins (Francois, Caprini et al. 2008). In the present experiments, 
the expression of Prox1 in the CD31-positive population was down-regulated from day 
3, with a slight up-regulation on days 6 and 8. Sox18 had a significantly higher 
expression in the CD31-positive population vs. CD31-negative population from day 3, 
especially at later differentiation days. Sox17 together with Sox18 has been shown to 
have a role in arteriovenous specification. Morphants have been reported to have 
vasculature defects with aberrances in the arterial EC-related gene patterns, as well as 
defects in lymphatic vasculature (Cermenati, Moleri et al. 2008; Francois, Caprini et al. 
2008; Pendeville, Winandy et al. 2008; Francois, Short et al. 2012). The modifying 
effect by Sox7 and Sox17 in lymphangiogenesis in Sox18-deficient mice has been 
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demonstrated in previous studies (Hosking, Francois et al. 2009). In the present thesis, 
similar to Sox18, the expression of Sox17 was higher in CD31-positive cells vs.  CD31-
negative population. However, its expression level in the CD31-positive population 
alone decreased significantly from day 3. The exact interacting mechanisms of these 
transcription factors in orchestration with other genes in the induction of arterial vs. 
venous vs. lymphatic differentiation during the course of EC development is a complex 
network, which requires specific detailed investigations in future studies. This may have 
an impact in cellular therapy approaches for the derivation of a special phenotype of 
vessels based on the underlying pathological vascular lesion.  
4.4.4 Late markers of endothelial cell differentiation  
Tie-1 and VE-cadherin are 2 examples of EC markers, which are expressed later during 
the course of differentiation of ES cells to ECs. Tie-1 is expressed in day 5 EBs 
following Flk-1 and CD31 (Vittet, Prandini et al. 1996). The results of this study 
showed a higher overall expression of Tie-1 in CD31-positive vs. CD31-negative 
populations, with the highest expression in the CD31-positive cells alone on day 8. Tie-
1, which is activated by hypoxia or VEGF treatment, has been shown to be involved in 
angiogenesis and neovascularization (McCarthy, Crowther et al. 1998; Seegar, Eller et 
al. 2010). Therefore, it is not expressed in mature vessels, where no neovascularization 
takes place. This is in obvious contrast to Tie-2, which is expressed ubiquitously in all 
ECs and is important for proliferation and maintenance of ECs in all stages (Dumont, 
Gradwohl et al. 1994; Seegar, Eller et al. 2010). The peak expression of Tie-1 in CD31-
positive cells at day 8 may implicate the high angiogenic activity at this point. In line 
with these considerations, cell culture also confirmed the angiogenic sprouting in day 8 
CD31-positive cells cultured on matrigel, while an earlier time point resulted in a more 
proliferative state of ECs. 
VE-cadherin as another late marker of ECs and the major endothelial specific cell 
adhesion molecule (Lampugnani and Dejana 1997) has several structural, as well as 
functional role involved in angiogenesis (Bäumer, Keller et al. 2006; Dejana, Orsenigo 
et al. 2008; Vestweber 2008). In a previous study, gene analysis of the VE-cadherin-
positive vs. -negative cells had shown an increased expression of EC markers in the VE-
cadherin-positive cells in day 6.5 EBs. VE-cadherin expression at an earlier stage was 
associated with hematopoietic markers (Nikolova-Krstevski, Bhasin et al. 2008). In my 
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study, VE-cadherin showed a statistically significant steady increase in expression 
during the course of differentiation in the CD31-positive population. At day 8, there was 
a 560-fold increase in VE-cadherin expression in CD31-positive vs. CD31-negative 
populations. The high level of association of VE-cadherin and CD31 may indicate the 
robustness of taking advantage of the VE-cadherin promoter and CD31 for labeling and 
selection purposes, respectively. In my view, EC selection based on CD31 was 
advantageous to sorting based on GFP, which rendered the cells fragile following the 
detrimental, lengthy FACS sorting procedures.  
 
4.5  Culture of sorted cells  
It was possible to obtain a significant number of CD31-positive/GFP-positive cells 
representing ECs with a high purity level by treating the cells with 20 ng/mL VEGF 
prior to and after isolation, and during culture. Isolation of the cells on day 6 and further 
culture with VEGF for two days led to a robust endothelial phenotype in culture, which 
is in agreement with the gene expression analyses showing the most pronounced 
expression of EC-specific genes in CD31 sorted cells on day 8 of differentiation.  
Treatment of isolated cells with growth factor cocktails in serum-dependent 
conditions may enhance both immature vascular structures containing SMCs and 
hematopoietic cells (Boyd, Dhara et al. 2007; Pearson, Sroczynska et al. 2008; Sun, 
Cheng et al. 2009; Irion, Clarke et al. 2010). A growth factor cocktail of VEGF, FGF-2, 
IL-6, and erythropoietin, as well as VEGF alone, have been shown to increase the 
percentage of CD31-positive cells within the EBs, as well as the cellularity and number 
of EBs (Vittet, Prandini et al. 1996; Marchetti, Gimond et al. 2002; Sun, Cheng et al. 
2009). A combination of other growth factors such as BMP-4 and Activin A has also 
demonstrated to increase the primitive vasculogenesis outgrowths (Boyd, Dhara et al. 
2007; Pearson, Sroczynska et al. 2008), along with hematopoietic development (Irion, 
Clarke et al. 2010). As the development of hematopoietic cells was not desirable, EBs 
were treated with VEGF alone, which led to a significant level of CD31/GFP-double 
positive populations. Recently, Chiang  and his colleagues defined a new system for the 
efficient development of murine ES cells to hemangioblast and angioblast fates and an 
efficient production of ECs through successive treatment of the cells to accurately-
scaled doses of growth factors (Chiang and Wong 2011). Though very promising, these 
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systems require further optimization for the high-throughput production of ECs with 
applications in cellular therapy. 
While the effect of different growth factors on the formation of vascular networks 
has gained widespread interest, less is known about the mechanical forces of the 
environment on the growth of ECs and development of vascular networks. The traction 
forces exerted by some substrates like fibronectin may lead to an enhanced endothelial-
endothelial connectivity (Califano and Reinhart-King 2009). These compliant substrates 
mimic the normal healthy conditions, while in pathological conditions the substrate 
becomes stiffer, leading to gaps between the cells (Krishnan, Klumpers et al. 2011). 
Matrigel is derived from Engelbreth-Holm-Swarm mouse sarcoma cells (Kleinman and 
Martin 2005). The main components of matrigel are laminin and collagen, as structural 
proteins. However, matrigel is also enriched with growth factors that promote the 
formation of angiogenic tubules. In line with these findings, the results of this project 
also demonstrated the development of variant EC phenotypes upon culture of the sorted 
cells on different substrates. The results of these experiments showed that the culture of 
ES cell-derived ECs on matrigel leads to the formation of angiogenic sprouts, while 
culture on gelatin-coated plates gave rise to EC cobblestone morphology. These 
differences may have an impact in tissue engineering in providing the proper milieu for 
therapeutic vasculogenesis.  
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5 Conclusions and future prospects 
In this study, an ES cell clone was generated carrying an integrated VE-cadherin 
transgene expressing GFP upon differentiation to ECs using a lentiviral-based construct. 
This model can be applied to trace the activity of VE-cadherin promoter in single cells 
within embryoid bodies. Moreover, the VE-cadherin/GFP-positive clones may 
constitute a proper model for observing the effects of several pro- or anti-angiogenic 
factors. This may aid to understand the molecular mechanisms regulating VE-cadherin 
promoter activity under physiological and pathological condition. Additionally, the 
introduction of an antibiotic resistance gene under the control of the VE-cadherin 
promoter for the selection of ECs may be used as model to generate other constructs 
with various antibiotic resistance genes and potentially more efficient cell selection. In 
these studies, the robustness of EC selection based on the expression of CD31, as 
another EC-specific marker could be demonstrated. Based on the analysis of some 
established and candidate genes involved in the early and later stages of EC 
differentiation, as well as pattern of growth in cell culture, a specific time point for 
efficient, high purity selection of GFP-labeled ECs from differentiating ES cells using 
CD31-based cell sorting could be determined. 
These studies may serve as a fundament for future investigations on the detailed 
mechanisms of ES cell development and differentiation into ECs, as well as a model for 
drug discovery and prospective cellular therapy approaches in various diseases 
associated with vascular damage. The GFP-labeling may allow us to track and study the 
cells as they migrate, proliferate, or differentiate at sites of vascular injury. The sorted 
cells at different developmental stages may be applied to coat the inner layer of many 
devices in models of neovascularizarion, as well as of the artificial devices such as 
extracorporeal membrane oxygenation (ECMO) machines to provide a physiological 
environment for the circulation of oxygen and nutrients. Tissue engineering may aid to 
construct a proper milieu for further therapeutic vasculogenesis.  
Despite the huge benefits about stem cell research, there are limitations about their 
application. For instance, the issue of immunogenicity in stem cell studies must be taken 
into account in all therapeutic models with embryonic stem cells. Moreover, the results 
of successful treatment of various diseases using embryonic stem cells in animal models 
may not be extrapolated to human studies due to ethical issues. For this reason, the 
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reprogramming of autologous human somatic cells to produce induced pluripotent stem 
cells may offer a cell resource for the differentiation of desired target cells, thus 
alleviating the ethical as well as immunogenicity issues. The methods and results of this 
project may be used as a model for applicative studies on the derivation of pure ECs and 
functional vasculature from induced pluripotent stem cells in human.  
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6 Summary  
Embryonic stem (ES) cell-derived endothelial cells (EC)s may be used as a therapeutic 
option in experimental models of diseases originating from vascular lesions. Moreover, 
studies on these cells may provide insight into EC development and differentiation in 
the human body. In this regard, it is fundamentally required to label, track, and finally 
isolate a pure population of ES-cell-derived ECs. In this study, a murine ES cell line 
was established, which expressed green fluorescent protein (GFP) as well as a zeocin 
resistance gene under the control of the murine Vascular Endothelial (VE)-cadherin 
promoter after lentiviral transduction of single ES cells. 192 ES colonies derived from 
single transduced ES cells were picked randomly and directed to differentiation. From 
day 6 of differentiation, 12.5% of the clones showed GFP-positive vessel-like 
structures. Immunofluorescence microscopy demonstrated the co-expression of various 
EC markers (VE-cadherin, CD31) on ES cell-derived vascular structures. Based on flow 
cytometry, the highest GFP expression level could be observed in embryoid bodies at 
differentiation day 8. Flow-cytometric cell sorting at this time point revealed a 
significantly higher level of expression of the majority of investigated EC markers in 
the GFP-positive compared to the GFP-negative population. In addition, magnetic beads 
were used for the isolation of ECs based on CD31 expression. The sorted cells were 
subsequently subjected to gene profiling, in order to determine the optimal time point 
for the isolation and subsequent culture of ECs. In the sorted cells on days 6 and 8 of 
differentiation, all investigated markers of EC differentiation and transcription factors of 
vasculogenesis demonstrated a markedly higher expression in the CD31-positive versus 
CD31-negative population. Cultured CD31-positive cells at differentiation day 6 
developed a characteristic EC cobblestone morphology, co-expressed GFP and different 
endothelial markers, and eventually formed tube-like structures. In conclusion, 
generation of ES cell clones expressing GFP upon differentiation to ECs, and their 
sorting based on CD31, provides a feasible method for the production of pure labeled 
ECs. This system may serve as a powerful tool for studies on the differentiation of ECs 
from ES cells and induced pluripotent stem cells, as well as prospective cellular 
therapeutic approaches in various diseases associated with vascular damage.   
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7 Zusammenfassung 
Aus embryonalen Stammzellen (ES-Zellen) abgeleitete Endothelzellen können in 
Modellen zur Therapie von Erkrankungen, die mit vaskulären Läsionen assoziiert sind, 
eingesetzt werden. Außerdem geben ES Zellstudien wichtige Einblicke in die 
Entwicklung und Differenzierung von Endothelzellen im menschlichen Organismus. 
Für diese Zwecke ist es essentiell, die aus ES-Zellen abgeleiteten Endothelzellen zu 
markieren und nachzuverfolgen und die differenzierten Zellen schließlich in eine reine 
Zellpopulation zu überführen. In der vorliegenden Arbeit wurde eine murine ES-Zell-
Linie generiert, welche nach lentivirusbasierter Transduktion von ES Zellen das grün 
fluoreszierende Protein (GFP) sowie ein Zeocin-Resistenzgen unter Kontrolle des 
murinen vaskulären endothelialen (VE)-Cadherin-Promotors exprimiert. 192 aus einzel-
transduzierten ES-Zellen abstammende ES-Zellkolonien wurden zufällig selektiert. Ab 
Tag 6 der Differenzierung zeigten 12,5% der Klone GFP-positive vaskuläre Strukturen 
mit Co-Expression verschiedener vaskulärer Marker (VE-Cadherin, CD31). Die durch 
Durchflusszytometrie am Tag 8 der Differenzierung selektierten GFP-positiven Zellen 
zeigten eine signifikant höhere Genexpression verschiedener Endothelzellmarker als die 
GFP-negative Zellpopulation. Darüber hinaus wurde ein weiteres, auf der Expression 
von CD31 basierendes Verfahren zur Selektion der aus ES Zellen abgeleiteten 
Endothelzellen angewendet und das Genprofil der selektierten Endothelzellen zu 
verschiedenen Zeitpunkten der Differenzierung analysiert. Auf diese Weise wurde der 
optimale Zeitpunkt für die Isolierung und anschließende Kultivierung und 
Charakterisierung dieser Zellen festgelegt. Alle untersuchten Marker sowie 
Transkriptionsfaktoren der Endotheldifferenzierung zeigten eine deutlich höhere 
Expression in der CD31-positiven gegenüber der -negativen Zellpopulation am Tag 6 
und 8 der Differenzierung. Die Kultivierung der CD31- positiven Zellen am Tag 6 der 
Differenzierung führte zu einer für Endothelzellen charakteristischen 
Kopfsteinpflastermorphologie mit Co-Expression des GFPs mit verschiedenen 
endothelialen Markern. Schließlich bildeten die kultivierte Zellen tubuläre Strukturen 
aus. Zusammenfassend stellt die Generierung embryonaler Stammzellklone, welche 
während der Differenzierung zu Endothelzellen GFP exprimieren, und die Selektion 
dieser Zellen auf Basis der Expression von CD31, eine  effiziente Methode für die 
Entwicklung reiner Endothelzellen dar. Diese Studien repräsentieren darüber hinaus die 
Voraussetzung für zukünftige detaillierte Studien zur Differenzierung von 
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Endothelzellen aus ES Zellen und induzierten pluripotenten Stammzellen, und für die 
Anwendung Zell-basierter experimenteller therapeutischer Strategien bei verschiedenen 
vaskulären Erkrankungen. 
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BL-CFC Blast colony forming cells 
BMP  Bone morphogenic protein 
bp  base pairs 
CD  cluster of differentiation 
CMV Cytomegalovirus 
COUP-TF-II  Chicken ovalbumin upstream promoter transcription factor IIS 
cPPT  Central polypurine tract 
CVDs   Cardiovascular diseases 
DMEM  Dulbecco's modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNAse I   deoxyribonuclease I 
dsDNA   double stranded DNA  
EBs  embryoid bodies 
ES  embryonic stem 
ECs  Endothelial cells 
EDTA  Ethylenediaminetetraacetic acid 
EfnB2 EphrinB2 
EGCs Embryonic germ cells 
EPCs   endothelial progenitor cells 
EphB4 EphrinB4 receptor 
ECMO extracorporeal membrane oxygenation 
FBS Fetal Bovine Serum  
FGF fibroblast growth factor 
FACS fluorescence activated cell sorting 
Flk-1  Fetal liver kinase-1 
GFP  Green fluorescent protein 
Gp Glycoprotein 
HEK  human embryonic kidney 
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HIV  human immunodeficiency virus  
Abbreviations 
95 
 
ICM inner cell mass 
IMDM  Iscove's Modified Dulbecco's Medium 
IL Interleukin 
iPSCs  induced pluripotent stem cells 
LB. .Luria Broth 
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MEFs mouse embryonic fibroblasts 
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Oct4 Octamer-binding transcription factor 
PBS phosphate buffered saline 
PECAM-1 platelet endothelial adhesion molecule-1  
Pen/Strep penicillin/Streptomycin 
Prox1 Prospero homeodomain transcription factor 1 
RRE rev response element 
RNA ribonucleic acid 
RSV respiratory syncytial virus 
SMA smooth muscle actin 
SMCs smooth muscle cells  
SOB Super optimal Broth medium 
Sox Sex determining region Y-box 
S1P Sphingosine-1-phosphate 
TGF Transforming Growth Factor 
Tie Tyrosine kinase with Ig-like and EGF-like domains 
VCAM vascular cell adhesion molecule 
VEGF vascular endothelial growth factor 
VEGF-R vascular endothelial growth factor receptor 
VSV-G vesicular stomatitis virus-G 
WPRE woodchuck hepatitis virus post-transcription regulatory element 
 
 
List of Tables 
96 
 
  
List of Tables 
 
Table 1 List of primary antibodies 
 
30 
Table 2 Primer sequences used for PCR 
 
31 
Table 3 List of restriction endonucleases 
 
32 
Table 4   List of Vectors 
 
33 
Table 5 List of enzymes for molecular biology techniques 
 
33 
Table 6 Transfection of HEK 293 T cells and production of 
pseudoviral particles 
 
49 
Table 7 Ratio of vectors and transfection reagent for the 
transfection of HEK 293 T cells with total amounts of 8µg 
and 18µg DNA 
49 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Figures 
97 
 
Table of Figures  
 
Figure 1 Schematic view of mammalian embryo 
 
8 
Figure 2 Parallel signaling pathways contributing to pluripotency in 
mammalian embryonic stem cells 
 
9 
Figure 3 Maintenance of self-renewal in mouse embryonic stem cells 
using cytokines and chemical inhibitors  
 
10 
Figure 4   Schematic view of culture and differentiation of embryonic 
stem cells  
 
11 
Figure 5 Model of endothelial and blood cell formation from the 
hemangioblast 
 
12 
Figure 6 Schematic illustration of different mechanisms contributing to 
blood vessel formation.  
 
14 
Figure 7 Specification toward an arterial vs. venous vs. lymphatic fate 
in the early embryo 
 
17 
Figure 8 Molecular organization of VE-cadherin  
 
  20 
Figure 9 Mechanism of lentiviral transduction using second generation 
vectors 
 
24 
Figure 10   Forward and reverse primers used for amplification of VE-
cadherin promoter 
 
40 
Figure 11 Generation of pGZ-VEcadherin construct from pGZ-CMV 
vector 
 
44 
Figure 12   Vectors used for transfection of HEK 293 T cells; a 
combination of the main construct (pGZ-VE-cadherin), 
packaging vector (psPax2), and envelope vector (pMD2.G) 
 
48 
Figure 13 Undifferentiated and differentiated states of embryonic stem 
cells  
 
53 
Figure 14 Characterization of different endothelial cell markers in 
embryoid bodies day 4 plated for 4 additional days in 
differentiation medium on gelatin-coated plates  
 
54 
Figure 15 Assessing GFP expression in embryoid bodies derived from 
embryonic stem cells that were transduced with pGZ-CMV 
vector  
 
55 
Figure 16 GFP expression in mouse embryonic fibroblasts (MEFs) and 
mouse endothelioma cells transduced with the pGZ-VE-
cadherin construct  
56 
Figure 17 GFP expression in mouse embryoid bodies (EBs) derived 57 
Table of Figures 
98 
 
from mouse embryonic stem (ES) cells transduced with the 
pGZ-VE-cadherin construct both in suspension culture and 
plated on gelatin  
 
Figure 18 Co-localization of GFP and endothelial cell markers in 
vascular structures observed in plated embryoid bodies that 
were derived from transgenic embryonic stem cells  
 
58 
Figure 19 Expression patterns of endothelial markers upon dissociation 
of day 5 embryoid bodies with different dissociation solutions 
 
59 
Figure 20 Co-localization of GFP and endothelial cell markers in 
vascular structures observed in dissociated and re-plated 
embryoid bodies derived from transgenic embryonic stem 
cells  
 
59 
Figure 21 Treatment of cultured dissociated embryoid bodies 
expressing GFP and a zeocin resistance gene with different 
concentrations of  zeocin  
 
60 
Figure 22 Flow cytometric time-course analysis of GFP, CD31 and 
CD34 in embryoid bodies (EBs) derived from transgenic 
embryonic stem (ES) cells at differentiation days 2.5-12 
 
61 
Figure 23 Gene expression analysis in GFP-sorted transgenic embryoid 
bodies  
 
62 
Figure 24 CD31-positive cells derived from dissociated embryoid bodies 
expressing GFP under the control of the VE-cadherin 
promoter  
 
63 
Figure 25 Gene expression analysis in CD31-sorted transgenic 
embryoid bodies (EBs)  
 
64-65 
Figure 26 Time course gene expression analysis in the CD31-positive 
cell population  
 
66-67 
Figure 27 Gene expression analyses in CD31-sorted transgenic 
embryoid bodies (EBs) for embryonic stem cell markers as 
well as markers of early differentiation  
 
68 
 
Figure 28 Difference in the expression of markers of the undifferentiated 
state and early markers of differentiation in the CD31+ (closed 
columns) vs. CD31- (open columns) at differentiation day 8 
 
69 
Figure 29 Culture of CD31-positive cells in EBs differentiation day 8 on 
matrigel  
70 
   
Figure 30 Isolation of CD31-positive cells derived from EBs on 
differentiation day 6 and their culture on gelatin-coated plates 
 
71-73 
Figure 31 Formation of GFP-positive tube-like structures in CD31-
positive cells  
74 
References 
99 
 
References  
(2010). Promoting Cardiovascular Health in the Developing World: A Critical 
Challenge to Achieve Global Health. V. Fuster and B. B. Kelly. Washington 
(DC). 
Adams, B., Q. Xiao, et al. (2007). "Stem cell therapy for vascular disease." Trends 
Cardiovasc Med 17(7): 246-251. 
Adams, R. H. and K. Alitalo (2007). "Molecular regulation of angiogenesis and 
lymphangiogenesis." Nat Rev Mol Cell Biol 8(6): 464-478. 
Ahlbrecht, K., J. Schmitz, et al. (2008). "Spatiotemporal expression of flk-1 in 
pulmonary epithelial cells during lung development." Am J Respir Cell Mol Biol 
39(2): 163-170. 
Aird, W. C. (2012). "Endothelial cell heterogeneity." Cold Spring Harb Perspect Med 
2(1): a006429. 
Aranguren, X. L., A. Luttun, et al. (2007). "In vitro and in vivo arterial differentiation of 
human multipotent adult progenitor cells." Blood 109(6): 2634-2642. 
Asahara, T., H. Masuda, et al. (1999). "Bone marrow origin of endothelial progenitor 
cells responsible for postnatal vasculogenesis in physiological and pathological 
neovascularization." Circ Res 85(3): 221-228. 
Asahara, T., T. Murohara, et al. (1997). "Isolation of putative progenitor endothelial 
cells for angiogenesis." Science 275(5302): 964-967. 
Atkins, G. B., M. K. Jain, et al. (2011). "Endothelial differentiation: molecular 
mechanisms of specification and heterogeneity." Arterioscler Thromb Vasc Biol 
31(7): 1476-1484. 
Bajada, S., I. Mazakova, et al. (2008). "Updates on stem cells and their applications in 
regenerative medicine." J Tissue Eng Regen Med 2(4): 169-183. 
Barde, I., P. Salmon, et al. (2010). "Production and titration of lentiviral vectors." Curr 
Protoc Neurosci Chapter 4: Unit 4 21. 
Bartunek, J., A. Behfar, et al. (2013). "Cardiopoietic Stem Cell Therapy in Heart 
Failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) 
Multicenter Randomized Trial With Lineage-Specified Biologics." Journal of 
the American College of Cardiology 61(23): 2329-2338. 
Bäumer, S., L. Keller, et al. (2006). "Vascular endothelial cell–specific phosphotyrosine 
phosphatase (VE-PTP) activity is required for blood vessel development." Blood 
107(12): 4754-4762. 
Benavides, O. M., J. J. Petsche, et al. (2012). "Evaluation of endothelial cells 
differentiated from amniotic fluid-derived stem cells." Tissue Eng Part A 18(11-
12): 1123-1131. 
Bergom, C., C. Paddock, et al. (2008). "An alternatively spliced isoform of PECAM-1 
is expressed at high levels in human and murine tissues, and suggests a novel 
role for the C-terminus of PECAM-1 in cytoprotective signaling." J Cell Sci 
121(Pt 8): 1235-1242. 
Bhirde, A., J. Xie, et al. (2011). "Nanoparticles for cell labeling." Nanoscale 3(1): 142-
153. 
Bissels, U., D. Eckardt, et al. (2013). Characterization and Classification of Stem Cells. 
Regen Med. G. Steinhoff, Springer Netherlands: 155-176. 
Blancas, A. A., N. E. Lauer, et al. (2008). "Endothelial differentiation of embryonic 
stem cells." Curr Protoc Stem Cell Biol Chapter 1: Unit 1F 5. 
References 
100 
 
Bobryshev, Y. V., S. M. Cherian, et al. (1999). "Neovascular expression of VE-cadherin 
in human atherosclerotic arteries and its relation to intimal inflammation." 
Cardiovasc Res 43(4): 1003-1017. 
Boisset, J. C., W. van Cappellen, et al. (2010). "In vivo imaging of haematopoietic cells 
emerging from the mouse aortic endothelium." Nature 464(7285): 116-120. 
Bonetti, P. O., L. O. Lerman, et al. (2003). "Endothelial dysfunction: a marker of 
atherosclerotic risk." Arterioscler Thromb Vasc Biol 23(2): 168-175. 
Boyd, N. L., S. K. Dhara, et al. (2007). "BMP4 promotes formation of primitive 
vascular networks in human embryonic stem cell-derived embryoid bodies." Exp 
Biol Med (Maywood) 232(6): 833-843. 
Boyer, L. A., T. I. Lee, et al. (2005). "Core transcriptional regulatory circuitry in human 
embryonic stem cells." Cell 122(6): 947-956. 
Bradley, A., M. Evans, et al. (1984). "Formation of germ-line chimaeras from embryo-
derived teratocarcinoma cell lines." Nature 309(5965): 255-256. 
Breier, G., F. Breviario, et al. (1996). "Molecular cloning and expression of murine 
vascular endothelial- cadherin in early stage development of cardiovascular 
system." Blood 87(2): 630-641. 
Breier, G., M. Clauss, et al. (1995). "Coordinate expression of vascular endothelial 
growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of 
murine vascular development." Dev Dyn 204(3): 228-239. 
Brignier, A. C. and A. M. Gewirtz (2010). "Embryonic and adult stem cell therapy." J 
Allergy Clin Immunol 125(2 Suppl 2): S336-344. 
Brilakis, E. S., V. G. Patel, et al. (2013). "Medical management after coronary stent 
implantation: a review." JAMA 310(2): 189-198. 
Brunner, H., J. R. Cockcroft, et al. (2005). "Endothelial function and dysfunction. Part 
II: Association with cardiovascular risk factors and diseases. A statement by the 
Working Group on Endothelins and Endothelial Factors of the European Society 
of Hypertension." J Hypertens 23(2): 233-246. 
Burdon, T., A. Smith, et al. (2002). "Signalling, cell cycle and pluripotency in 
embryonic stem cells." Trends in Cell Biology 12(9): 432-438. 
Burt, R. K., Y. Loh, et al. (2008). "Clinical applications of blood-derived and marrow-
derived stem cells for nonmalignant diseases." JAMA 299(8): 925-936. 
Califano, J. P. and C. A. Reinhart-King (2009). "The effects of substrate elasticity on 
endothelial cell network formation and traction force generation." Conf Proc 
IEEE Eng Med Biol Soc 2009: 3343-3345. 
Cao, F., S. Lin, et al. (2006). "In vivo visualization of embryonic stem cell survival, 
proliferation, and migration after cardiac delivery." Circulation 113(7): 1005-
1014. 
Carmeliet, P., V. Ferreira, et al. (1996). "Abnormal blood vessel development and 
lethality in embryos lacking a single VEGF allele." Nature 380(6573): 435-439. 
Carmeliet, P. and R. K. Jain (2011). "Molecular mechanisms and clinical applications of 
angiogenesis." Nature 473(7347): 298-307. 
Carmeliet, P., M.-G. Lampugnani, et al. (1999). "Targeted Deficiency or Cytosolic 
Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated 
Endothelial Survival and Angiogenesis." Cell 98(2): 147-157. 
Carrithers, M., S. Tandon, et al. (2005). "Enhanced susceptibility to endotoxic shock 
and impaired STAT3 signaling in CD31-deficient mice." Am J Pathol 166(1): 
185-196. 
Cattoglio, C., G. Facchini, et al. (2007). "Hot spots of retroviral integration in human 
CD34+ hematopoietic cells." Blood 110(6): 1770-1778. 
References 
101 
 
Cermenati, S., S. Moleri, et al. (2008). "Sox18 and Sox7 play redundant roles in 
vascular development." Blood 111(5): 2657-2666. 
Chadli, L., M. T. Martin, et al. (2011). "Investigating human keratinocyte stem cell 
identity." Eur J Dermatol 21 Suppl 2: 4-11. 
Chen, Z. and E. Tzima (2009). "PECAM-1 is necessary for flow-induced vascular 
remodeling." Arterioscler Thromb Vasc Biol 29(7): 1067-1073. 
Chhabra, P. and K. L. Brayman (2013). "Stem cell therapy to cure type 1 diabetes: from 
hype to hope." Stem Cells Transl Med 2(5): 328-336. 
Chiang, P. M. and P. C. Wong (2011). "Differentiation of an embryonic stem cell to 
hemogenic endothelium by defined factors: essential role of bone morphogenetic 
protein 4." Development 138(13): 2833-2843. 
Choi, K., M. Kennedy, et al. (1998). "A common precursor for hematopoietic and 
endothelial cells." Development 125(4): 725-732. 
Chu, H. and Y. Wang (2012). "Therapeutic angiogenesis: controlled delivery of 
angiogenic factors." Ther Deliv 3(6): 693-714. 
Chung, Y. S., W. J. Zhang, et al. (2002). "Lineage analysis of the hemangioblast as 
defined by FLK1 and SCL expression." Development 129(23): 5511-5520. 
Ciarrocchi, A., V. Jankovic, et al. (2007). "Id1 restrains p21 expression to control 
endothelial progenitor cell formation." PLoS One 2(12): e1338. 
Coucouvanis, E. and G. R. Martin (1995). "Signals for death and survival: a two-step 
mechanism for cavitation in the vertebrate embryo." Cell 83(2): 279-287. 
Das, H., J. C. George, et al. (2009). "Stem cell therapy with overexpressed VEGF and 
PDGF genes improves cardiac function in a rat infarct model." PLoS One 4(10): 
e7325. 
de Bruijn, M. F., N. A. Speck, et al. (2000). "Definitive hematopoietic stem cells first 
develop within the major arterial regions of the mouse embryo." EMBO J 
19(11): 2465-2474. 
De Miguel, M. P., S. Fuentes-Julian, et al. (2010). "Pluripotent stem cells: origin, 
maintenance and induction." Stem Cell Rev 6(4): 633-649. 
De Val, S. (2011). "Key transcriptional regulators of early vascular development." 
Arterioscler Thromb Vasc Biol 31(7): 1469-1475. 
Dejana, E. (2004). "Endothelial cell-cell junctions: happy together." Nat Rev Mol Cell 
Biol 5(4): 261-270. 
Dejana, E. and C. Giampietro (2012). "Vascular endothelial-cadherin and vascular 
stability." Curr Opin Hematol 19(3): 218-223. 
Dejana, E., F. Orsenigo, et al. (2008). "The role of adherens junctions and VE-cadherin 
in the control of vascular permeability." J Cell Sci 121(13): 2115-2122. 
Deveza, L., J. Choi, et al. (2012). "Therapeutic angiogenesis for treating cardiovascular 
diseases." Theranostics 2(8): 801-814. 
Dimaio, T. A., S. Wang, et al. (2008). "Attenuation of retinal vascular development and 
neovascularization in PECAM-1-deficient mice." Dev Biol 315(1): 72-88. 
Doetschman, T. C., H. Eistetter, et al. (1985). "The in vitro development of blastocyst-
derived embryonic stem cell lines: formation of visceral yolk sac, blood islands 
and myocardium." J Embryol Exp Morphol 87: 27-45. 
Dooley, K. A., A. J. Davidson, et al. (2005). "Zebrafish scl functions independently in 
hematopoietic and endothelial development." Dev Biol 277(2): 522-536. 
Du, Y., S. E. Spence, et al. (2005). "Cooperating cancer-gene identification through 
oncogenic-retrovirus-induced insertional mutagenesis." Blood 106(7): 2498-
2505. 
References 
102 
 
Dumont, D. J., G. H. Fong, et al. (1995). "Vascularization of the mouse embryo: a study 
of flk-1, tek, tie, and vascular endothelial growth factor expression during 
development." Dev Dyn 203(1): 80-92. 
Dumont, D. J., G. Gradwohl, et al. (1994). "Dominant-negative and targeted null 
mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in 
vasculogenesis of the embryo." Genes Dev 8(16): 1897-1909. 
Eilken, H. M., S. Nishikawa, et al. (2009). "Continuous single-cell imaging of blood 
generation from haemogenic endothelium." Nature 457(7231): 896-900. 
Escors, D. and K. Breckpot (2010). "Lentiviral Vectors in Gene Therapy: Their Current 
Status and Future Potential." Arch Immunol Ther Exp (Warsz). 
Evans, M. J. and M. H. Kaufman (1981). "Establishment in culture of pluripotential 
cells from mouse embryos." Nature 292(5819): 154-156. 
Fadini, G. P., D. Losordo, et al. (2012). "Critical Reevaluation of Endothelial Progenitor 
Cell Phenotypes for Therapeutic and Diagnostic Use." Circulation Research 
110(4): 624-637. 
Fearon, D. T., P. Manders, et al. (2001). "Arrested differentiation, the self-renewing 
memory lymphocyte, and vaccination." Science 293(5528): 248-250. 
Folkman, J. (1998). "Angiogenic therapy of the human heart." Circulation 97(7): 628-
629. 
Francois, M., A. Caprini, et al. (2008). "Sox18 induces development of the lymphatic 
vasculature in mice." Nature 456(7222): 643-647. 
Francois, M., K. Short, et al. (2012). "Segmental territories along the cardinal veins 
generate lymph sacs via a ballooning mechanism during embryonic 
lymphangiogenesis in mice." Dev Biol 364(2): 89-98. 
Freed, E. O. and M. A. Martin (1994). "HIV-1 infection of non-dividing cells." Nature 
369(6476): 107-108. 
Frid, M. G., V. A. Kale, et al. (2002). "Mature vascular endothelium can give rise to 
smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro 
analysis." Circ Res 90(11): 1189-1196. 
Fujisue, K., S. Sugiyama, et al. (2013). "Effects of Endothelial Dysfunction on Residual 
Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and 
Clopidogrel in Patients With Stable Coronary Artery Disease." Circ Cardiovasc 
Interv. 
Fujiwara, H., Y. Hayashi, et al. (2007). "Regulation of mesodermal differentiation of 
mouse embryonic stem cells by basement membranes." J Biol Chem 282(40): 
29701-29711. 
Fukata, M., F. Ishikawa, et al. (2013). "Contribution of bone marrow-derived 
hematopoietic stem/progenitor cells to the generation of donor-marker(+) 
cardiomyocytes in vivo." PLoS One 8(5): e62506. 
Fukuhara, S., K. Sako, et al. (2008). "Differential function of Tie2 at cell-cell contacts 
and cell-substratum contacts regulated by angiopoietin-1." Nat Cell Biol 10(5): 
513-526. 
Gao, X., P. Kouklis, et al. (2000). "Reversibility of increased microvessel permeability 
in response to VE-cadherin disassembly." Am J Physiol Lung Cell Mol Physiol 
279(6): L1218-1225. 
Gardner, R. L. (2007). "Stem cells and regenerative medicine: principles, prospects and 
problems." C R Biol 330(6-7): 465-473. 
Gardner, R. L. and R. S. Beddington (1988). "Multi-lineage 'stem' cells in the 
mammalian embryo." J Cell Sci Suppl 10: 11-27. 
References 
103 
 
Gavard, J. and J. S. Gutkind (2006). "VEGF controls endothelial-cell permeability by 
promoting the beta-arrestin-dependent endocytosis of VE-cadherin." Nat Cell 
Biol 8(11): 1223-1234. 
Gering, M., A. R. Rodaway, et al. (1998). "The SCL gene specifies haemangioblast 
development from early mesoderm." EMBO J 17(14): 4029-4045. 
Glaser, D. E., R. M. Gower, et al. (2011). "Functional characterization of embryonic 
stem cell-derived endothelial cells." J Vasc Res 48(5): 415-428. 
Goel, R., B. Boylan, et al. (2007). "The proinflammatory phenotype of PECAM-1-
deficient mice results in atherogenic diet-induced steatohepatitis." Am J Physiol 
Gastrointest Liver Physiol 293(6): G1205-1214. 
Goel, R., B. R. Schrank, et al. (2008). "Site-specific effects of PECAM-1 on 
atherosclerosis in LDL receptor-deficient mice." Arterioscler Thromb Vasc Biol 
28(11): 1996-2002. 
Goldie, L. C., J. L. Lucitti, et al. (2008). "Cell signaling directing the formation and 
function of hemogenic endothelium during murine embryogenesis." Blood 
112(8): 3194-3204. 
Gory-Faure, S., M. H. Prandini, et al. (1999). "Role of vascular endothelial-cadherin in 
vascular morphogenesis." Development 126(10): 2093-2102. 
Gory, S., M. Vernet, et al. (1999). "The Vascular Endothelial-Cadherin Promoter 
Directs Endothelial-Specific Expression in Transgenic Mice." Blood 93(1): 184-
192. 
Greco, V. and S. Guo (2010). "Compartmentalized organization: a common and 
required feature of stem cell niches?" Development 137(10): 1586-1594. 
Gu, A. and J. E. Shively (2011). "Angiopoietins-1 and -2 play opposing roles in 
endothelial sprouting of embryoid bodies in 3D culture and their receptor Tie-2 
associates with the cell-cell adhesion molecule PECAM1." Exp Cell Res 
317(15): 2171-2182. 
Harry, B. L., J. M. Sanders, et al. (2008). "Endothelial cell PECAM-1 promotes 
atherosclerotic lesions in areas of disturbed flow in ApoE-deficient mice." 
Arterioscler Thromb Vasc Biol 28(11): 2003-2008. 
Hayashi, K., S. M. de Sousa Lopes, et al. (2007). "Germ cell specification in mice." 
Science 316(5823): 394-396. 
Hayashi, M. A., J. R. Guerreiro, et al. (2010). "Long-term culture of mouse embryonic 
stem cell-derived adherent neurospheres and functional neurons." Tissue Eng 
Part C Methods 16(6): 1493-1502. 
He, S., D. Nakada, et al. (2009). "Mechanisms of stem cell self-renewal." Annu Rev 
Cell Dev Biol 25: 377-406. 
Hedman, M., J. Hartikainen, et al. (2011). "Progress and prospects: hurdles to 
cardiovascular gene therapy clinical trials." Gene Ther 18(8): 743-749. 
Heil, M., I. Eitenmuller, et al. (2006). "Arteriogenesis versus angiogenesis: similarities 
and differences." J Cell Mol Med 10(1): 45-55. 
Heinke, J., C. Patterson, et al. (2012). "Life is a pattern: vascular assembly within the 
embryo." Front Biosci (Elite Ed) 4: 2269-2288. 
Heitzer, T., T. Schlinzig, et al. (2001). "Endothelial dysfunction, oxidative stress, and 
risk of cardiovascular events in patients with coronary artery disease." 
Circulation 104(22): 2673-2678. 
Herzog, E. L., L. Chai, et al. (2003). "Plasticity of marrow-derived stem cells." Blood 
102(10): 3483-3493. 
Hirai, H., P. Karian, et al. (2011). "Regulation of embryonic stem cell self-renewal and 
pluripotency by leukaemia inhibitory factor." Biochem J 438(1): 11-23. 
References 
104 
 
Hirai, H., M. Ogawa, et al. (2003). "Hemogenic and nonhemogenic endothelium can be 
distinguished by the activity of fetal liver kinase (Flk)-1 promoter/enhancer 
during mouse embryogenesis." Blood 101(3): 886-893. 
Hirschi, K. K. (2012). "Hemogenic endothelium during development and beyond." 
Blood 119(21): 4823-4827. 
Hohenstein, K. A., A. D. Pyle, et al. (2008). "Nucleofection mediates high-efficiency 
stable gene knockdown and transgene expression in human embryonic stem 
cells." Stem Cells 26(6): 1436-1443. 
Horwitz, E. M. (2008). "Mesenchymal stromal cells moving forward." Cytotherapy 
10(1): 5-6. 
Hosking, B., M. Francois, et al. (2009). "Sox7 and Sox17 are strain-specific modifiers 
of the lymphangiogenic defects caused by Sox18 dysfunction in mice." 
Development 136(14): 2385-2391. 
Hotkar, A. J. and W. Balinsky (2012). "Stem cells in the treatment of cardiovascular 
disease--an overview." Stem Cell Rev 8(2): 494-502. 
Huang, N. F., H. Niiyama, et al. (2009). "Embryonic stem cell-derived endothelial cells 
for treatment of hindlimb ischemia." J Vis Exp(23). 
Huang, N. F., H. Niiyama, et al. (2010). "Embryonic stem cell-derived endothelial cells 
engraft into the ischemic hindlimb and restore perfusion." Arterioscler Thromb 
Vasc Biol 30(5): 984-991. 
Huang, N. F., J. Okogbaa, et al. (2012). "Bioluminescence imaging of stem cell-based 
therapeutics for vascular regeneration." Theranostics 2(4): 346-354. 
Huber, T. L., V. Kouskoff, et al. (2004). "Haemangioblast commitment is initiated in 
the primitive streak of the mouse embryo." Nature 432(7017): 625-630. 
Hur, J., C.-H. Yoon, et al. (2004). "Characterization of Two Types of Endothelial 
Progenitor Cells and Their Different Contributions to Neovasculogenesis." 
Arteriosclerosis, Thrombosis, and Vascular Biology 24(2): 288-293. 
Ilan, N. and J. A. Madri (2003). "PECAM-1: old friend, new partners." Curr Opin Cell 
Biol 15(5): 515-524. 
Iljin, K., T. V. Petrova, et al. (2002). "A fluorescent Tie1 reporter allows monitoring of 
vascular development and endothelial cell isolation from transgenic mouse 
embryos." FASEB J 16(13): 1764-1774. 
Irion, S., R. L. Clarke, et al. (2010). "Temporal specification of blood progenitors from 
mouse embryonic stem cells and induced pluripotent stem cells." Development 
137(17): 2829-2839. 
Ishikawa, K., L. Tilemann, et al. (2011). "Gene delivery methods in cardiac gene 
therapy." J Gene Med 13(10): 566-572. 
Ishitobi, H., A. Wakamatsu, et al. (2011). "Molecular basis for Flk1 expression in 
hemato-cardiovascular progenitors in the mouse." Development 138(24): 5357-
5368. 
James, D., H. S. Nam, et al. (2010). "Expansion and maintenance of human embryonic 
stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependent." Nat 
Biotechnol 28(2): 161-166. 
James, D., Q. Zhan, et al. (2011). "Lentiviral transduction and clonal selection of hESCs 
with endothelial-specific transgenic reporters." Curr Protoc Stem Cell Biol 
Chapter 1: Unit1F 12. 
Jawad, E. and R. Arora (2008). "Chronic stable angina pectoris." Dis Mon 54(9): 671-
689. 
References 
105 
 
Jiang, H., X. Lin, et al. (2010). "Hemato-endothelial differentiation from lentiviral-
transduced human embryonic stem cells retains durable reporter gene expression 
under the control of ubiquitin promoter." Cytotechnology. 
Johnson, N. C., M. E. Dillard, et al. (2008). "Lymphatic endothelial cell identity is 
reversible and its maintenance requires Prox1 activity." Genes Dev 22(23): 
3282-3291. 
Kanda, A., Y. Sotomaru, et al. (2012). "Establishment of ES cells from inbred strain 
mice by dual inhibition (2i)." J Reprod Dev 58(1): 77-83. 
Kanji, S., V. J. Pompili, et al. (2011). "Plasticity and maintenance of hematopoietic 
stem cells during development." Recent Pat Biotechnol 5(1): 40-53. 
Kastrup, J. (2010). "Gene therapy and angiogenesis in patients with coronary artery 
disease." Expert Rev Cardiovasc Ther 8(8): 1127-1138. 
Kataoka, H., M. Hayashi, et al. (2011). "Etv2/ER71 induces vascular mesoderm from 
Flk1+PDGFRα+ primitive mesoderm." Blood 118(26): 6975-6986. 
Keller, G. M. (1995). "In vitro differentiation of embryonic stem cells." Curr Opin Cell 
Biol 7(6): 862-869. 
Kelly, M. A. and K. K. Hirschi (2009). "Signaling Hierarchy Regulating Human 
Endothelial Cell Development." Arteriosclerosis, Thrombosis, and Vascular 
Biology 29(5): 718-724. 
Kerem, A., J. Yin, et al. (2010). "Lung endothelial dysfunction in congestive heart 
failure: role of impaired Ca2+ signaling and cytoskeletal reorganization." Circ 
Res 106(6): 1103-1116. 
Kidder, B. L., J. Yang, et al. (2008). "Stat3 and c-Myc Genome-Wide Promoter 
Occupancy in Embryonic Stem Cells." PLoS One 3(12). 
Kim, G. D., S. Y. Bae, et al. (2012). "Honokiol inhibits vascular vessel formation of 
mouse embryonic stem cell-derived endothelial cells via the suppression of 
PECAM and MAPK/mTOR signaling pathway." Cell Physiol Biochem 30(3): 
758-770. 
Kim, G. D., G. J. Kim, et al. (2008). "Differentiation of endothelial cells derived from 
mouse embryoid bodies: a possible in vitro vasculogenesis model." Toxicol Lett 
180(3): 166-173. 
Kim, H., H. J. Cho, et al. (2010). "CD31+ cells represent highly angiogenic and 
vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in 
neovascularization and their therapeutic effects on ischemic vascular disease." 
Circ Res 107(5): 602-614. 
Kim, J. W., S. Y. Suh, et al. (2008). "Six-month comparison of coronary endothelial 
dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting 
stent." JACC Cardiovasc Interv 1(1): 65-71. 
Kim, S. and H. A. von Recum (2009). "Endothelial progenitor populations in 
differentiating embryonic stem cells I: Identification and differentiation 
kinetics." Tissue Eng Part A 15(12): 3709-3718. 
Kim, S. and H. A. von Recum (2010). "Endothelial progenitor populations in 
differentiating embryonic stem cells. II. Drug selection and functional 
characterization." Tissue Eng Part A 16(3): 1065-1074. 
Kimura, Y., B. Ding, et al. (2011). "c-Kit-mediated functional positioning of stem cells 
to their niches is essential for maintenance and regeneration of adult 
hematopoiesis." PLoS One 6(10): e26918. 
Kleinman, H. K. and G. R. Martin (2005). "Matrigel: basement membrane matrix with 
biological activity." Semin Cancer Biol 15(5): 378-386. 
References 
106 
 
Komarova, Y. A., D. Mehta, et al. (2007). "Dual regulation of endothelial junctional 
permeability." Sci STKE 2007(412): re8. 
Krishnan, R., D. D. Klumpers, et al. (2011). "Substrate stiffening promotes endothelial 
monolayer disruption through enhanced physical forces." Am J Physiol Cell 
Physiol 300(1): C146-154. 
Kullo, I. J. and A. R. Malik (2007). "Arterial ultrasonography and tonometry as adjuncts 
to cardiovascular risk stratification." J Am Coll Cardiol 49(13): 1413-1426. 
Lampugnani, M. G. and E. Dejana (1997). "Interendothelial junctions: structure, 
signalling and functional roles." Curr Opin Cell Biol 9(5): 674-682. 
Lampugnani, M. G., M. Resnati, et al. (1992). "A novel endothelial-specific membrane 
protein is a marker of cell-cell contacts." J Cell Biol 118(6): 1511-1522. 
Lancrin, C., P. Sroczynska, et al. (2010). "Blood cell generation from the 
hemangioblast." J Mol Med (Berl) 88(2): 167-172. 
Lancrin, C., P. Sroczynska, et al. (2009). "The haemangioblast generates haematopoietic 
cells through a haemogenic endothelium stage." Nature 457(7231): 892-895. 
Larson, J. D., S. A. Wadman, et al. (2004). "Expression of VE-cadherin in zebrafish 
embryos: a new tool to evaluate vascular development." Dev Dyn 231(1): 204-
213. 
Laslett, L. J., P. Alagona, Jr., et al. (2012). "The worldwide environment of 
cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a 
report from the American College of Cardiology." J Am Coll Cardiol 60(25 
Suppl): S1-49. 
Lawson, N. D., N. Scheer, et al. (2001). "Notch signaling is required for arterial-venous 
differentiation during embryonic vascular development." Development 128(19): 
3675-3683. 
le Noble, F., D. Moyon, et al. (2004). "Flow regulates arterial-venous differentiation in 
the chick embryo yolk sac." Development 131(2): 361-375. 
Lee, K. H., C. K. Chuang, et al. (2012). "Simple and efficient derivation of mouse 
embryonic stem cell lines using differentiation inhibitors or proliferation 
stimulators." Stem Cells Dev 21(3): 373-383. 
Lee, S., J. Kang, et al. (2009). "Prox1 physically and functionally interacts with COUP-
TFII to specify lymphatic endothelial cell fate." Blood 113(8): 1856-1859. 
Leeper, N. J., A. L. Hunter, et al. (2010). "Stem cell therapy for vascular regeneration: 
adult, embryonic, and induced pluripotent stem cells." Circulation 122(5): 517-
526. 
Leitch, H. G., K. Blair, et al. (2010). "Embryonic germ cells from mice and rats exhibit 
properties consistent with a generic pluripotent ground state." Development 
137(14): 2279-2287. 
Lescaudron, L., P. Naveilhan, et al. (2012). "The use of stem cells in regenerative 
medicine for Parkinson's and Huntington's Diseases." Curr Med Chem 19(35): 
6018-6035. 
Levenberg, S., J. S. Golub, et al. (2002). "Endothelial cells derived from human 
embryonic stem cells." Proc Natl Acad Sci U S A 99(7): 4391-4396. 
Li, A. C. and C. K. Glass (2002). "The macrophage foam cell as a target for therapeutic 
intervention." Nat Med 8(11): 1235-1242. 
Li, W. and S. Ding (2010). "Small molecules that modulate embryonic stem cell fate 
and somatic cell reprogramming." Trends Pharmacol Sci 31(1): 36-45. 
Li, W., H. Wang, et al. (2012). "An essential role for the Id1/PI3K/Akt/NFkB/survivin 
signalling pathway in promoting the proliferation of endothelial progenitor cells 
in vitro." Mol Cell Biochem 363(1-2): 135-145. 
References 
107 
 
Li, Z., S. Hu, et al. (2011). "Functional characterization and expression profiling of 
human induced pluripotent stem cell- and embryonic stem cell-derived 
endothelial cells." Stem Cells Dev 20(10): 1701-1710. 
Li, Z., K. D. Wilson, et al. (2009). "Functional and transcriptional characterization of 
human embryonic stem cell-derived endothelial cells for treatment of 
myocardial infarction." PLoS One 4(12): e8443. 
Li, Z., J. C. Wu, et al. (2007). "Differentiation, survival, and function of embryonic 
stem cell derived endothelial cells for ischemic heart disease." Circulation 
116(11 Suppl): I46-54. 
Li, Z. J., Z. Z. Wang, et al. (2005). "Kinetic expression of platelet endothelial cell 
adhesion molecule-1 (PECAM-1/CD31) during embryonic stem cell 
differentiation." J Cell Biochem 95(3): 559-570. 
Liao, F., Y. Li, et al. (2000). "Monoclonal antibody to vascular endothelial-cadherin is a 
potent inhibitor of angiogenesis, tumor growth, and metastasis." Cancer Res 
60(24): 6805-6810. 
Libby, P. (2002). "Inflammation in atherosclerosis." Nature 420(6917): 868-874. 
Libby, P., D. Schwartz, et al. (1992). "A cascade model for restenosis. A special case of 
atherosclerosis progression." Circulation 86(6 Suppl): III47-52. 
Libby, P. and P. Theroux (2005). "Pathophysiology of coronary artery disease." 
Circulation 111(25): 3481-3488. 
Liew, C. G., J. S. Draper, et al. (2007). "Transient and stable transgene expression in 
human embryonic stem cells." Stem Cells 25(6): 1521-1528. 
Lim, W. F., T. Inoue-Yokoo, et al. (2013). "Hematopoietic cell differentiation from 
embryonic and induced pluripotent stem cells." Stem Cell Res Ther 4(3): 71. 
Lois, C., E. J. Hong, et al. (2002). "Germline transmission and tissue-specific 
expression of transgenes delivered by lentiviral vectors." Science 295(5556): 
868-872. 
Losordo, D. W. and S. Dimmeler (2004). "Therapeutic angiogenesis and vasculogenesis 
for ischemic disease. Part I: angiogenic cytokines." Circulation 109(21): 2487-
2491. 
Lu, J., V. J. Pompili, et al. (2011). "Neovascularization and Hematopoietic Stem Cells." 
Cell Biochem Biophys. 
Lugus, J. J., Y. S. Chung, et al. (2007). "GATA2 functions at multiple steps in 
hemangioblast development and differentiation." Development 134(2): 393-405. 
Luo, L. J., F. Liu, et al. (2012). "An essential function for MKP5 in the formation of 
oxidized low density lipid-induced foam cells." Cell Signal 24(10): 1889-1898. 
Luplertlop, N., D. Misse, et al. (2006). "Dengue-virus-infected dendritic cells trigger 
vascular leakage through metalloproteinase overproduction." EMBO Rep 7(11): 
1176-1181. 
Magid, R., D. Martinson, et al. (2003). "Optimization of isolation and functional 
characterization of primary murine aortic endothelial cells." Endothelium 10(2): 
103-109. 
Marcelo, K. L., L. C. Goldie, et al. (2013). "Regulation of endothelial cell 
differentiation and specification." Circ Res 112(9): 1272-1287. 
Marchetti, S., C. Gimond, et al. (2002). "Endothelial cells genetically selected from 
differentiating mouse embryonic stem cells incorporate at sites of 
neovascularization in vivo." J Cell Sci 115(Pt 10): 2075-2085. 
Mariappan, D., J. Winkler, et al. (2009). "Transcriptional profiling of CD31(+) cells 
isolated from murine embryonic stem cells." Genes Cells 14(2): 243-260. 
References 
108 
 
Marom, K., V. Levy, et al. (2005). "Temporal analysis of the early BMP functions 
identifies distinct anti-organizer and mesoderm patterning phases." Dev Biol 
282(2): 442-454. 
Martin, G. R. (1981). "Isolation of a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma stem cells." Proc Natl Acad 
Sci U S A 78(12): 7634-7638. 
Matsuyoshi, N., K. Toda, et al. (1997). "In vivo evidence of the critical role of cadherin-
5 in murine vascular integrity." Proc Assoc Am Physicians 109(4): 362-371. 
McCarthy, M. J., M. Crowther, et al. (1998). "The endothelial receptor tyrosine kinase 
tie-1 is upregulated by hypoxia and vascular endothelial growth factor." FEBS 
Lett 423(3): 334-338. 
McCloskey, K. E., I. Lyons, et al. (2003). "Purified and proliferating endothelial cells 
derived and expanded in vitro from embryonic stem cells." Endothelium 10(6): 
329-336. 
McFalls, E. O., H. B. Ward, et al. (2004). "Coronary-artery revascularization before 
elective major vascular surgery." N Engl J Med 351(27): 2795-2804. 
Medina, R. J., C. L. O'Neill, et al. (2010). "Molecular analysis of endothelial progenitor 
cell (EPC) subtypes reveals two distinct cell populations with different 
identities." BMC Med Genomics 3: 18. 
Medine, C. N., B. Lucendo-Villarin, et al. (2008). Robust generation of hepatocyte-like 
cells from human embryonic stem cell populations. StemBook. Cambridge 
(MA). 
Mendis, S., P. Puska, et al. (2011). Global atlas on cardiovascular disease prevention 
and control. Geneva, World Health Organization. 
Mestas, J. and K. Ley (2008). "Monocyte-endothelial cell interactions in the 
development of atherosclerosis." Trends Cardiovasc Med 18(6): 228-232. 
Mikkers, H., J. Allen, et al. (2002). "High-throughput retroviral tagging to identify 
components of specific signaling pathways in cancer." Nat Genet 32(1): 153-
159. 
Miquerol, L., B. L. Langille, et al. (2000). "Embryonic development is disrupted by 
modest increases in vascular endothelial growth factor gene expression." 
Development 127(18): 3941-3946. 
Montini, E., D. Cesana, et al. (2006). "Hematopoietic stem cell gene transfer in a tumor-
prone mouse model uncovers low genotoxicity of lentiviral vector integration." 
Nat Biotechnol 24(6): 687-696. 
Moore, J. C., L. W. van Laake, et al. (2005). "Human embryonic stem cells: genetic 
manipulation on the way to cardiac cell therapies." Reprod Toxicol 20(3): 377-
391. 
Moore, K. J. and I. Tabas (2011). "Macrophages in the pathogenesis of atherosclerosis." 
Cell 145(3): 341-355. 
Morrison, S. J., N. M. Shah, et al. (1997). "Regulatory mechanisms in stem cell 
biology." Cell 88(3): 287-298. 
Mothe, A. J. and C. H. Tator (2013). "Review of Transplantation of Neural 
Stem/Progenitor Cells for Spinal Cord Injury." Int J Dev Neurosci. 
Muller, W. A., C. M. Ratti, et al. (1989). "A human endothelial cell-restricted, 
externally disposed plasmalemmal protein enriched in intercellular junctions." J 
Exp Med 170(2): 399-414. 
Murakami, M., L. T. Nguyen, et al. (2008). "The FGF system has a key role in 
regulating vascular integrity." J Clin Invest 118(10): 3355-3366. 
References 
109 
 
Murry, C. E. and G. Keller (2008). "Differentiation of embryonic stem cells to clinically 
relevant populations: lessons from embryonic development." Cell 132(4): 661-
680. 
Naldini, L., U. Blomer, et al. (1996). "In vivo gene delivery and stable transduction of 
nondividing cells by a lentiviral vector." Science 272(5259): 263-267. 
Nasu, T. (2005). "Scanning electron microscopic study on the microarchitecture of the 
vascular system in the pigeon lung." J Vet Med Sci 67(10): 1071-1074. 
Newman, P. J. (1994). "The role of PECAM-1 in vascular cell biology." Ann N Y Acad 
Sci 714: 165-174. 
Newman, P. J. (1997). "The biology of PECAM-1." J Clin Invest 100(11 Suppl): S25-
29. 
Newman, P. J. and D. K. Newman (2003). "Signal transduction pathways mediated by 
PECAM-1: new roles for an old molecule in platelet and vascular cell biology." 
Arterioscler Thromb Vasc Biol 23(6): 953-964. 
Nguyen, T. H., J. Oberholzer, et al. (2002). "Highly efficient lentiviral vector-mediated 
transduction of nondividing, fully reimplantable primary hepatocytes." Mol Ther 
6(2): 199-209. 
Nikolova-Krstevski, V., M. Bhasin, et al. (2008). "Gene expression analysis of 
embryonic stem cells expressing VE-cadherin (CD144) during endothelial 
differentiation." BMC Genomics 9: 240. 
Nirmalanandhan, V. S. and G. S. Sittampalam (2009). "Stem cells in drug discovery, 
tissue engineering, and regenerative medicine: emerging opportunities and 
challenges." J Biomol Screen 14(7): 755-768. 
Nishikawa, S. I., S. Nishikawa, et al. (1998). "Progressive lineage analysis by cell 
sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of 
endothelial and hemopoietic lineages." Development 125(9): 1747-1757. 
Nishimura, K. and J. Takahashi (2013). "Therapeutic application of stem cell 
technology toward the treatment of Parkinson's disease." Biol Pharm Bull 36(2): 
171-175. 
Niwa, H., K. Ogawa, et al. (2009). "A parallel circuit of LIF signalling pathways 
maintains pluripotency of mouse ES cells." Nature 460(7251): 118-122. 
Nolkrantz, K., C. Farre, et al. (2002). "Functional screening of intracellular proteins in 
single cells and in patterned cell arrays using electroporation." Anal Chem 
74(16): 4300-4305. 
Nowak, G., A. Karrar, et al. (2004). "Expression of vascular endothelial growth factor 
receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell 
populations capable of reendothelialization." Circulation 110(24): 3699-3707. 
Oliva-Trastoy, M., M. Defais, et al. (2005). "Resistance to the antibiotic Zeocin by 
stable expression of the Sh ble gene does not fully suppress Zeocin-induced 
DNA cleavage in human cells." Mutagenesis 20(2): 111-114. 
Pearson, S., P. Sroczynska, et al. (2008). "The stepwise specification of embryonic stem 
cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, 
bFGF and VEGF." Development 135(8): 1525-1535. 
Pendeville, H., M. Winandy, et al. (2008). "Zebrafish Sox7 and Sox18 function together 
to control arterial-venous identity." Dev Biol 317(2): 405-416. 
Penn, J. S. (2008). Retinal and choroidal angiogenesis. Dordrecht, Springer. 
Pennisi, D., J. Gardner, et al. (2000). "Mutations in Sox18 underlie cardiovascular and 
hair follicle defects in ragged mice." Nat Genet 24(4): 434-437. 
References 
110 
 
Perin, E. C., H. F. Dohmann, et al. (2003). "Transendocardial, autologous bone marrow 
cell transplantation for severe, chronic ischemic heart failure." Circulation 
107(18): 2294-2302. 
Pfeifer, A., M. Ikawa, et al. (2002). "Transgenesis by lentiviral vectors: lack of gene 
silencing in mammalian embryonic stem cells and preimplantation embryos." 
Proc Natl Acad Sci U S A 99(4): 2140-2145. 
Pham, V. N., N. D. Lawson, et al. (2007). "Combinatorial function of ETS transcription 
factors in the developing vasculature." Dev Biol 303(2): 772-783. 
Pittenger, M. F. and B. J. Martin (2004). "Mesenchymal stem cells and their potential as 
cardiac therapeutics." Circ Res 95(1): 9-20. 
Rama, P., S. Matuska, et al. (2010). "Limbal stem-cell therapy and long-term corneal 
regeneration." N Engl J Med 363(2): 147-155. 
Ramalho-Santos, M. and H. Willenbring (2007). "On the Origin of the Term “Stem 
Cell”." Cell Stem Cell 1(1): 35-38. 
Rando, T. A. (2006). "Stem cells, ageing and the quest for immortality." Nature 
441(7097): 1080-1086. 
Rao, R. M., L. Yang, et al. (2007). "Endothelial-dependent mechanisms of leukocyte 
recruitment to the vascular wall." Circ Res 101(3): 234-247. 
Red-Horse, K., H. Ueno, et al. (2010). "Coronary arteries form by developmental 
reprogramming of venous cells." Nature 464(7288): 549-553. 
Risau, W. and I. Flamme (1995). "Vasculogenesis." Annu Rev Cell Dev Biol 11: 73-91. 
Risau, W., H. Sariola, et al. (1988). "Vasculogenesis and angiogenesis in embryonic-
stem-cell-derived embryoid bodies." Development 102(3): 471-478. 
Robertson, E. (1997). Derivation and Maintenance of Embryonic Stem Cell Cultures. 
Basic Cell Culture Protocols. J. Pollard and J. Walker, Humana Press. 290: 173-
184. 
Roger, V. L., A. S. Go, et al. (2012). "Heart disease and stroke statistics--2012 update: a 
report from the American Heart Association." Circulation 125(1): e2-e220. 
Romero-Lanman, E. E., S. Pavlovic, et al. (2012). "Id1 maintains embryonic stem cell 
self-renewal by up-regulation of Nanog and repression of Brachyury 
expression." Stem Cells Dev 21(3): 384-393. 
Ross, R., D. Bowen-Pope, et al. (1982). "Endothelial injury: blood-vessel wall 
interactions." Ann N Y Acad Sci 401: 260-264. 
Rossig, L., C. Urbich, et al. (2005). "Histone deacetylase activity is essential for the 
expression of HoxA9 and for endothelial commitment of progenitor cells." J Exp 
Med 201(11): 1825-1835. 
Saitou, M., S. Kagiwada, et al. (2012). "Epigenetic reprogramming in mouse pre-
implantation development and primordial germ cells." Development 139(1): 15-
31. 
Sakakura, K., M. Nakano, et al. (2013). "Pathophysiology of atherosclerosis plaque 
progression." Heart Lung Circ 22(6): 399-411. 
Sakao, S., K. Tatsumi, et al. (2009). "Endothelial cells and pulmonary arterial 
hypertension: apoptosis, proliferation, interaction and transdifferentiation." 
Respir Res 10: 95. 
Sakuma, T., M. A. Barry, et al. (2012). "Lentiviral vectors: basic to translational." 
Biochem J 443(3): 603-618. 
Salvucci, O., M. de la Luz Sierra, et al. (2006). "EphB2 and EphB4 receptors forward 
signaling promotes SDF-1-induced endothelial cell chemotaxis and branching 
remodeling." Blood 108(9): 2914-2922. 
References 
111 
 
Salvucci, O. and G. Tosato (2012). "Essential roles of EphB receptors and EphrinB 
ligands in endothelial cell function and angiogenesis." Adv Cancer Res 114: 21-
57. 
Sarkar, K., S. Rey, et al. (2012). "Tie2-dependent knockout of HIF-1 impairs burn 
wound vascularization and homing of bone marrow-derived angiogenic cells." 
Cardiovasc Res 93(1): 162-169. 
Sasaki, T., R. Fassler, et al. (2004). "Laminin: the crux of basement membrane 
assembly." J Cell Biol 164(7): 959-963. 
Scadden, D. T. (2006). "The stem-cell niche as an entity of action." Nature 441(7097): 
1075-1079. 
Scarlett, C. J. (2013). "Contribution of bone marrow derived cells to the pancreatic 
tumor microenvironment." Front Physiol 4: 56. 
Schambach, A., D. Zychlinski, et al. (2013). "Biosafety features of lentiviral vectors." 
Hum Gene Ther 24(2): 132-142. 
Schuh, A. C., P. Faloon, et al. (1999). "In vitro hematopoietic and endothelial potential 
of flk-1(-/-) embryonic stem cells and embryos." Proc Natl Acad Sci U S A 
96(5): 2159-2164. 
Schulz, T. C., H. Y. Young, et al. (2012). "A scalable system for production of 
functional pancreatic progenitors from human embryonic stem cells." PLoS One 
7(5): e37004. 
Seegar, T. C., B. Eller, et al. (2010). "Tie1-Tie2 interactions mediate functional 
differences between angiopoietin ligands." Mol Cell 37(5): 643-655. 
Seiler, C. (2010). "The human coronary collateral circulation." Eur J Clin Invest 40(5): 
465-476. 
Shalaby, F., J. Rossant, et al. (1995). "Failure of blood-island formation and 
vasculogenesis in Flk-1-deficient mice." Nature 376(6535): 62-66. 
Sivertsson, L., J. Synnergren, et al. (2013). "Hepatic differentiation and maturation of 
human embryonic stem cells cultured in a perfused three-dimensional 
bioreactor." Stem Cells Dev 22(4): 581-594. 
Smith, A. G., J. K. Heath, et al. (1988). "Inhibition of Pluripotential Embryonic Stem-
Cell Differentiation by Purified Polypeptides." Nature 336(6200): 688-690. 
Smith, S. C., Jr., A. Collins, et al. (2012). "Our time: a call to save preventable death 
from cardiovascular disease (heart disease and stroke)." J Am Coll Cardiol 
60(22): 2343-2348. 
Sneddon, J. B., M. Borowiak, et al. (2012). "Self-renewal of embryonic-stem-cell-
derived progenitors by organ-matched mesenchyme." Nature 491(7426): 765-
768. 
Srinivas, M., P. Boehm-Sturm, et al. (2012). "Labeling cells for in vivo tracking using 
(19)F MRI." Biomaterials 33(34): 8830-8840. 
Srinivasan, R. S., M. E. Dillard, et al. (2007). "Lineage tracing demonstrates the venous 
origin of the mammalian lymphatic vasculature." Genes & Development 21(19): 
2422-2432. 
Srinivasan, R. S., X. Geng, et al. (2010). "The nuclear hormone receptor Coup-TFII is 
required for the initiation and early maintenance of Prox1 expression in 
lymphatic endothelial cells." Genes & Development 24(7): 696-707. 
Srivastava, D. and K. N. Ivey (2006). "Potential of stem-cell-based therapies for heart 
disease." Nature 441(7097): 1097-1099. 
Steinberg, D. (2002). "Atherogenesis in perspective: hypercholesterolemia and 
inflammation as partners in crime." Nat Med 8(11): 1211-1217. 
References 
112 
 
Sumpio, B. E., J. T. Riley, et al. (2002). "Cells in focus: endothelial cell." Int J Biochem 
Cell Biol 34(12): 1508-1512. 
Sun, G. and S. Gerecht (2009). "Vascular regeneration: engineering the stem cell 
microenvironment." Regen Med 4(3): 435-447. 
Sun, X., L. Cheng, et al. (2009). "Effects of an endothelial cell-conditioned medium on 
the hematopoietic and endothelial differentiation of embryonic stem cells." Cell 
Biol Int 33(11): 1201-1205. 
Suzuki, S., K. Sano, et al. (1991). "Diversity of the cadherin family: evidence for eight 
new cadherins in nervous tissue." Cell Regul 2(4): 261-270. 
Swift, M. R. and B. M. Weinstein (2009). "Arterial-venous specification during 
development." Circ Res 104(5): 576-588. 
Tabit, C. E., W. B. Chung, et al. (2010). "Endothelial dysfunction in diabetes mellitus: 
molecular mechanisms and clinical implications." Rev Endocr Metab Disord 
11(1): 61-74. 
Tallini, Y. N., K. S. Greene, et al. (2009). "c-kit expression identifies cardiovascular 
precursors in the neonatal heart." Proc Natl Acad Sci U S A 106(6): 1808-1813. 
Taylor, A. A. (2001). "Pathophysiology of hypertension and endothelial dysfunction in 
patients with diabetes mellitus." Endocrinol Metab Clin North Am 30(4): 983-
997. 
Tesar, P. J., J. G. Chenoweth, et al. (2007). "New cell lines from mouse epiblast share 
defining features with human embryonic stem cells." Nature 448(7150): 196-
199. 
Thanyasiri, P., K. Kathir, et al. (2007). "Endothelial dysfunction and restenosis 
following percutaneous coronary intervention." Int J Cardiol 119(3): 362-367. 
Toh, W. S., X. M. Guo, et al. (2009). "Differentiation and enrichment of expandable 
chondrogenic cells from human embryonic stem cells in vitro." J Cell Mol Med 
13(9B): 3570-3590. 
Trentin, A., C. Glavieux-Pardanaud, et al. (2004). "Self-renewal capacity is a 
widespread property of various types of neural crest precursor cells." Proc Natl 
Acad Sci U S A 101(13): 4495-4500. 
Urbich, C., A. Aicher, et al. (2005). "Soluble factors released by endothelial progenitor 
cells promote migration of endothelial cells and cardiac resident progenitor 
cells." Journal of Molecular and Cellular Cardiology 39(5): 733-742. 
Van Blokland, H. J., F. Hoeksema, et al. (2011). "Methods to create a stringent selection 
system for mammalian cell lines." Cytotechnology 63(4): 371-384. 
Van der Jeught, M., T. O'Leary, et al. (2013). "The combination of inhibitors of 
FGF/MEK/Erk and GSK3beta signaling increases the number of OCT3/4- and 
NANOG-positive cells in the human inner cell mass, but does not improve stem 
cell derivation." Stem Cells Dev 22(2): 296-306. 
Vazao, H., R. P. das Neves, et al. (2011). "Towards the maturation and characterization 
of smooth muscle cells derived from human embryonic stem cells." PLoS One 
6(3): e17771. 
Versari, D., E. Daghini, et al. (2009). "Endothelium-dependent contractions and 
endothelial dysfunction in human hypertension." Br J Pharmacol 157(4): 527-
536. 
Vestweber, D. (2008). "VE-cadherin: the major endothelial adhesion molecule 
controlling cellular junctions and blood vessel formation." Arterioscler Thromb 
Vasc Biol 28(2): 223-232. 
Virmani, R., A. P. Burke, et al. (2006). "Pathology of the vulnerable plaque." J Am Coll 
Cardiol 47(8 Suppl): C13-18. 
References 
113 
 
Vittet, D., M. H. Prandini, et al. (1996). "Embryonic stem cells differentiate in vitro to 
endothelial cells through successive maturation steps." Blood 88(9): 3424-3431. 
Voelkel, N. F. and S. Rounds (2009). The pulmonary endothelium : function in health 
and disease. Oxford, Wiley-Blackwell. 
Vogeli, K. M., S. W. Jin, et al. (2006). "A common progenitor for haematopoietic and 
endothelial lineages in the zebrafish gastrula." Nature 443(7109): 337-339. 
Wang, H., Y. Yu, et al. (2010). "Inhibitor of DNA binding-1 promotes the migration 
and proliferation of endothelial progenitor cells in vitro." Mol Cell Biochem 
335(1-2): 19-27. 
Wang, H. U., Z. F. Chen, et al. (1998). "Molecular distinction and angiogenic 
interaction between embryonic arteries and veins revealed by ephrin-B2 and its 
receptor Eph-B4." Cell 93(5): 741-753. 
Wang, R., R. Clark, et al. (1992). "Embryonic stem cell-derived cystic embryoid bodies 
form vascular channels: an in vitro model of blood vessel development." 
Development 114(2): 303-316. 
Wang, Y. and N. Sheibani (2006). "PECAM-1 isoform-specific activation of 
MAPK/ERKs and small GTPases: implications in inflammation and 
angiogenesis." J Cell Biochem 98(2): 451-468. 
Wei, H., O. Juhasz, et al. (2005). "Embryonic stem cells and cardiomyocyte 
differentiation: phenotypic and molecular analyses." J Cell Mol Med 9(4): 804-
817. 
Wigle, J. T., N. Harvey, et al. (2002). "An essential role for Prox1 in the induction of 
the lymphatic endothelial cell phenotype." EMBO J 21(7): 1505-1513. 
Williams, R. L., D. J. Hilton, et al. (1988). "Myeloid leukaemia inhibitory factor 
maintains the developmental potential of embryonic stem cells." Nature 
336(6200): 684-687. 
Wong, W. T., S. L. Wong, et al. (2010). "Endothelial dysfunction: the common 
consequence in diabetes and hypertension." J Cardiovasc Pharmacol 55(4): 300-
307. 
Woodfin, A., M. B. Voisin, et al. (2007). "PECAM-1: a multi-functional molecule in 
inflammation and vascular biology." Arterioscler Thromb Vasc Biol 27(12): 
2514-2523. 
Woods, T. C., C. R. Blystone, et al. (2002). "Activation of EphB2 and its ligands 
promotes vascular smooth muscle cell proliferation." J Biol Chem 277(3): 1924-
1927. 
Wu, S. M., Y. Fujiwara, et al. (2006). "Developmental origin of a bipotential 
myocardial and smooth muscle cell precursor in the mammalian heart." Cell 
127(6): 1137-1150. 
Xiao, K., D. F. Allison, et al. (2003). "Mechanisms of VE-cadherin processing and 
degradation in microvascular endothelial cells." J Biol Chem 278(21): 19199-
19208. 
Xu, K. and O. Cleaver (2011). "Tubulogenesis during blood vessel formation." Semin 
Cell Dev Biol 22(9): 993-1004. 
Yamashita, A., S. Nishikawa, et al. (2010). "Microenvironment modulates osteogenic 
cell lineage commitment in differentiated embryonic stem cells." PLoS One 
5(3): e9663. 
Yamashita, J., H. Itoh, et al. (2000). "Flk1-positive cells derived from embryonic stem 
cells serve as vascular progenitors." Nature 408(6808): 92-96. 
Yamashita, J. K. (2007). "Differentiation of arterial, venous, and lymphatic endothelial 
cells from vascular progenitors." Trends Cardiovasc Med 17(2): 59-63. 
References 
114 
 
Yancopoulos, G. D., M. Klagsbrun, et al. (1998). "Vasculogenesis, angiogenesis, and 
growth factors: ephrins enter the fray at the border." Cell 93(5): 661-664. 
Yao, Y., M. Jumabay, et al. (2013). "A Role for the Endothelium in Vascular 
Calcification." Circ Res. 
Yates, F. and G. Q. Daley (2006). "Progress and prospects: gene transfer into embryonic 
stem cells." Gene Ther 13(20): 1431-1439. 
Yoder, M. C., L. E. Mead, et al. (2007). "Redefining endothelial progenitor cells via 
clonal analysis and hematopoietic stem/progenitor cell principals." Blood 
109(5): 1801-1809. 
You, L. R., F. J. Lin, et al. (2005). "Suppression of Notch signalling by the COUP-TFII 
transcription factor regulates vein identity." Nature 435(7038): 98-104. 
Yu, J. and J. A. Thomson (2008). "Pluripotent stem cell lines." Genes Dev 22(15): 
1987-1997. 
Zape, J. P. and A. C. Zovein (2011). "Hemogenic endothelium: origins, regulation, and 
implications for vascular biology." Semin Cell Dev Biol 22(9): 1036-1047. 
Zhang, J. G., C. M. Owczarek, et al. (1997). "Evidence for the formation of a 
heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits 
in solution." Biochemical Journal 325: 693-700. 
Zovein, A. C., J. J. Hofmann, et al. (2008). "Fate tracing reveals the endothelial origin 
of hematopoietic stem cells." Cell Stem Cell 3(6): 625-636. 
 
Declaration of Intent 
115 
 
Declaration of Intent 
I declare that I have completed this dissertation single-handedly without the 
unauthorized help of a second party and only with the assistance acknowledged therein. 
I have appropriately acknowledged and referenced all text passages that are derived 
literally from or are based on the content of published or unpublished work of others, 
and all information that relates to verbal communications. I have abided by the 
principles of good scientific conduct laid down in the charter of the Justus Liebig 
University of Giessen in carrying out the investigations described in the dissertation.
Acknowledgments 
116 
 
Acknowledgments   
At this point of time, I am at a state of ecstasy of just the few moments before 
completion, before the last pieces of a puzzle are put together to make the final view of 
a couple of years of passionate work with stem cells. Stem cells were often a reflection 
of my own character and deed; a small world in which the bigger outer one could repeat 
and experience itself. In addition to an opportunity for personal growth, it was an 
invaluable experience to pursue scientific work in an outstanding research center, to 
achieve problem-solving techniques in confrontation with questions and challenges, and 
to do group work in an international environment.  
My special whole-hearted gratitude goes to my family, to whom this thesis is 
dedicated. Mom and Dad you have given me your unconditional love. Without that, 
nothing of this would have been possible. You have persuaded me to be myself and 
given me the wings to fly, at a time that you needed help and support. I have learned 
from you the passion for life and happiness.  I am honored to be your daughter. My 
whole-hearted thanks go to my beloved siblings Mitra, Mandana, and Babak. As your 
little sister, I was blessed to get familiar with the concept of humanity, affection, and 
devotion. You have always supported me in all situations of my life. I am so proud to be 
your little sister. Farzaneh, Rainer, Armin, Jasmin, and Sara your kindness and love has 
motivated me to move forward.  
My deep gratitude goes to my mentor, PD Dr. Robert Voswinckel, for the 
opportunity that he gave me to work as a PhD student in his group, and for his trust and 
frankness. With his support, I was able to develop my basic science skills, which was 
not easy at the beginning, as I came from a medical background. This opportunity 
enabled me to get familiar with the difficulties of bench work, and to sincerely value 
and respect the biologists, who are the fundamental driving forces for medical 
advancements.  
I would like to sincerely appreciate Professor Dr. Werner Seeger for the opportunity 
and kind support that I was given to do research as well as pursue my medical career in 
his department. This combination allowed me to be more sensitive about an urgent need 
for more advanced therapeutic options for patients. It was not uncommon to receive 
questions from patients about cell therapy possibilities for their advanced diseases.   
Acknowledgments 
117 
 
My sincere appreciations go to Professor Dr. Philipp Markart for his kind 
encouragement and support to finalize my thesis parallel to clinical practice, for the 
generous devotion of his time on correction of my thesis and manuscript, and for his 
invaluable ideas for the improvement of my thesis.                             
I would like to appreciate Professor Thomas Braun for accepting me at the first place 
to be a member of and study at the international Max Planck research school.  
I am sincerely grateful to Professor Dr. Werner Seeger, Professor Dr. Dieter 
Walmrath, Professor Dr. Konstantin Mayer, Professor Dr. Philipp Markart, and 
Professor Dr. Richard Schulz for all the medical knowledge that I learned from them. 
My appreciations also go to my other colleagues at the hospital, for the collaborative 
and joyous teamwork that we made together.  
I am deeply grateful to Germany for the opportunity that I was offered to do research 
and clinical practice in my favorite field.  
My appreciations go to our lab technicians, Uta, Diana, and Nilüfer, and my labmates 
Kirsten, Celimene, Daria, Frederike, Peter, Minmin, Manish, Anita, Nicola, and Dr. 
Katrin Albrecht for the fruitful and pleasurable time that we had together. I would like 
to specially thank Dr. Sven Becker for basic science techniques that I learned from him.  
My sincere thanks go to all my friends in Bad Nauheim and Giessen, as well as in 
Iran, America, and all over the world, for all the good times that we shared together, and 
for their support during my darker times. Thank you to everybody who helped me to 
move forward in the direction of happiness. I wish the gates of happiness swing open 
for you.  
My eternal gratitude goes to our terrific world and the divine forces keeping it 
upright, for leading me to the place that I am, and for allowing me to become who I am. 
I feel blessed to be alive. I feel grateful for every motivation that I receive from you to 
live and love passionately, and to serve gratefully.  
 
Publications 
118 
 
Publications  
1. Argani H, Ayromlou H, and Raisii M: Sympathetic skin response in 
Hemodialysis and renal transplantation. Transplantation proceedings; 34, 2128 
(2002).  
2.  Fallah N, Mohammad K, Nourijelyani K, Eshraghian MR, Seyyedsalehi SA, 
Raiessi M, Rahmani M, Goodarzi HR, Darvish S, Zeraati H, Davoodi G, 
Sadeghian S. Nonlinear association between serum testosterone levels and 
coronary artery disease in Iranian men. Eur J Epidemiol. 2009 Apr 9.  
3. Alidoosti M, Salarifar M, Zeinali AM, Kassaian SE, Dehkordi MR. Comparison 
of outcomes of percutaneous coronary intervention on proximal versus non-
proximal left anterior descending coronary artery, proximal left circumflex, and 
proximal right coronary artery: a cross-sectional study. BMC Cardiovasc Disord. 
2007 Mar 4;7:7.  
4. Davoodi Gh, Amirzadegan A, Borumand MA, Dehkordi MR, Kazemisaied A, 
and Yaminisharif A. The relationship between level of androgenic hormones and 
coronary artery disease in men. Cardiovasc J Afr. 2007; March/August 18 (4): 
43-48.  
5. Amirzadegan A, Davoodi G, Boroumand MA, Darabyan S, Dehkordi MR, 
Goodarzynejad H. Association between hepatitis B surface antibody 
seropositivity and coronary artery disease. Indian J Med Sci. 2007 
Dec;61(12):648-55.  
6. Sadeghian S, Taleghani F, Doarfshan A, Raissi Dehkordi M: Periodontal disease 
as a risk factor for coronary artery disease. J Teh Univ Heart Ctr. 2006; 1 (2): 
105-109.  
7.  Alidoosti M, Salarifar M, Zeinali AM, Kassaian SE, Dehkordi MR, Fatollahi 
MS. Short- and long-term outcomes of percutaneous coronary intervention in 
patients with low, intermediate and high ejection fraction .Cardiovasc J Afr. 
2008 Jan-Feb;19(1):17-21  
8. Alidoosti M, Salarifar M, Kassaian SE, Haji Zeinali AM, Raissi Dehkordi M, 
Sheikh Fathollahi M. Outcomes of drug-eluting versus bare metal stents in our 
routine clinical practice Hellenic J Cardiol. 2008; 49: 132-138.  
Publications 
119 
 
9. Kassaian SE, Alidoosti M, Sadeghian H, Raissi Dehkordi M, Amplatzer 
vascular plug for the treatment of a coronary fistula in a 15-yearl old boy Should 
a Retrograde Approach Be Standard? Texas Heart Inst J 2008; 35: 58- 61.  
10. Alidoosti M, Salarifar M, Kassaian SE, Zeinali AM, Fathollahi MS, Dehkordi 
MR. In-hospital and mid-term adverse clinical outcomes of a direct stenting 
strategy versus stenting after pre-dilatation for the treatment of coronary artery 
lesions. Cardiovasc J Afr. 2008 Nov-Dec;19(6):297-302.  
11. Alidoosti M, Jam MS, Dehkordi MR. Successful deployment of an atrial septal 
occluder device in a patient with an insufficient posterosuperior defect rim. 
Anadolu Kardiyol Derg 2008; 8: 456-8.  
12. Darabian S, Amirzadegan AR, Sadeghian H, Sadeghian S, Abbasi A, Raeesi M. 
Ostial lesions of left main and right coronary arteries: demographic and 
angiographic features. Angiology. 2008 Dec-2009 Jan;59(6):682-7.  
13. Darabian S, Raissi Dehkordi M, Goodarzynejad H: Myocardial bridges: A case 
series of 19 patients J Teh Univ Heart Ctr 2 (2007) 105-110. 
14. Kazemisaeid A, Zeinali AH, Davoodi G, Amirzadegan A, Jam MS, Dehkordi 
MR, Azadbakht F, Abedini M. Premedication for coronary angiography: effects 
on anxiety and hemodynamic status. Indian Heart J. 2007 Nov-Dec;59(6):454-8.  
15. Kazemisaeid A, Yaminisharif A, Alamzadeh M, Raissi Dehkordi M, Davoodi 
Gh: Urinary Sodium and hemodynamic changes after implantation of permanent 
pacemakers. Arak journal of medical sciences (article in Persian).  
16. Manuscript in preparation: Raissi M, Becker S, Markart P, Martin U, Werner 
Seeger W, and Voswinckel R. Purification and characterization of endothelial 
cells derived from murine embryonic stem cells transduced with a lentiviral 
vector expressing GFP under the control of the VE-cadherin promoter   
 
Poster/Oral presentations 
1. Endothelial Cells developed from Embryonic Stem Cells for cell-based 
Therapy– Institute’s Colloquium. Max Planck Institute for heart and lung 
research October 2012.  
2. Driving murine embryonic stem cells toward endothelial phenotype for cell-
based therapy. Poster presentation. UGMLC seminar on lung diseases, poster 
presentation Marburg, Germany, June 2012.  
Publications 
120 
 
3. VE-Cadherin as a Specific Promoter for Genetic Labeling and Selection of Pure 
Embryonic Stem Cell-Derived Endothelial Cells for Therapeutic Purposes. 
Poster presentation. Bremen DGP Meeting. Pneumologie 2012; 66 - A703  
4. VE-Cadherin as a Specific Promoter for Genetic Labeling and Selection of Pure 
Embryonic Stem Cell-Derived Endothelial Cells for Therapeutic Purposes. 
American Thoracic Society San Francisco May 2012. Poster presentation ATS 
journals Chapter DOI: 10.1164/ajrccm  
5. Driving murine embryonic stem cells toward endothelial phenotype for cell-
based therapy. Poster presentation. Dresden DGP Meeting Pneumologie 2011; 
65 - P407.  
6. Development and purification of embryonic stem cells-derived endothelial cells 
for therapeutic purposes. Poster presentation at the Keystone Symposia, Stem 
Cells, Development and Homeostasis Santa Fe, USA. February 2011.  
7. Effect of body mass index in the outcomes of stenting for the treatment of 
coronary artery lesions, International Congress of the Iranian HeartAssociation 
in collaboration with the American College of Cardiology on Heart Disease 
(November 2008) 
8. Outcomes of percutaneous coronary intervention in patients aged 65 and over vs. 
those under the age of 65, International Congress of the Iranian Heart 
Association in collaboration with the American College of Cardiology on Heart 
Disease (November 2008) 
9. Comparison of sirolimus-vs. paclitaxel-eluting stents for the treatment of 
coronary artery lesions, International Congress of the Iranian Heart Association 
in collaboration with the French Society of Cardiology (October 2006). 
 
Medical Translations (English-Persian) 
1. Skeleton: Discover the evolution and structure of bones (2009) 
2. Cecil's Infectious diseases (2007)  
3. Harrison's Rheumatologic diseases (2005)  
4. Cecil's Musculoskeletal and Connective tissue diseases (2004)  
5. Harrison's Rheumatologic diseases (2001)  
6. Adams Orthopaedics principles (2001)  
7. Habif's Dermatology textbook (1996) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Der Lebenslauf wurde aus der elektronischen 
Version der Arbeit entfernt. 
 
 
 
 
The curriculum vitae was removed from the 
electronic version of the paper. 
VVB
VVB LAUFERSWEILER VERLAG
édition scientifique
VVB LAUFERSWEILER VERLAG
STAUFENBERGRING 15
D-35396 GIESSEN
Tel: 0641-5599888 Fax: -5599890
redaktion@doktorverlag.de
www.doktorverlag.de
VVB LAUFERSWEILER VERLAG
édition scientifique
9 7 8 3 8 3 5 9 6 3 1 6 0
ISBN: 978-3-8359-6316-0
Photo cover: 
M
A
R
I
A
 
R
A
I
S
S
I
 
D
E
H
K
O
R
D
I
 
 
 
 
E
M
B
R
Y
O
N
I
C
 
S
T
E
M
 
C
E
L
L
-
D
E
R
I
V
E
D
 
E
N
D
O
T
H
E
L
I
A
L
 
C
E
L
L
S
 
Maria Raissi Dehkordi
Generation of pure endothelial cells from 
transgenic embryonic stem cells exhibiting an
endothelial cell-specific expression of
green fluorescent protein
upon differentiation
INAUGURAL DISSERTATION
submitted to the Faculty of Medicine
in partial fulfillment of the Doctoral Degree
in Human Biology (Dr. biol. hom.)
Justus Liebig University Giessen, Germany
 
 
INAUGURAL DISSERTATION
submitted to the Faculty of Medicine
in fulfillment of the Doctoral Degree
in Human Biology (Dr. biol. hom.)
Justus Liebig University Giessen, Germany
